netFormulary
 Report : A-Z of formulary items 19/11/2018 21:48:12
[Back]
 
Section Name Details
A2.04.02  Renavit® Tablet per 450 mg

Energy 3.15 kJ (0.75 kcal)

Protein Nil

Carbohydrate 170 mg

Fat Nil

Fibre Nil

ACBS Indications Dietary management of water-soluble vitamin deficiency in adults with renal failure on dialysis
11.04.01 Minims®Dexamethasone drops 0.1%  Preservative free
03.01.05 Vortex® Spacer   First line spacer option.

Not at RBCH
13.06 10 mg (1%) clindamycin (as clindamycin phosphate) and 0.25 mg (0.025%) tretinoin Treclin ®
13.05.03 5-methoxypsoralen  Unlicensed product - hospital use only
Take tablets 2-3 hours before PUVA treatment.

DCHFT: Restricted Item  Consultant use only.
13.05.03 8-methoxypsoralen  Unlicensed product - hospital use only
Apply gel 30 minutes before PUVA treatment

DCHFT: Restricted Item Consultant use only.
13.05.03 8-methoxypsoralen  Unlicensed product - hospital use only
Take tablets 2-3 hours before PUVA treatment

DCHFT: Restricted Item Consultant use only.
05.03.01 Abacavir Ziagen® See commissioning and funding guidance from NHS England.
05.03.01 Abacavir and Lamivudine generic brands Commissioned by NHS England (for HIV in combination with anti-retroviral drugs). See BHIVA Guidelines.

Use generic formulations - Kivexa® is non-formulary
05.03.01 Abacavir and Lamivudine and Zidovudine Trizivir® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs). As per BHIVA Guidelines.
05.03.01 Abacavir with Lamivudine and Dolutegravir Triumeq® Commissioned by NHS England for HIV in combination with other anti-retroviral drugs.
10.01.03 Abatacept Orencia®

NHSE Commissioned by NHS England for:

  • Juvenile idiopathic arthritis in line with NICE TA373.
  • Paediatric indications where an adult NICE TA is available.

NHSE Commissioned by CCG for the treatment of rheumatoid arthritis in line with NICE TA195 and TA375.

02.09 Abciximab ReoPro® Injection / infusion.
  • Cardiology consultant use only.
  • 09.06.07 Abidec® 

    For paediatrics, to be initiated in hospital

    08.03.04.02 Abiraterone acetate Zytiga ®

    For use in accordance with NICE TA259 and TA387 reccomendations.

    04.10.01 Acamprosate  EC tablets.
    For maintenance of abstinence in alcohol dependent patients in accordance with local shared care guideline.
    06.01.02.03 Acarbose Glucobay® Consider acarbose for a person unable to use other oral glucose lowering medications
    06.01.06 Accu-chek ® Performa Test Strips 
    06.01.06 Accu-chek®Mobile 
    02.08.02 Acenocoumarol Sinthrome® Tablets.
  • Specialist initiation in patients intolerant of warfarin (where other oral agents are not indicated).

  • 01.05 Acetarsol Suppositories  Arsenic Suppositories Restricted Item  RBCH only: Consultant Gastroenterologist prescription only to treat severe refractory proctitis
    11.06 Acetazolamide Diamox® Tablets 250mg
    11.06 Acetazolamide Diamox® SR Capsules 250mg
    11.06 Acetazolamide injection 500mg 
    11.08.02 Acetylcholine Chloride solution Miochol-E®
    03.07 Acetylcysteine  Injection.

    RBCH: Injection used for nebulisation in Critical Care and Respiratory in-patients (off-label):
  • Mix 1mL injection with 4mL sodium chloride 0.9%


  • DCHFT: Injection used for nebulisation in Critical Care (off-label). Regimen / dose depends on individual patient.
    16.01 Acetylcysteine 600mg tablets  unlicensedUnlicensed
    For prevention of contrast-induced nephropathy
    11.08.01 Acetylcysteine drops 5% Ilube® Preserved
    18 Acetylcysteine IV Parvolex See BNF for treatment graph and acetylcysteine treatment protocols for paracetamol overdose.
    13.10.03 Aciclovir  Cream, aciclovir 5%
    12.03.02 Aciclovir 5% cream 
    11.03.03 Aciclovir eye ointment 3%  Consider oral aciclovir as an alternative to aciclovir eye ointment as systemic therapy is less toxic to the cornea and affords adequate concentration into the cornea.
    05.03.02.01 Aciclovir IV 
    05.03.02.01 Aciclovir oral 
    13.05.02 Acitretin Neotigason® Hospital use only - not recommended in women of child bearing age.
    Pregnancy Prevention Scheme applies if prescribed in women of child bearing age.

    DCHFT: Consultant use only.
    03.01.02 Aclidinium (Eklira Genuair®)  Inhaler.
    Long acting option
    Use with caution in patients with history of myocardial infarction within last 6 months, unstable angina, newly diagnosed arrhythmia within last 3 months, hospitalisation with moderate or severe heart failure within last 12 months.

    Use second line
    03.01.04 Aclidinium bromide/Formoterol fumarate dihydrate Duaklir Genuair ®
    13.06.01 Acnecide® 

    Gel, benzoyl peroxide 5% in an aqueous gel basis
    Excipients include propylene glycol

    For use within acne guideline when required in combination with antibiotics

    Not RBCH

    Self Care Self Care Medicine

    A5.08.06 Actico Cohesive ® 

    10cm x 6m only: Seek specialist advice for when to use other widths

    Available as a latex free option

    13.08.01 Actikerall®  Solution, fluorouracil 0.5%, salicylic acid 10%

    Not stocked at RBCH
    DCHFT: Not routinely stocked.
    18 Activated charcoal  For reduction of absorption of poisons in the gastro-intestinal system. Useful for many oral poisons (but see Toxbase or NPIS for advice on use).
    A5.02.01 ActivHeal Hydrogel 

    Available as 8g or 15g

    ActivHeal® Hydrogel is used as a primary dressing indicated for use on dry and sloughy wounds with nil to low exudate:

    • Pressure ulcers
    • Cavity wounds
    • Leg ulcers
    • Graft and Donor sites
    • Diabetic ulcers
    • Post op surgical wounds
    • Lacerations and abrasions
    01.05.03 Adalimumab Humira®
    10.01.03 Adalimumab Humira® For rheumatoid arthritis in accordance with NICE TA 375.

    Paediatric indications (where adult TA available) - commissioned by NHS England.

    Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis in accordannce with NICE TA373.
    11.04.02 Adalimumab Humira®

    Restricted Item Commissioned by NHS England for non-infectious uveitis in line with NICE TA460 at specialist centres only.

    Specialist centres in the South region:

    • University Hospital Southampton NHS Foundation Trust
    • Oxford University Hospitals NHS Foundation Trust
    • University Hospital Bristol NHS Foundation Trust

    13.05.03 Adalimumab Humira®

    Commissioned by CCG for psoriasis in accordance with NICE TA146.

    Restricted Item Commissioned by NHS England via specialist centres only for treating moderate to severe hidradenitis suppurativa in accordance with NICE TA392.

    19.07 Adapt barrier ring  Hollister Ltd
    Product size:48mm. Product reference code:7805
    Pack size 10

    Product size:98mm. Product reference code:7806
    Pack size 10
    19.09 Adapt Lubricating Deodorant  Hollister Ltd
    Product reference code 78500
    Approved pack size 236ml

    Amber only after a trial of baby oil or alternative simple measures
    19.09 Adapt Lubricating Deodorant Sachets  Hollister Ltd
    Product reference code 78501
    Approved pack size 50

    Amber only after a trial of baby oil or alternative simple measures
    19.01 Adapt No-Sting medical adhesive remover aerosol  Hollister Ltd
    Product reference code 7737
    Approved pack size 50ml
    19.07 Adapt slim barrier ring  Hollister Ltd
    Product size:48mm. Product reference code:7815
    Pack size 10
    19.10 Adapt stoma powder™  Hollister Ltd
    Product reference code 7906
    Approved pack size 28.3g

    AMBER – only to be initiated by stoma nurse; Protective powder for broken skin or Mucocutaneous Separation.
    09.06.04 Adcal-D3® 

    Colecalciferol with calcium
    Alternative preparations are available subject to patient preference

    09.03 Addiphos® 
    09.03 Additrace® 
    02.03.02 Adenosine  Injection.
    23.08 Adhesive Remover 
    Company Product Codes Price Per Unit Comments
    Clinimed Appeel no sting medical adhesive remover

    Sterile Adhesive remover sprat 100ml 1x1 Code: 392-8579

    Sterile Wipes 1x30 pack of single use wipes Code: 362-6983

    16.50

     

    15.43

    These adhesive removal products can be used to help remove sheaths

     

    23.04 Adjustable leg bags (for sheath user) 
    Company Code Price Comment

    Coloplast
    Simpla Profile

    Adjustable bag
    500mls/750mls
    Codes – 21583

    £2.91
    (Box of 10)

    For sheath use only.
    Safety lock tap and anti-kink tubing.

    02.07.03 Adrenaline / Epinephrine  Injection.
  • The algorithm for cardiopulmonary resuscitation can be found at http://www.resus.org.uk/
  • See Section 3.4.3 for management of anaphylaxis.


  • 03.04.03 Adrenaline / Epinephrine IM/SC 

    Pre-filled syringe - various brands available. Injection technique is device specific. To ensure patients receive the auto-injector device that they have been trained to use, prescribers should normally prescribe by brand.

     

    03.04.03 Adrenaline / Epinephrine IV  Intravenous route should only be used by specialists where there is doubt about the adequacy of circulation and absorption of IM adrenaline/epinephrine.

    Ensure that the correct strength of adrenaline injection is used.
    03.01.05 AeroChamber Plus Flo-Vu® 

    First line spacer option.

    03.01.05 AeroChamber Plus®  First line spacer option.
    08.01.05 Afatinib Giotrif®

    Commissioned by NHS England in line with NICE TA310.

    11.08.02 Aflibercept Eylea® PbR excluded: Commissioned by CCG in accordance with NICE guidance - refer to Commissioning Statements.
    09.08.01 Agalsidase Alfa  Commissioned by NHS England - For initiation by specialist centres only.
    09.08.01 Agalsidase Beta  Commissioned by NHS England - For initiation by specialist centres only
    16.01 Ajmaline  unlicensedUnlicensed
    For diagnosis of Brugada’s syndrome
    13.07 Aldara®  Hospital use only for anogenital warts
    Cream, imiquimod 5%
    Excipients include benzyl alcohol, cetyl alcohol, hydroxybenzoates (parabens), polysorbate 60, stearyl alcohol

    May damage latex condoms and diaphragms

    DCHFT: Restricted Item  Consultant only.
    13.08.01 Aldara®  Cream, imiquimod 5%
    08.02.04 Aldesleukin Proleukin® Commissioned by NHS England for cancer, but not routinely.
    08.01.05 Alectinib Alecensa®

    Commissioned by NHSE in line with NICE TA536 recommendations.

    08.02.03 Alemtuzumab Lemtrada®

    This is no longer licensed but is available through a patient access programme for oncological and transplant indications.

    Refer to the medicines management team for commissioning arrangements.

    NHS England commissioned for MS (TA312). Also commissioned by NHS England for CLL and pre-transplant immunosuppression (islet transplantation) only if provided at zero drug cost.

    08.02.04 Alemtuzumab Lemtrada®

    Commissioned by NHS England for treatment multiple sclerosis in accordance with NICE TA312.

    Commissioned for two treatment courses only as per marketing authorisation. Any subsequent courses by IFR only.

    06.06.02 Alendronic Acid 

    For use in osteoporosis

    Binosto® 70mg effervescent tablets are non-formulary - see below

    09.06.04 Alfacalcidol 
    A2.03.01 Alfamino®  On advice of dietitian or hospital specialist, for cow's milk protein allergy and other ACBS indications
    15.01.04.03 Alfentanil Rapifen® Injection.
    04.07.02 Alfentanil Buccal/Nasal Spray  unlicensedUnlicensed
    RBCH: Palliative care only for in-patient use - see policy.
    DCHFT: Palliative care consultant only for Joseph Weld Hospice or inpatient use only.
    07.04.01 Alfuzosin  including MR formulations (Besavar® XL, Vasran® XL, Xatral® XL)
    09.08.01 Alglucosidase Alfa Myozyme® Commissioned by NHS England: For initiation by specialist centres only
    02.12 Alirocumab Praluent®

    RED, Initiation by lipid specialist – this can be by written or verbal approval to other secondary care consultant clinicians. A copy of any letters should be forwarded to the patient’s GP.

    Commissioned by CCG in accordance with NICE TA 393 for primary non-familial hypercholesterolaemia or mixed dyslipidaemia and primary heterozygous familial hypercholesterolaemia.

    Commissioned by NHS England via specialist centres only for homozygous familial hypercholesterolaemia.

    02.05.05.03 Aliskiren Rasilez® Tablet.
  • Aliskiren should be considered as a fourth-line agent for addition to step 4 of the hypertension flowchart. Refer to local shared care guideline for aliskiren.
  • DCHFT: Consultant use only and in line with SCG.
  • 13.05.01 Alitretinoin Toctino® PbR excluded: Commissioned by CCG

    Treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids. Use within the criteria defined by NICE TA177 and its licensed indication. Criteria for discontinuation of Alitretinoin treatment are also specified by NICE.
    10.01.04 Allopurinol 
    04.07.04.01 Almotriptan  Alternative prescribing option.

    DCHFT: Not routinely stocked.
    06.01.02.03 Alogliptin Vipidia®
    • Dosing adjustment required in renal impairment, see SPC
    • The SPC says: "Experience of alogliptin use in clinical trials in patients with congestive heart failure (NYHA functional class III and IV) is limited and caution is warranted in these patients.
    • DMAG recommends to avoid alogliptin use in patients with ischaemic heart disease (IHD) and that GPs search for patients on alogliptin with IHD and review them at their next planned review appointment.
    09.06.05 Alpha Tocopheryl Acetate 
    07.04.05 Alprostadil injection  Not prescribable on the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIB of the Drug Tariff. The prescription must be endorsed ’SLS’.

    DCHFT: Consultant only.
    07.04.05 Alprostadil injection 

    DCHFT: Consultant only.
    02.10.02 Alteplase Actilyse® Injection / infusion.
  • Use in accordance with NICE TA 52.
  • Also use in accordance with NICE TA 264.

  • A2.03.01 Althera® 

    Alternative option for cow’s milk protein allergy 

    A2.01.02.03 Altraplen® Compact 

    NICE CG32 (Feb 2006) Nutrition support in adults

    This has a smaller volume and more than 2kcals /ml these can very useful in those who struggle with a larger volume

    A2.01.02.03 Altraplen® Protein 

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Restrict use to those patients with increased protein requirement. Use only under direction of dietitian. Not to be used for those with renal insufficiency

    A2.04.01.02 Altrashot 
    01.01.01 Aluminimum Hydroxide  Specialist use only.
    09.05.02.02 Aluminium Hydroxide Alu-Cap®
    04.09.01 Amantadine  Tablets, syrup.
    For dyskinesia in advanced Parkinson's Disease.

    See shared care guideline for amantadine.
    05.03.04 Amantadine Hydrochloride Lysovir® Use in accordance with NICE TA158.
    02.05.01 Ambrisentan Volibris® Only to be initiated by approved Tertiary Centres in accordance with NHS England commissioning policies for Pulmonary Hypertension.
    05.01.04 Amikacin  For microbiology use only.

    DCHFT: Consultant only.

    Amikacin liposomal commissioned by NHS England in CF but not routinely.
    11.03.01 Amikacin Intravitreal injection  unlicensedUnlicensed

    DCHFT: Not routinely stocked.
    02.02.03 Amiloride Hydrochloride  Tablets.
    03.01.03 Aminophylline IV  Hospital only.
    03.01.03 Aminophylline modified release  Prescribe by brand.
    02.03.02 Amiodarone  Tablets, (Injection - secondary care only).
    Hospital initiation.
    04.02.01 Amisulpride  Hospital or specialist initiation.

    In accordance with NICE CG178 recommendations for the use of atypical antipsychotic drugs for the treatment of schizophrenia and local shared care guideline.


    See guidance on the use of antipsychotics in conditions other than schizophrenia (NICE CG 82).
    04.03.01 Amitriptyline 

    Not first line with regard to depression, as per the Dorset Primary Care Protocol for Depression (see link above)

    04.07.03 Amitriptyline  Tablets, syrup.
    unlicensedunlicensed
    02.06.02 Amlodipine  Tablets.

    1st Line Choice

    Option choices agreed for new initiations, existing patients will not be switched unless clinically appropriate.
    05.01.01.03 Amoxicillin 
    05.01.01.03 Amoxicillin IV 
    05.02.03 Amphotericin  Fungizone®

    Must be prescribed by brand.

    RBCH: for ocular injection or intravesical administration only

    11.03.02 Amphotericin drops 0.15%  Preservative free
    unlicensedunlicensed

    DCHFT: On formulary but not stocked.
    05.02.03 Amphotericin Liposomal AmBisome®

    Must be prescribed by brand.

    For neutropenic sepsis or on advice of microbiology

    08.01.05 Amsacrine 
    13.10.01.02 Anabact®  Gel, metronidazole 0.75%
    Excipients include hydroxybenzoates (parabens), propylene glycol

    For malodourous fungating tumours and ulcers
    09.01.04 Anagrelide  When used in combination with hydroxycarbamide or outside licensed indications.
    09.01.04 Anagrelide  For treatment of essential thrombocythaemia in accordance with local shared care guideline.
    10.01.03 Anakinra Kineret®

    Commissioned by NHS England for the treatment of Adult-Onset Still’s Disease refractory to second-line therapy in line with clinical commissioning policy 170056P via specilaist centres only.

    Commissioned by NHS England in Cryopyrin Assoicated Periodic Syndrome via specilaist centres only in line with highly specialised criteria.

    08.03.04.01 Anastrozole  For early breast cancer.
    Also for advanced disease in postmenopausal women who are oestrogen-receptor positive or responsive to tamoxifen
    13.12 Anhydrol Forte® 

    Restrict to patients in exceptional circumstances, this is a Self Care Self Care Medicine

    Solution (= application), aluminium chloride hexahydrate 20% in an alcoholic basis

     

    05.02.04 Anidulafungin Ecalta®

    Commissioned by NHS England according to agreed Trust Guidelines for fungal infections.

    DCHFT: Not routinely stocked.

    01.01.01 Antacid and oxetacaine  Restricted Item  Restricted use at PHT, RBCH and DCHFT : Specialist use only.
    11.04.02 Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin® First choice for
  • Seasonal allergies

  • Short term allergies
  • A5.03.01 Antibacterial Medical Honey, honey (medical grade, Leptospermum sp.),  Medihoney®
    Antibacterial Medical Honey, honey (medical grade, Leptospermum sp.),


    Antibacterial Wound Gel, honey (medical grade, Leptospermum sp.), 80% in natural waxes and oils,
    02.11 Antihaemophilic Factor/von Willebrand Factor Complex  Non pharmacy item please contact blood bank for details and availability.

    Recombinant Von Willebrand Factor not routinely commissioned by NHS England. As per IFR approval.
    09.01.03 Anti-Human Thrombocyte Globulin (horse) Inj 100 mg in 5mL  RBCH: Aplastic anaemia - See guidelines
    09.01.03 Antilymphocyte immunoglobulin  Commissioned by NHS England in accordance with BCSH guidelines
    02.11 Antithrombin III  Non pharmacy item please contact blood bank for details and availability.

    Commissioned by NHS England as per BCSH Guidelines.
    08.02.02 Antithymocyte immunoglobulin (rabbit)  Thymoglobuline®

    Commissioned by NHS England as per British Committee for Standards in Haemotology (BCSH) Guidelines.

    Not recommended as initial treatments to prevent organ rejection in patients having a kidney transplant as per NICE TA481 and TA482.

    01.07.01 Anusol® 

    Ointment, cream, suppositories.

    01.07.02 Anusol-HC® 

    Ointment, suppositories.

    • On formulary at DCHFT.
    02.08.02 Apixaban Eliquis®

    Tablets.

    • For prevention of stroke or systemic embolism in patients with AF within NICE TA275 and local guidance, as per licensed indications.

     

    02.08.02 Apixaban Eliquis® Tablets.
  • In accordance with NICE TA245 for prevention of VTE in patients undergoing hip or knee replacement surgery, as per licensed indications.
  • RBCH: 1st line option is dalteparin.
  • DCHFT: 1st line option is enoxaparin.


  • 02.08.02 Apixaban Eliquis® For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE technology appraisal 341
    02.08.02 Apixaban Eliquis®

    Red

    • In accordance with NICE TA for prevention of VTE in patients undergoing hip or knee replacement surgery, as per licensed indications.
      • Note routine 1st line option at RBCH and DCH is LMWH


    Green

    • For prevention of stroke or systemic embolism in patients with AF within NICE TA and local guidance, as per licensed indications.
    • For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE TA. 

     

    02.08.02 Apixaban Eliquis®

    Prophylaxis in Superficial Thrombophlebitis - refer to Anticoagulation policy. 6 week course unlicensed Unlicensed

    04.09.01 Apomorphine injection  Hospital only.

    Treatment is managed by the Parkinson's Disease speciality nurses.
    19.02 Appeel No sting medical adhesive remover wipes®   CliniMed Ltd ®
    Product reference code 3505
    Approved pack size 30
    11.08.02 Apraclonidine drops 0.5% Iopidine® DCHFT: 0.5% and 1% stocked. The two strengths have different licensed indications.
    10.01.03 Apremilast Otezla®
    13.05.03 Apremilast Otezla®

    In accordance with NICE guidance.

    04.06 Aprepitant Emend® Capsules.
    Hospital use only.

    In accordance with locally agreed criteria as an adjunct to dexamethasone and 5HT3 antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy.
    13.02.01 AproDerm Colloidal Oat Cream® 

    Prescribe by BRAND

    The AproDerm® range is suitable from birth for those suffering from:

    Eczema
    Psoriasis and
    Other Dry Skin Conditions as well as for those requiring a daily moisturiser or pre-bathing emollient

    Paraffin free

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition. 

     

    A2.03.01 Aptamil Pepti 1®  Alternative option for cow's milk protein allergy in infants under 6 months of age
    A2.03.01 Aptamil Pepti 2®  Alternative option for cow’s milk protein allergy in infants over 6 months of age
    A2.03.01 Aptamil Pepti Junior® 

    Alternative option for cow's milk protein allergy

    13.02.01 Aquadrate®  Cream, urea 10%

    DCHFT: Not routinely stocked.
    13.02.01.01 Aqueous Cream, BP 

    Cream, emulsifying ointment 30%, (1)phenoxyethanol 1% in freshly boiled and cooled purified water

    Excipients include cetostearyl alcohol

    Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation. 

    Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required

    06.02.02 Aqueous iodine oral solution Lugol's solution Hospital only
    01.06.03 Arachis Oil 

    Enema.

    • Contains peanut oil. DO NOT give to patients with PEANUT ALLERGY.
    02.08.01 Argatroban Exembol®

    For treatment of Heparin-Induced Thrombocytopaenia (HIT)in critically unwell patients or those with severe renal impairment on advice of Consultant Haematologist.

    04.02.01 Aripiprazole (oral) Abilify®

    Tablets, Orodispersible tablets.

    Use in accordance with NICE CG178 recommendations for the use of atypical antipsychotic drugs for the treatment of schizophrenia and local shared care guidelines.

    See guidance on the use of antipsychotics in conditions other than schizophrenia (NICE CG 82)

    To be initiated on specialist advice only for:
    -schizophrenia.
    -the treatment of moderate to severe manic episodes in Bipolar I Disorder.
    -the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.

    Solution shouldn't be used routinely as is very expensive (30mg = ~£600 per month)

    Option based on NICE guidance and licence.

    04.02.01 Aripiprazole (oral) Abilify®

    Red when used in children with neuro-developmental disorders.

    Use in accordance with NICE TA292 in moderate to severe manic episodes in adolescents with bipolar 1 disorder.

    04.02.02 Aripiprazole intramuscular injection Abilify Maintena®

    For the maintenance of adult patients with schizophrenia who have responded to oral aripiprazole but who are non-compliant.

    see guidelines for the use of aripiprazole long acting injections

    08.01.05 Arsenic Trioxide Trisenox®

    Commissioned by NHSE in line NICE TA526 recommendations.

    05.04.01 Artemether with lumefantrine Riamet®
    09.06.03 Ascorbic Acid 200 mg, 500mg, 1g effervescent strengths only

    This has been re-categorised as "red" for Scurvy only as per DMAG November 2017. 200mg twice a day is the most cost-effective dose.

    Approved as Red at RBCH:

    • Acute Corneal conditions 500mg twice a day for 6 week course (Eye Consultant only)
    • Palliative Care consultant only: Tongue "descaling" where other options insufficient (1/4 x 1g tablet per dose)
    A5.03.03 Askina® Calgitrol® Ag Silver Paste Dressing 

    Indicated for the management of exuding partial to full thickness wounds, stage I -IV pressure sores, venous ulcers, second degree burns and donor sites. It is indicated for external use only and may be used in the management of infected wounds under medical supervision at the discretion of the physician.

    Sterile dressing consisting of two layers:

    • an absorbent polyurethane foam layer which provides for the absorption of wound exudate.
    • an ionic silver alginate matrix which provides for broad anti-microbial effectiveness and helps prevent contamination from external bacteria.
    02.09 Aspirin   Tablets, suppositories.
  • Enteric coated tablets are non-formulary.

  • Dual antiplatelet therapy in acute coronary syndrome.
  • 04.07.01 Aspirin 

    Tablets, suppositories.

    Dispersible tablets are considered 2nd Line 

    05.03.01 Atazanavir Reyataz® Commissioned by NHS England as per BHIVA Guidelines.
    02.04 Atenolol  Tablet, Liquid, (Injection - secondary care only).
    08.01.05 Atezolizumab Tecentriq®

    Commissioned by CDF in line with CDF criteria and NICE TA492 recommendations.

    Commissioned by NHSE in line with NICE TA520 and TA525 recommendations.

    Note (July 2018): The European Medicines Agency restricted the use of atezolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. 

    04.04 Atomoxetine Strattera® Capsules.
    For use in ADHD in accordance with recommendations made by NICE (TA98) and locally agreed treatment algorithm and shared care guideline.

    DCHFT: Restricted Item  Consultant psychiatrist only.
    02.12 Atorvastatin  Tablets.
    07.01.03 Atosiban  Not at RBCH
    05.04.08 Atovaquone Wellvone® suspension
    15.01.05 Atracurium Besilate Tracrium® Injection.
    A5.01.01 Atrauman   Non-adherent knitted polyester primary dressing impregnated with neutral triglycerides
    15.01.03 Atropine  Injection.
    18 Atropine injection  For bradycardia and organophosphate or carbamate insecticide poisoning.
    11.05 Atropine Sulfate drops 1%  DCHFT: unlicensedUnlicensed 1% eye ointment also on local formulary.
    13.04 Aureocort®  Ointment, triamcinolone acetonide 0.1%, chlortetracycline hydrochloride 3%, in an anhydrous greasy basis containing wool fat and white soft paraffin
    Potency: potent
    Excipients include wool fat
    12.02.01 Avamys®  Fluticasone furoate 27.5micrograms/dose nasal spray
    13.02.01 Aveeno® 

    Cream, colloidal oatmeal in emollient basis
    Excipients include benzyl alcohol, cetyl alcohol, isopropyl palmitate

    RBCH: Dermatology only

    Only to be used under ACBS specified conditions as follows:

    Endogenous and exogenous eczema, xeroderma, ichthyosis and senile pruritus associated with dry skin.

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.

    13.02.01.01 Aveeno® 

    Reserved for patients with severe eczema and infants under the age of 1 year. 

    Bath oil, colloidal oatmeal, white oat fraction in emollient basis

    Excipients include beeswax, fragrance

    Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation.

    Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required

    08.01.05 Avelumab Bavencio®

    Commissioned by NHSE for the treatment of previously treated (with systemic cytotoxic chemotherapy) metastatic Merkel cell carcinoma in line with NICE TA517.

    Available via CDF managed access agreement for the treatment of previously untreated (with systemic therapy) metastatic Merkel cell carcinoma - see link below.

    08.01.05 Axitinib Inlyta®

    Commissioned by NHS England in line with NICE TA333.

    10.03.02 Axsain®  Capsaicin 0.075% cream
    Specialist initiation
    A2.02.01.02 AYMES Shake Milkshake style and Juice shakes

    Calorie content is based on a sachet being made up with 200ml of full cream milk and contains approx. 385 Kcals.

    If patient likes milky drinks, prescribe as a supplement to diet 1-2 servings/day.

    Not suitable for patient with cow's milk intolerence or galactosaemia.

    Not nutritionally complete.

    If patient dislikes milky drinks choose from the juice style supplements instead.

    A2.02.01.02 Aymes® Complete 

    NICE CG32 (Feb 2006) Nutrition support in adults www.nice.org.uk/page.aspx?o=cg032niceguideline

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)

    Adult sip feeds containing 1kcal/ml (Fresubin Original, Ensure, Fortimel, Clinutren ISO) should not be prescribed as they are less cost effective compared to 1.5kcal/ml sip feeds

    08.01.03 Azacitidine Vidaza®

    Commissioned by NHS England in line with NICE TA218.

    Azacitadine is not recommended for treating acute myeloid leukaemia with more than 30% bone marrow blasts as per NICE TA399.

    01.05.03 Azathioprine  Tablets, suspension (unlicensed special).
  • Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults unlicensedUnlicensed for these indications but in line with national guidelines.
  • There are a number of different indications for azathioprine. Please see here for other indications.
  • unlicensedUnlicensed suspension 50mg/5mL (expensive) may be available as a special. At RBCH, suspension is Consultant Gastroenterologist for Crohn's disease in conjunction with allopurinol only.
  • 08.02.01 Azathioprine  Commissioned by NHS England (for transplant immunosuppression only) in new patients only until formal repatriation agreed. As per Trust Guidelines. Hospital initiation.
    10.01.03 Azathioprine 
    13.05.03 Azathioprine 

    Hospital use only - unlicensed
    For severe refractory eczema

    Unlicensed use: 0.5-3mg/kg daily dependent on TPMT activity

    05.01.05 Azithromycin 

    Green for Sexual Health indications in Primary Care - see Sexual Health Dorset Guidelines below

    Amber with Shared Care Guideline: For bronchiectasis, in line with local shared care guideline

    RedFor COPD or other indications.

    11.03.01 Azithromycin dihydrate drops 1.5% 
    05.01.02.03 Aztreonam Azactam®

    Consultant microbiologist or specialist use only.

    05.01.02.03 Aztreonam Lysine nebuliser solution Cayston®

    Commissioned by NHS England for use in CF as per policy A01/P/b.

    Adult patients: specialist centre only (University Hospital Southampton)

    Paediatric patients: PHFT use in line with network arrangements with UHS.

    Not at DCH or RBCH.

    10.02.02 Baclofen  Withdraw slowly as abrupt cessation may precipitate seizures
    13.02.01.01 Balneum Plus® bath oil 

    Reserved for patients with severe eczema and infants under the age of 1 year. 

    Bath oil,soya oil 82.95%, mixed lauromacrogols 15%

    Excipients include butylated hydroxytoluene, propylene glycol, fragrance

    Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation.

    Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required

    13.02.01 Balneum®  Cream, urea 5%, ceramide 0.1%

    Excipients include cetostearyl alcohol, polysorbates, propylene glycol

    Not RBCH
    13.02.01.01 Balneum® bath oil 

    Reserved for patients with severe eczema and infants under the age of 1 year. 

    Bath oil, soya oil 84.75%

    Excipients include butylated hydroxytoluene, propylene glycol, fragrance

    Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation.

    Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required

    10.01.03 Baricitinib Olumiant®
    08.02.02 Basiliximab Simulect®

    Commissioned by NHS England at specialist centres only in line with NICE TA recommendations.

    08.02.04 BCG bladder instillation OncoTICE® 1st line at RBCH
    08.02.04 BCG bladder instillation ImmuCyst® Bacillus Calmette-Guérin

    14.04 BCG vaccine diagnostic agent  Tuberculin PPD (Mantoux test) - named patient.
    14.04 BCG vaccine Intradermal  Bacillus Calmette-Guérin Vaccine
    BCG Vaccine, Dried/Tub/BCG

    This vaccine is not available at NHS expense in Dorset for Overseas Travel : See Dorset Guidance on Prescribing for Overseas Travel
    22.01 BD Viva 

    Size: 4mm/32g
    Size: 5mm/31g

    Pack Size : 90

    03.02 Beclometasone (Beclomethasone)  Inhalers.
    Prescribe by brand

    MHRA/CHM advice (July 2008):
    Beclometasone dipropionate CFC-free pressurised metered-dose inhalers (Clenil® and QVAR®)are not interchangeable and should be prescribed by brand name; QVAR® has extra-fine particles, is more potent than traditional beclometasone dipropionate CFC-containing inhalers, and is approximately twice as potent as Clenil®
    03.02 Beclometasone 100 micrograms/Formoterol 6 micrograms Fostair® Inhaler (MDI and NEXThaler)
    MHRA/CHM advice (July 2008):
    Fostair® has extra-fine particles and is more potent than traditional beclometasone dipropionate CFC-free inhalers.

    When switching patients from other beclometasone dipropionate and formoterol fumarate inhalers, Fostair® 100/6 can be prescribed for patients already using beclometasone dipropionate 250 micrograms in another CFC-free inhaler; the dose of Fostair® should be adjusted according to response
    03.02 Beclometasone 200mcg / Formoterol 6mcg Fostair® 200/6
    12.02.01 Beclometasone dipropionate 50micrograms/dose nasal spray 
    01.05.02 Beclometasone tablets Clipper® M/R tablets.
  • Not at DCHFT
  • 03.02.03 Beclomethasone / Formoterol / Glycopyrronium Trimbow®

    For use within its licensed indication for COPD

    10.01.03 Belimumab Benlysta®
    08.01.01 Bendamustine Levact®

    Commissioned by NHS England in line with TA216 and NHSE clinical commissioning policies (see below).

    Commissioned by CDF for the treatment of relapsed multiple myeloma in lince with CDF criteria.

    02.02.01 Bendroflumethiazide  Tablets.
    05.01.01.01 Benzathine benzylpenicillin   For GUM
    10.01.04 Benzbromarone 

    unlicensed Approved at RBCH and PHT for the long-term managment of chronic gout where:

    • previous intolerance/failure of allopurinol and/or febuxostat
    • renal impairment precludes use of allopurinol and/or febuxostat
    12.03.01 Benzydamine hydrochloride mouthwash 0.15% 
    12.03.01 Benzydamine hydrochloride oralmucosal spray 0.15% 
    11.03.01 Benzylpenicillin intravitreal injection  unlicensedUnlicensed

    DCHFT: Not routinely stocked.
    05.01.01.01 Benzylpenicillin IV Crystapen®
    03.05.02 Beractant Survanta® Hospital only.

    Commissioned by NHS England for Respiratory Distress Syndrome in neonates - use in line with Trust guidelines
    13.04 Betacap®  Scalp application, betamethasone (as valerate) 0.1% in a water-miscible basis containing coconut oil derivative Potency: potent

    09.06.01 Beta-Carotene 
    04.06 Betahistine Dihydrochloride  Tablets.
    For Méničre's disease
    09.08.01 Betaine Cystadane® Commissioned by NHS England in Homocystinuria according to service specification.
    06.03.02 Betamethasone  RBCH: 500microgram tablets used in preference to Dexamethasone 500microgram tablets (apart from Dexamethasone suppression testing)
    13.04 Betamethasone and clioquinol  Non-proprietary Cream, betamethasone (as valerate) 0.1%, clioquinol 3% Potency: potent
    Excipients may include cetostearyl alcohol, chlorocresol
    Note Stains clothing

    Ointment, betamethasone (as valerate) 0.1%, clioquinol 3%
    Potency: potent
    Note Stains clothing

    13.04 Betamethasone and neomycin Non-proprietary Cream, betamethasone (as valerate) 0.1%, neomycin sulfate 0.5%
    Potency: potent
    Excipients may include cetostearyl alcohol, chlorocresol

    Ointment, betamethasone (as valerate) 0.1%, neomycin sulfate 0.5%
    Potency: potent

    11.04.01 Betamethasone drops 0.1% 
    11.04.01 Betamethasone drops 0.1% with Neomycin 0.5%  Betnesol N® Not DCHFT.
    11.04.01 Betamethasone ointment 0.1% 
    12.01.01 Betamethasone Sodium Phosphate drops 0.1% Betnesol®, Vistamethasone®
    12.02.01 Betamethasone sodium phosphate drops 0.1% Betnesol®, Vistamethasone®
    12.01.01 Betamethasone sodium phosphate drops 0.1% and neomycin sulfate 0.5% Betnesol-N®
    12.02.03 Betamethasone sodium phosphate drops 0.1% with neomycin sulfate 0.5% Betnesol-N®
    11.06 Betaxolol Betoptic® Drops 0.25% and 0.5%
    11.06 Betaxolol Unit dose eye drop suspension 0.25% Betoptic® Preservative-free.

    DCHFT: Not routinely stocked.
    13.04 Betnovate®  Cream, betamethasone (as valerate) 0.1% in a water-miscible basis
    Potency: potent
    Excipients include cetostearyl alcohol, chlorocresol

    Ointment, betamethasone (as valerate) 0.1% in an anhydrous paraffin basis
    Potency: potent
    13.04 Betnovate®  Scalp application, betamethasone (as valerate) 0.1% in a water-miscible basis
    Potency: potent
    13.04 Betnovate-RD® cream  Cream, betamethasone (as valerate) 0.025% in a water-miscible basis (1 in 4 dilution of Betnovate® cream)
    Potency: moderate
    Excipients include cetostearyl alcohol, chlorocresol
    13.04 Betnovate-RD® ointment  Ointment, betamethasone (as valerate) 0.025% in an anhydrous paraffin basis (1 in 4 dilution of Betnovate® ointment)
    Potency: moderate
    08.01.05 Bevacizumab Avastin®

    For use in line with CDF criteria.

    Restricted Item Commissioned by NHS England for neurofibromatosis by NHS England as per national protocol (see NF2 service specification) at specialist centres only.

    11.08.02 Bevacizumab 1.25mg/0.05ml syringe for intravitreal injection 

    unlicensedUnlicensed

    Restricted Item RBCH: Approved for Eye specialist use in the following indications where there is no licensed product available:

    • Iris/drainage angle neovascularization - single injection
    • Pre-operative use to reduce the risk of vitreous hemorrhage during vitreoretinal surgery - single injection
    • Treatment of choroidal neovascularisation non-age related macular degeneration (AMD) or myopic CNV causes - repeated injection up to maximum frequency of monthly according to condition.
    • Treatment of choroidal neovascularisation due to age related macular degeneration where clinical benefit is present but patient falls outside the criteria for licensed drug treatment i.e. better than 6/12
    08.01.05 Bexarotene Targretin® When approved for an individual patient
    02.12 Bezafibrate  Tablets, modified release tablets.
    A5.02.05 Biatain Silicone ® 

    A soft, absorbent polyurethane foam pad with a vapour-permeable film backing and a silicone adhesive border.

    A5.02.05 Biatain Silicone Lite Dressings 

    All sizes 

    Biatain® Silicone Lite is a thin and ultra flexible foam dressing with gentle silicone adhesive. It can be used on a wide range of exuding wounds and is to be used whenever a thin foam dressing is needed. Biatain® Silicone Lite combines superior absorption and increased mobility.

    08.03.04.02 Bicalutamide 

    50mg - for use in advanced/metastatic disease.
    150mg - for locally advanced disease as an alternative to LHRH and also as neo-adjuvant/adjuvant treatment prior to and after radiotherapy in accordance with locally agreed criteria and shared care guideline.

     

     

    There is currently a supply problem with generic 50mg bicalutamide tablets which is expected to be resolved by the end of January 2018. GPs are requested to issue a 1 month prescription for the Casodex brand in the interim as this remains available at present.

    11.06 Bimatoprost drops 0.01% Lumigan®

    0.01% is only strength on formulary

    11.06 Bimatoprost drops 300micrograms/ml with timolol 5mg/ml Ganfort® Includes preservative-free option where appropriate.

    DCHFT: Preservative free option - Consultant only and in patients with proven intolerance to preserved eye drops.
    12.03.05 BioXtra®  Gel, lactoperoxidase, lactoferrin, lysozyme, whey colostrum, xylitol and other ingredients
    06.01.01.02 Biphasic Insulin Aspart NovoMix® 30
    06.01.01.02 Biphasic Insulin Lispro Humalog® Mix Humalog®Mix25
    Humalog®Mix50
    06.01.01.02 Biphasic Isophane Insulin Humulin® M3
    01.06.02 Bisacodyl  Tablets, suppositories.
    Tablets most cost effective option as at Feb'2015
  • Alternative prescribing option.
  • 01.03.03 Bismuth subsalicylate Pepto-Bismol®

    As part of Helicobacter pylori eradication quadruple therapy in resistant cases ( unlicensed unlicensed).

    The recommended dose of 525mg QDS is equivalent to:

    • Pepto-bismol SUSPENSION 30ml QDS (this is blacklisted in primary care)
    • Pepto-bismol TABLETS 2 tabs QDS
    02.04 Bisoprolol  Tablets.
    02.08.01 Bivalirudin Angiox® Injection.
  • Cardiology use only in accordance with NICE TA230.

  • See commissioning statement for bivalirudin.
  • DCHFT: Consultant use only, in accordance with NICE TA230 (ST elevated myocardial infarction) or for anticoagulant patients who develop heparin induced thrombocytopeania (HIT).
  • 08.01.02 Bleomycin  In addition to licensed indications, approved at RBCH for treatment of venous malformations by Interventional Radiology unlicensedunlicensed
    08.02.03 Blinatumomab Blincyto®

    In accordance with NICE TA450 for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia.

    12.03.01 Bonjela®  

    Choline salicylate dental gel

    13.08.01 Borderline Substances Anthelios® Anthelios® XL SPF 50+ Melt-in cream is a borderline substance and regarded as a drug when prescribed for skin protection against ultraviolet radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photodermatoses, including vitiligo and those resulting from radiotherapy; chronic or recurrent herpes simplex labialis. Preparations with SPF less than 30 should not normally be prescribed
    08.01.05 Bortezomib Velcade®

    In accordance with NICE TA (TA129, TA228, TA311) or CDF policy.

    02.05.01 Bosentan Tracleer® Only to be initiated by approved Tertiary Centres in accordance with NHS England commissioning policies for Pulmonary Hypertension.
    08.01.05 Bosutinib Bosulif®

    Commissioned by NHS England in line with NICE TA401.

    04.07.04.02 Botulinum Toxin Type A 
    04.09.03 Botulinum Toxin Type A  For all commissioned indications, use in accordance with the Interim Criteria Based Access Protocol and the access protocol for overactive bladder.

    When used for migraine also in accordance with recommendations of NICE TA 260.

    Preparations are not interchangeable and should be used under specialist supervision.

    Commissioned by NHS England for use in focal spasticity in children according to agreed Trust Guidelines, but not routinely commissioned for intravesical use in spinal cord injury in new patients.

    13.12 Botulinum toxin type A  Botox® For severe axillary hyperhidrosis that has not responded to topical therapy in accordance with local guidelines
    14.04 Botulism antitoxin  Specialist clinics only

    DCHFT: Not routinely stocked.
    08.01.05 Brentuximab vedotin Adcetris®

    Commissioned by NHSE in line with NICE TA478 and TA524 recommendations.

    13.06.01 Brevoxyl® 

    Cream, benzoyl peroxide 4% in an aqueous basis
    Excipients include cetyl alcohol, fragrance, stearyl alcohol

    For use within acne guideline when required in combination with antibioticsFor use within acne guideline when required in combination with antibiotics

    Self Care Self Care Medicine

    Not RBCH

    13.06.03 Brimonidine Tartrate Mirvaso® A routine European review has identified post-marketing reports of systemic cardiovascular effects including bradycardia, hypotension and dizziness. Warn patients not to apply the gel to irritated or damaged skin, including after laser therapy. For more information refer to MHRA link below.
    11.06 Brimonidine tartrate drops 0.2% 
    11.06 Brinzolamide 10mg / Brimonidine 2mg Eye Drops Simbrinza® For recommendation by Glaucoma specialists only as a precursor or to avoid a Trabeculectomy.
    11.06 Brinzolamide drops 10mg with timolol 5mg/ml Azarga® Consultant ophthalmologist
    11.06 Brinzolamide drops 10mg/ml Azopt®
    13.05.03 Brodalumab Kyntheum® 210 mg Solution for Injection
    06.07.01 Bromocriptine  1st line use in pregnancy
    03.02 Budesonide  Inhaler, nebuliser solution.
    Alternative prescribing option.
    03.02 Budesonide / Formoterol Fobumix®

    For use within its licensed indications for asthma and COPD

    01.05.02 Budesonide capsules Budenofalk®
  • Capsules containing EC granules - standard release (thrice daily administration).
  • Prescribe by brand name.

  • For patients with active Crohn's disease who are at high risk of corticosteroid side effects with, or intolerant of conventional steroids (e.g. prednisolone).
    01.05.02 Budesonide CR capsules Entocort®
  • MR Capsules - once daily administration.
  • Prescribe by brand name.
  • MR capsules not stocked at RBCH

    For patients with active Crohn's disease who are at high risk of corticosteroid side effects with, or intolerant of conventional steroids (e.g. prednisolone).
  • 03.02 Budesonide/Formoterol DuoResp Spiromax®


    *prescribe by brand to ensure the patient receives the same inhaler at each dispensing*

    If generic prescription - patients should be supplied with the combination inhaler they have been using or trained in 

    March 2018: Non Formulary for new initiations

    03.02 Budesonide/Formoterol Symbicort®

    Inhalers.

    200/6 metered dose inhaler, licensed for COPD only.

    200/6 and 400/12 turbohalers are licensed for COPD and asthma.

    100/6 turbohaler, licensed for asthma only.

    *prescribe by brand to ensure the patient receives the same inhaler at each dispensing*

    For generic prescription - patients should be supplied with the combination inhaler they have been using or trained in.

    02.02.02 Bumetanide  Tablets.
    15.02 Bupivacaine and Adrenaline  Bupivacaine 0.25% + Adrenaline 1 in 200,000 Injection.
    Bupivacaine 0.5% + Adrenaline 1 in 200,000 Injection.
    15.02 Bupivacaine hydrochloride Marcain® 0.25% and 0.5% injections.
  • DCHFT: 0.5% injection only.
  • RBCH also: Bupivacaine 0.15% in Sodium Chloride 0.9% Epidural Infusion.
  • 15.02 Bupivacaine Hydrochloride with Glucose Marcain Heavy® 0.5% Injection.
    04.10.03 Buprenorphine Subutex®

    Sublingual tablets.

    Red for substance misuse as per DMAG March 2018

    04.10.03 Buprenorphine and Naloxone Suboxone® For Specialist Use Only
    04.10.02 Bupropion  Tablets.
    As an adjunct to smoking cessation in combination with motivational support in accordance with NICE recommendations (PH45).
    06.07.02 Buserelin Suprefact® Nasal spray and injection
    08.03.04.02 Buserelin Suprefact®
    08.01.01 Busulfan Myleran®, Busilvex®
    03.04.03 C1 esterase inhibitor Berinert®, Cinryze® Injection.

    Acute Treatment or Short-term prophylaxis prior to planned procedures for Hereditary Angioedema and Acquired Angioedema
  • In accordance with NHS England commissioning policy
  • May only be initiated by (or on advice of) Specialist Centres - locally this centre is University Hospitals of Southampton
  • Drug costs for emergency use in other hospitals will be reimbursed through the Specialist Centre


  • Prophylactic treatment of hereditary angioedema (HAE) types I and II
  • In accordance with NHS England commissioning policy in patients who fail, are intolerant or have contra-indications to oral prophylactic therapies.
  • May only be initiated by Specialist Centres (local centre is University Hospital of Southampton)
  • Prior approval must be given via Blueteq system
  • 08.01.05 Cabazitaxel Jevtana®

    Commissioned in accordance with NICE guidance.

    06.07.01 Cabergoline 
    08.01 Cabozantinib Cometriq® Commissioned by CDF (for cancer) as per CDF policy.
    08.01.05 Cabozantinib Cometriq®, Cabometyx®

    Cabometyx®:

    • Commissioned by NHSE in accordance with NICE TA463 for the treatment of previously treated advanced renal cell carcinoma.
    • Commissioned by CDF in line with CDF criteria and NICE TA542 for the treatment of untreated locally advanced or metastatic renal cell carcinoma.
    • Patients initiated on the Named Patient Programme should remain on free of charge stock for the duration of their treatment.

    Cometriq®:

    • Commissioned in accordance with NICE TA516 for the first line treatment of medullary thyroid cancer.
    03.05.01 Caffeine citrate  Infusion.
    NICU/SCBU only.
    13.05.02 Calcipotriol Non-proprietary Ointment, calcipotriol 50 micrograms/g
    Note Not licensed for use in children under 18 years
    13.05.02 Calcipotriol Non-proprietary Scalp solution, calcipotriol 50 micrograms/mL
    13.05.02 Calcipotriol and Betamethasone cutaneous foam Enstilar ®

    One gram of cutaneous foam contains 50 micrograms of calcipotriol (as monohydrate) and 0.5 mg of betamethasone (as dipropionate).

     

    Not stocked at RBCH

    13.05.02 Calcipotriol and betamethasone dipropionate ointment Dovobet® In accordance with the local guideline for prescribing in stable plaque psoriasis in adults.

    Ointment, betamethasone 0.05%, calcipotriol (as monohydrate) 50 micrograms/g. Excipients include butylated hydroxytoluene.

    Gel; betamethasone 0.05%, calcipotriol (as monohydrate) 50 micrograms/g.

    RBCH: Gel and Ointment not stocked
    DCHFT: Ointment only.
    09.05.01.02 Calcitonin  Calcitonin can be used for the treatment of hypercalcaemia associated with malignancy

    DCHFT: Restricted Item  Renal consultant only.
    06.06.01 Calcitonin (salmon) / Salcatonin (Miacalcic®) For hypercalcaemia of malignancy
    06.06.01 Calcitonin (salmon) / Salcatonin Miacalcic® For prevention of acute bone loss due to sudden immobility
    09.06.04 Calcitriol  Injection = Red
    09.06.04 Calcium 1000mg and colecalciferol 880iu chewable tablets Theical D3
    09.05.01.01 Calcium 5.1mmol / 10ml syrup Alliance Calcium Syrup® Replaces Calcium Sandoz syrup
    09.05.02.02 Calcium Acetate Phosex®
    09.06.04 Calcium and Ergocalciferol 

    DCHFT: Local formulary states that there is insufficient calcium for prevention of osteoporosis.

    09.05.01.01 Calcium carbonate Adcal®
    09.05.02.02 Calcium Carbonate 
    09.06.04 Calcium carbonate and colecalciferol Calceos®

    2nd line option at RBCH for patients intolerat of Adcal D3

    09.06.04 Calcium Carbonate with Colecalciferol Cacit® D3

    Not at DCHFT and RBCH

    09.05.01.01 Calcium Chloride  IV injection/infusion
    18 Calcium chloride injection  For calcium channel blocker overdose and systemic effects of hydrofluoric acid.
    08.01 Calcium Folinate  DCHFT: 15mg and 350mg injections and 15mg tablets available.
    18 Calcium folinate  For methotrexate overdose or poisoning and methanol or formic acid poisoning.
    18 Calcium gluconate  Injection (by local infiltration) and gel (topically) for hydrofluoric acid burns.

    RBCH: Gel kept in ED Resus
    09.05.01.01 Calcium Gluconate injection 
    09.05.01.01 Calcium lactate  Not DCHFT and RBCH.
    09.05.01.01 Calcium-Sandoz® liquid  Now discontinued. Use Alliance Calcium Syrup
    A2.04.01.02 Calogen Extra®  

    Energy supplement.

    To be used under direction of dietitian only.

    Paediatric patients: not suitable in children under the age of 3, use with caution in children aged 3-6 years. 

    A2.04.01.02 Calogen Extra® shots 

    Energy supplement.

    Calogen and Calogen extra contain some vitamins & minerals

    To be used under direction of dietitian only.

    Paediatric patients: not suitable in children under the age of 3, use with caution in children aged 3-6 years. 

    A2.04.01.02 Calogen®  

    Energy supplement.

    Calogen and Calogen extra contain some vitamins & minerals 

    To be used under direction of dietitian only.

    Dilute before use in child under the age of 5.

    A2.04.01.02 Calshake®  

    Generally use as a second choice to 1.5kcal/ml sip feeds as not nutritionally complete. However these supplements do provide more calories per ml approx. 600kcal in 250ml so useful for those with very high calorie needs (when reconstituted with whole milk) e.g. CF Patients

    06.01.02.03 Canagliflozin Invokana®

    Green When used as monotherapy or with oral hyperglycaemics in patients with Type 2 Diabetes
     
     Amber When used in combination with insulin

     

    08.02.04 Canakinumab Ilaris® Commissioned by NHS England as per Cryopyrin Associated Periodic Syndrome service specification.

    Not routinely commissioned by NHS England for juvenile arthritis - see NICE TA302.
    02.05.05.02 Candesartan  Tablets.
  • For heart failure.
  • 13.04 Canesten HC®  Cream, hydrocortisone 1%, clotrimazole 1%
    Potency: mild
    Excipients include benzyl alcohol, cetostearyl alcohol
    13.09 Capasal® 

    Restrict to where moderate to severe skin condition requires it (not for cradle cap)

    Shampoo, coal tar 1%, coconut oil 1%, salicylic acid 0.5%

    Self Care Self Care Medicine

    08.01.03 Capecitabine 
    12.03.01 Caphosol  Paediatrics only
    Only at PHFT and DCHFT.

    DCHFT: Restricted Item Paediatric patients undergoing intensive mucositis inducing chemotherapy.

    Mouth Rinse. Caphosol comprises two
    separately packaged aqueous solutions, (Caphosol A) and (Caphosol B) which when combined, forms a solution supersaturated with calcium and phosphate ions.
    Ingredients : Dibasic Sodium Phosphate 0.032, Monobasic Sodium Phosphate 0.009, Calcium Chloride 0.052, Sodium Chloride 0.569, Purified water qs (%w/w)

    10.03.02 Capsaicin 179mg cutaneous patch Qutenza®
    02.05.05.01 Captopril  Tablets, liquid.
  • Restricted Item  Restricted for paediatric or diagnostic use only.
  • 04.02.03 Carbamazepine 
    04.07.03 Carbamazepine  Tablets, chewable tablets, modified release tablets, liquid, suppositories.
    For trigeminal neuralgia.
    04.08.01 Carbamazepine  Tablets, modified release tablets, liquid, suppositories.
    Options based on licence.

    Category 1: ensure patient is maintained on a specific manufacturer's product.

    Tegretol Chewtabs discontinuation: 100mg tablet was depleted by the end of October 2014 and 200mg tablet expected to be depleted by May 2015.
    06.02.02 Carbimazole 
    03.07 Carbocisteine  Capsules, liquid.

    Restricted Item  DCHFT: Initiation restricted to consultant respiratory specialist only.
    13.05.02 Carbo-Dome®  Cream, coal tar solution 10%, in a water-miscible basis
    Excipients include beeswax, hydroxybenzoates (parabens)

    Not RBCH
    11.08.01 Carbomer 980 Gel  RBCH: Viscotears®
    08.01.05 Carboplatin 
    07.01.01 Carboprost 
    08.01.05 Carfilzomib Kyprolis®

    Commissioned in accordance with NICE TA457.

    09.08.01 Carglumic Acid Carbaglu® Commissioned by NHS England in urea cycle disorders. For initiation by specialist centres only as per NHS England Service Specification.
    11.08.01 Carmellose drops 0.5%   Preservative free

    NOT RBCH - if admitted on this convert to alternative lubricant.
    12.03.01 Carmellose Sodium Orabase®
    08.01.01 Carmustine Gliadel® Carmustine implants recommended as a possible treatment for people with newly diagnosed high-grade glioma only if 90% or more of their tumour has been removed.

    Carmustine implants are not recommended for people with newly diagnosed high-grade glioma if less than 90% of their tumour has been removed.

    A2.05.02 Carobel, Instant®  
    02.04 Carvedilol  Tablets.
    Specialist initiation.
  • DCHFT: Restricted Item  Restricted as adjunct for treatment of patients with heart failure. Not for routine post-acute myocardial infarction use.
  • 05.02.04 Caspofungin Generic, Cancidas®

    Generic drug should be used where possible

    For microbiology or haematology use only.

    Commissioned by NHS England for fungal infection according to agreed Trust Guidelines.

    23.16 Catheter Bags and Sleeves 
    Company Product codes and sizes Price per unit Comments
    Optium
    • Small - 3005
    • Medium - 3006
    • Large - 3007
    • Extra Large - 3008
    1.82 Comes with a wash bag and instructions.
    Clinisupplies
    • Small - PL53881
    • Medium - PL53904
    • Large - PL53928
    1.87

    Soft feel.

    Washable

     

    23.12 Catheter leg bags and night bags 
    Company Product Codes Price per unit Comments
    Convatec / Unomedical

    Day Bags:

    Available in short & long tubes, 500ml and 700ml

    T-tap 500ml

    • 45-05-SVCG - Short
    • 46-06-LVCG - Long

    Lever tap 500ml

    • 46-05-SVCG - Short
    • 46-06-LVCG - Long

    Night Bags:

    • 47-60 LBH (single use)
    • 46-20 INCG (drainable)

    2.57 (Box of 10)

     

     

     

     

     

     

     

    1.16 (Box of 10)

    Supplied by local hospitals to patients on discharge.

    Easy use taps, good instructions and sample port.

    Variety of taps and gloves with sterile bags.

    Good for Care Homes

    Qufora

    Day Bags:

    Sizes - 350ml, 500ml & 750ml are available in lever tap and T-tap, short and long tubes. Codes:

    Lever Tap

    500ml 

    • 12161804 Short
    • 12161504 Long

    T-tap

    500ml

    • 12151804 Short
    • 12151504 Long

    Night Bags

    • 14851204 (drainable)
    • 13803104 (single use)

    2.24 (Box of 10)

     

     

     

     

     

     

     

     

     

    0.97

    0.49

    Bed clip, tap and good instructions.

    3 litre bag also abailable in the range

     

    23.07 Catheter Maintenance Solutions 
    Company Product Price Per Unit Comments
    B Braun

    Uro-Tainer NaCl 0.9% 50ml

    Uro-Tainer Twin Suby G 2x30ml

    Uro-Tainer Twin Solution R 2x30ml

    3.48

     4.76

    4.76

    Preferred product as solution needs to drip into catheter.

    For Suby G and R solutions, catheters need to be inspected for encrustation by cutting down the length of the catheter after removal.

    Linc Medical Bladder Infusion Kit MC1/701 1.99 (Box of 10 (19.90) These are for administrating catheter maintenance solutions if used more than once a week.  The solution can be administered via the sample port rather than removing the bag every time and reducing the need to use more than one bag per week.

     

    23.15 Catheter Valves 
    Company Product Codes Price per unit Comments
    Qufora 21104204 1.70 Box of 5
    Linc Medical CF1 1.50 Box of 5

     

    23.10 Catheterisation packs - Cath-it (including catheter removal pack)
    Company Product Codes Price per unit Comments
    Richardson Health

    Sizes:

    Small-Medium Gloves 908410

    Medicum-Large Gloves 908420

    1.98 each Contains 3 pairs of gloves

     

    13.09 Ceanel Concentrate® 

    Restrict to where moderate to severe skin condition requires it

    Shampoo, cetrimide 10%, undecenoic acid 1%

    Self Care Self Care Medicine

    05.01.02.01 Cefalexin 
    05.01.02.01 Cefixime Suprax® For paediatrics and GUM indications only.
    DCHFT: 2nd line in GUM for women who are needle phobic.
    05.01.02.01 Cefotaxime IV  Not at RBCH.
    DCHFT: Restricted Item For use in paediatrics only.
    11.03.01 Ceftazidime 5% drops  Preservative-free
    unlicensedunlicensed

    Not DCHFT.
    05.01.02.01 Ceftazidime Injection  RBCH: On microbiology advice only
    05.01.02.01 Ceftazidime with Avibactam Zavicefta®

    Approved at RBCH and PHT only when recommended by a Consultant Microbiologist

    05.01.02.01 Ceftriaxone IV  RBCH: 1st line for suspected meningitis
    05.01.02.01 Cefuroxime Zinacef® RBCH: Oral formulations not available - use cefalexin
    DCHFT: Oral formulations not available - use cefalexin
    11.03.01 Cefuroxime drops 5%  Preservative-free
    unlicensedunlicensed

    RBCH: Store in freezer until required for use.
    DCHFT: Consultant use only. Unlicensed cefuroxime 5% kits available. Unlicensed frozen storage product not routinely stocked.
    05.01.02.01 Cefuroxime IV Zinacef®
    10.01.01 Celecoxib Celebrex® There is no good evidence to support the use of coxibs alone instead of NSAIDs co-prescribed with a PPI. Coxibs also have a higher CV risk than ibuprofen 1200mg/day or naproxen 1000mg/day (MeReC Extra no.30, Nov 2007).
    07.03.02.01 Cerazette®  Desogestrel 75 micrograms.

    DCHFT: Not stocked.
    08.02.03 Ceredase® Alglucerase Trusts are responsible for making the necessary arrangements for patients to receive intravenous treatment.
    08.01.05 Ceritinib Zykadia®

    Commissioned by NHS England in line with NICE TA395 and TA500.

    09.03 Cernevit®  Not DCHFT.
    10.01.03 Certolizumab Pegol Cimzia® Use in accordance with NICE guidance and local pathways for RA, AS or PSA.

    Not routinely commissioned by NHS England for paediatric indications - see NHS England drugs list.
    03.04.01 Cetirizine  Tablets, syrup.
    13.02.01 Cetraben® 

    Emollient cream; white soft paraffin 13.2%, light liquid paraffin 10.5%
    Excipients include cetostearyl alcohol
    Hydroxybenzoates (parabens) are no longer included as an excipient as per up to date SPC from manufacturer - BNF in the process of being updated.

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.

     

    13.02.01.01 Cetraben® 

    Reserved for patients with severe eczema and infants under the age of 1 year. 

    Emollient bath additive, light liquid paraffin 82.8%

    Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation.

    Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required

     

    08.01.05 Cetuximab Erbitux®

    For use in line with NICE TA recommendations.

    08.01 Chemotherapy drugs  Commissioned by NHS England/CDF as per Trust Guidelines, NICE/CDF policy.
    04.01.01 Chloral Hydrate 
    04.01.01 Chloral Hydrate 500mg in 5mL 
    08.01.01 Chlorambucil Leukeran®
    11.03.01 Chloramphenicol drops 0.5% 
    11.03.01 Chloramphenicol ointment 1% 
    05.01.07 Chloramphenicol oral or IV  PHT: For microbiology use only.

    RBCH: IV in accordance with local policy; Oral on microbiology advice only.

    DCHFT: IV in accordance with local policy (e.g. as per meningitis guideline). Otherwise, on microbiology advice only.
    04.01.02 Chlordiazepoxide  For alcohol withdrawal.
    13.11.02 Chlorhexidine  Various preparations available - see BNF
    13.11.02 Chlorhexidine 0.015% with Cetrimide 0.15% Tisept®; Travasept100®
    07.04.04 Chlorhexidine 0.02% 
    13.11.02 Chlorhexidine 2% in Isopropyl Alcohol 70% ChloraPrep® Not DCHFT.
    11.03.01 Chlorhexidine Digluconate 0.03% drops  unlicensedUnlicensed

    Not DCHFT.
    12.03.04 Chlorhexidine gluconate dental gel 1%  Also used as part of oral hygiene protocols for ventilated patients in Critical Care to prevent VAPunlicensedUnlicensed
    12.03.04 Chlorhexidine gluconate mouthwash 0.2% 
    15.02 Chloroprocaine Ampres® Injection.
  • Restricted Item DCHFT: Spinal anaesthesia in adults where the planned surgical procedure should not exceed 40 minutes.
  • 05.04.01 Chloroquine 
    02.02.01 Chlorothiazide  Suspension.
    unlicensedUnlicensed
    Suspension 250mg/5ml for paediatric use only. Available as an unlicensed import.
    03.04.01 Chlorphenamine (Chlorpheniramine)  Tablets, syrup.
    Sedating option
    04.02.01 Chlorpromazine  Hospital or specialist initiation.
    Option based on NICE guidance and licence.

    Tablet, Oral solution, Suppository.

    Use of intramuscular chlorpromazine is not recommended - can cause marked postural hypotension.
    04.06 Chlorpromazine Hydrochloride  Tablets, syrup, elixir,.
    Palliative care.
    04.06 Chlorpromazine Hydrochloride Injection 
    06.05.01 Chorionic gonadotrophin Choragon®, Pregnyl®
    03.02 Ciclesonide  Alvesco® Inhaler.
    01.05.03 Ciclosporin  Capsules, injection.
  • MHRA specify that ciclosporin must be prescribed and dispensed by brand as bioavailability differences exist between brands.
  • There are a number of different indications for ciclosporin. Please see
    here for other indications.
  • Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults unlicensedUnlicensed for these indications but in line with national guidelines.
  • 08.02.02 Ciclosporin 

    Commissioned by NHS England (for transplant immunosuppression only) for new patients only until formal repatriation of existing patients to specialist centres agreed, timescales to achieve this are variable. As per Trust Guidelines. Hospital initiation.

    10.01.03 Ciclosporin 

    For rheumatoid arthritis in accordance with NICE recommendations (CG79).

    13.05.03 Ciclosporin 

    Hospital use only
    For severe psoriasis or severe eczema

    DCHFT: Ciclosporin prescribing should be brand specific. Currently DCHFT does not stock Capimune®. Neoral® is currently the brand of choice at DCHFT. Restricted Item  Consultant use only.

    11.08.01 Ciclosporin 0.1% eye drops Ikervis® In accordance with NICE TA369 and Dorset Dry Eye Pathway for severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes.

    Preservative-free

    RBCH: Consultant prescription only
    05.03.02.02 Cidofovir Vistide®

    Commissioned by NHS England (for cytomegalovirus) according to agreed Trust Guidelines.

    07.03.01 Cilest®  Ethinylestradiol 35 micrograms/Norgestimate 250 micrograms
    01.03.01 Cimetidine  Tablets.
    Specialist use only - Dermatology and Palliative Care (both 'off-label' use).
    09.05.01.02 Cinacalcet Mimpara® Commissioned by NHS England for refractory secondary hyperparathyroidism in patients with end-stage renal disease in accordance with criteria in NICE TA 117
    DCHFT - renal consultant only
    09.05.01.02 Cinacalcet  Commissioned by NHS England (for complex primary hyperparathyroidism) for specialist centres.

    04.06 Cinnarizine  Tablets.
    Antihistamine option.
    12.01.01 Ciprofloxacin ear drops (single use) 2mg/ml 

    ENT use only: Treatent of ear infection

    1st line - use licensed ear drops 1st line in ear.

    2nd line - use eye drops in the earunlicensed - Off label use (UNLICENSED ROUTE)

    12.01.01 Ciprofloxacin eye 0.3% Drops Ciloxan®

    ENT use only: Treatent of ear infection

    1st line - use licensed ear drops 1st line in ear.

    2nd line - use eye drops in the earunlicensed - Off label use (UNLICENSED ROUTE)

    05.01.12 Ciprofloxacin IV  RBCH: Strictly on microbiology advice only or in accordance with neutropenic sepsis policy

    Excellent oral bioavailability - use oral route where possible
    11.03.01 Ciprofloxacin ointment 0.3%  DCHFT: Consultant use only.
    05.01.12 Ciprofloxacin oral  RBCH: Strictly on microbiology advice only or in accordance with neutropenic sepsis policy

    DCHFT: As per antibiotic treatment guidelines only.
    15.01.05 Cisatracurium Nimbex®
  • Not RBCH.
  • DCHFT: Only stocked to cover vecuronium shortages. Used as alternative non-depolarising neuromuscular blocker with low potential for histamine release for use in those patients who are allergic/intolerant to the other more commonly used agents such as atracurium and rocuronium.


  • 08.01.05 Cisplatin 
    04.03.03 Citalopram 
    01.06.05 CitraFleet®   Oral powder.
  • Choice to be determined by Trust.

  • DCHFT: Picolax® oral powder used as alternative.
  • 08.01.03 Cladribine Leustat®, Litak®
    08.02.04 Cladribine Mavenclad®

    Commissioned by NHS England for treatment of highly active relapsing multiple sclerosis at approved centres in accordance with NICE TA493.

    05.01.05 Clarithromycin IV 
    05.01.05 Clarithromycin oral 
    19.15 Clearway Bridge  Opus Healthcare
    Product reference code 7700
    Approved pack size 30

    AMBER – Used to help prevent leaks caused by pancaking of stool when problem not solved by simple measures
    19.15 Clearway Bridge Mini  Opus Healthcare
    Product reference code 8800
    Approved pack size 30



    AMBER – Used to help prevent leaks caused by pancaking of stool when problem not solved by simple measures
    05.01.06 Clindamycin 
    13.06.01 Clindamycin 1%  Topical solution, clindamycin 1% (as phosphate), in an aqueous alcoholic basis
    Excipients include propylene glycol

    Lotion, clindamycin 1% (as phosphate) in an aqueous basis
    Excipients include cetostearyl alcohol, hydroxybenzoates (parabens
    07.02.02 Clindamycin 2% Cream Dalacin®


    Excipients include benzyl alcohol, cetostearyl alcohol, polysorbates, propylene glycol
    May damage latex condoms and diaphragms

    05.01.06 Clindamycin IV 
    A5.08.03 Clinifast 

    Tubular bandage for fixation/retention and wet and dry wrapping

    Red Line 3.5cm x 1m

    Green Line 5cm x 1m / 3m / 5m

    Blue Line 7.5cm x 1m / 3m / 5m

    Yellow Line 10.75 x 1m / 3m / 5m

    Beige Line 17.5cm x 1m

    A5.07.03 Clinipore Surgical Adhesive Tape 

    Permeable Non-Woven Synthetic Adhesive Tape BP 1988

    Hypoallergenic and strictly conforms to Drug Tariff specifications

    Clinipore is gentle on the skin, leaving minimal adhesive residue upon removal 

    Available as 1.25cm x 5m / 2.5cm x 5m / 2.5cm x 10cm and 5cm x 5m

    A5.02.08 Clinisorb  

    Odour control via activated charcoal

    CliniSorb is indicated for the management of malodorous wounds. It can be used on fungating wounds and a variety of other chronic wounds with good results.

    • CliniSorb can be cut to size if necessary
    • CliniSorb can be applied either side down
    • A secondary dressing can be applied on top of CliniSorb if appropriate
    • CliniSorb can be secured in place using adhesive tape or in a manner appropriate for the indication
    • Change when necessary
    04.08.01 Clobazam  Category 2: base the need for continued supply of a particular manufacturer's product on clinical judgement and consultation with the patient and/or carer, taking into account factors such as seizure frequency and treatment history.

    13.04 Clobetasol with neomycin and nystatin Non-proprietary Cream, clobetasol propionate 0.05%, neomycin sulfate 0.5%, nystatin 100 000 units/g
    Potency: very potent

    Ointment, clobetasol propionate 0.05%, neomycin sulfate 0.5%, nystatin 100 000 units/g
    Potency: very potent

    Not DCHFT.
    08.01.03 Clofarabine Evoltra®

    Commissioned by CDF (for cancer) as per CDF policy.

    04.01.01 Clomethiazole  See 06.05.01 Clomifene Citrate  Prescribing should fall within NICE CG156:
    • Do not offer oral ovarian stimulation agents(such as
    clomifene citrate, anastrozole or letrozole) to women
    with unexplained infertility, and
    • For women who are taking clomifene citrate, do not
    continue treatment for longer than 6 months.
    In accordance with the product SPC, 3 courses should constitute an adequate trial.
    Due to the limited length of time it is used and that patients are likely to be receiving ongoing care in a specialist setting the number of requests to pick up this prescribing in primary care should be minimal.


    04.03.01 Clomipramine 
    04.08.01 Clonazepam  Tablets.
    Options based on licence.

    Category 2: base the need for continued supply of a particular manufacturer's product on clinical judgement and consultation with the patient and/or carer, taking into account factors such as seizure frequency and treatment history.
    04.08.02 Clonazepam IV 
    02.05.02 Clonidine injection Catapres® Ampoules Injection.
  • DCHFT: Tablets on formulary. Awaiting CCG advice on traffic light categorisation (Nov 2014).
  • 02.09 Clopidogrel 

    Tablets.

    • In accordance with NICE recommendations for the use of clopidogrel in the treatment of non-ST-segment-elevation in ACS (TA80), clopidogrel should be used for up to 12 months.

     

    • Post stent insertion (unless follows acute coronary syndrome, see above):
      - clopidogrel should be used for 1 month following insertion of non-drug eluting stent.
      - clopidogrel should be used for 12 months following insertion of a drug-eluting stent.

     

     

    • Update from the Cardiology Working Group July 2017 : The interaction of omeprazole on the antiplatelet efficacy of clopidogrel is no longer considered clinically significant.
    07.02.02 Clotrimazole 
    13.10.02 Clotrimazole  Cream, clotrimazole 1%
    11.03.02 Clotrimazole drops 1%  Preservative free
    unlicensedunlicensed
    Not RBCH
    DCHFT: On formulary but not stocked.
    12.01.01 Clotrimazole topical solution 1% Canesten® Solution, clotrimazole 1% in polyethylene glycol 400 (macrogol 400).
    04.02.01 Clozapine tablets Clozaril

    To be initiated by consultant psychiatrist only. For treatment-resistant schizophrenia.
    Clozaril is also indicated in psychotic disorders occurring during the course of Parkinson's disease, in cases where standard treatment has failed.


    24 hour helpline number for CPMS 08457 698269.

    Use in accordance with NICE recommendations for the treatment and management of psychosis and schizophrenia in adults (CG178 which replaces CG82) and local shared care guideline.

    (Amber in original pilot sites.)


    13.05.02 Coal tar strong in emulsifying ointment  Extemporaneous product.unlicensedunlicensed
    13.05.02 Coal tar strong with betamethasone  Extemporaneous productunlicensedUnlicensed

    Not RBCH: prescribe coal tar and steroids separately
    05.01.01.03 Co-Amoxiclav 
    05.01.01.03 Co-Amoxiclav IV Augmentin® RBCH: On microbiology advice
    04.09.01 Co-Beneldopa  Capsules, dispersible tablets, modified release capsules.
    = Benserazide/Levodopa.
    05.03.01 Cobicistat Tybost® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs).
    15.02 Cocaine 
  • DCHFT Only: 10% sterile nasal solution. unlicensedUnlicensed.
  • 11.07 Cocaine 4% Eye Drops  unlicensedUnlicensed
    For diagnosis of Horner's syndrome

    DCHFT: Not routinely stocked.
    04.09.01 Co-Careldopa  Tablets, modified release tablets.
    = Carbidopa/levodopa.
    04.09.01 Co-Careldopa and Entacapone Stalevo® Tablets.
    In accordance with local guidance on drug treatment of Parkinson's disease and shared care guidance.
    04.09.01 Co-Careldopa Intestinal gel Duodopa® Hospital only.

    Use following individual patient funding approval. For use with enteral tube. Commissioned by NHS England (for PD) but not routinely.
    04.07.01 Co-Codamol 

    Co-Codamol Soluble are considered 2nd Line

    13.06.02 Co-Cyprindiol 2000/35  Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms (equiv. Dianette®).
    01.06.02 Co-danthramer  Capsules, suspension.
  • Restricted Item For relief of constipation in palliative care.


  • DUE TO BE DISCONTINUED
    01.06.02 Co-danthrusate  Capsules.
  • Restricted Item For relief of constipation in palliative care.
  • 01.04.02 Codeine phosphate  Tablets.
    Alternative prescribing option.
    04.07.02 Codeine Phosphate  Tablets, linctus.
    04.07.01 Co-dydramol 

    Tablets.

    Updated Information February 2018: Previously co-dydramol (dihydrocodeine/paracetamol) was available only in the ratio 1:50 (co-dydramol 10/500 mg). Two additional products are now available with a higher strength of dihydrocodeine (codydramol 20/500 mg and 30/500 mg tablets). It is therefore important that co-dydramol products are prescribed and dispensed by strength to minimise dispensing errors and the risk of accidental opioid overdose.

    19.04 Cohesive Paste®   Pelican Healthcare Ltd
    Product reference code 839010
    Approved pack size 60g
    19.07 Cohesive slims washer small®   Pelican Healthcare Ltd
    Product size:48mm. Product reference code:839005
    Pack size:30
    10.01.04 Colchicine 
    09.06.04 Colecalciferol 20,000 units 

    In accordance with local guidance for the management of vitamin D deficiency and insufficiency in adults. Note dose is WEEKLY.

    Prescribers should use a LICENSED brand (e.g.Fultium D3®; Aviticol®;Plenachol®).


    Many other 20,000unit preparations are available(e.g.Pro D3®, Dekristol®). These do not have a marketing authorisation as they are marketed as nutritional supplements.unlicensedunlicensed

    09.06.04 Colecalciferol 800 units 

    Prescribers should use a LICENSED product (e.g.  Fultium D3®, Invita D3®;Desunin®)

    In accordance with local guidance for the management of vitamin D deficiency and insufficiency in adults.

    09.06.04 Colecalciferol and Calcium Carbonate Calcichew-D3®

    Not at DCHFT and RBCH.

    09.06.04 Colecalciferol and Calcium Carbonate Calcichew-D3® Forte

    Not at DCHFT and RBCH.

    09.06.04 Colecalciferol oral drops 2740 units/ml Fultium D3®,
    01.09.02 Colesevelam Cholestagel® For Bile Acid Malabsorption as a second line option where colestyramine has been found to be not effective or not tolerated.
    01.09.02 Colestyramine  Powder.
  • Currently supply problems since July 2013 with standard colestyramine, colestyramine 'light' may have to be used instead.
  • 02.12 Colestyramine  Sachets.
  • Long term shortage.
  • Colestyramine 'light' may have to be used instead.
  • 05.01.07 Colistimethate for nebulisation Colomycin®, Colistin®, Promixin®

    Commissioned by NHS England for use in CF as per policy A01/P/b.

    Amber SCG 

    • If provided by primary care for Cystic Fibrosis prior to April 2013 as per shared care guidelines.
    • For non-cystic fibrosis bronchiectasis as per shared care guidelines (Colomycin brand only).


    Red 

    For CF patients initiated after April 2013:

    • Adult patients: specilaist centres only.
    • Paediatric patients: PHFT use in line with network arrangements with UHS.
    05.01.07 Colistimethate inhaler Colobreathe®

    Commissioned by NHS England for use in CF as per policy A01/P/b and NICE TA276.

    Adult patients: specialist centre only (University Hospital Southampton)

    Paediatric patients: PHFT use in line with network arrangements with UHS.

    Not at DCH or RBCH.

    10.03.01 Collagenase Xiapex® For use in Dupuytren's Contracture in line with the existing criteria for access to treatment within the policy for common hand conditions.
    07.03.01 Combined Hormonal Contraceptives Evra® Transdermal combined contraceptive patch, which contains norelgestromin and ethinyloestradiol.

    Refer to local guidance.

    DCHFT: On local formulary.
    A5.02.04 Comfeel Plus Transparent Dressing  

    Comfeel Plus Transparent is a thin and flexible hydrocolloid dressing.

    Key benefits:

    • Transparency for wound inspection
    • Flexibilty to dress any part of the body
    A2.02.02.03 Complan® Shake 

    The calories are based on a sachet made up with 200ml of full cream milk and contain approx. 385 kcals.

    If your patient likes milky drinks prescribe as a supplement to diet 1-2 servings/day.

    Not suitable for patient with cow’s milk intolerance or galactosaemia. Not nutritionally complete.

    If your patient dislikes milky drinks choose from the juice style supplements instead.

    09.02.02.01 Compound Sodium Lactate Intravenous Infusion Compound Hartmann's Solution for Injection RBCH: 1st line for fluid resuscitation
    DCHFT: Rarely used
    13.07 Condyline®  Hospital use only
    Solution, podophyllotoxin 0.5% in alcoholic basis
    03.04.03 Conestat Alfa Ruconest® Commissioned by NHS England for Hereditary Angioedema (acute treatment only) and Acquired Angioedema for acute treatment or short-term prophylaxis prior to planned procedures. See NHS England Policy B09/P/b.

    Restricted Item May only be initiated by (or on advice of) Specialist Centres where:
  • there is a contraindication to the use of C1 esterase inhibitor derived from blood products(for obstetric, religious or medical reasons)

  • the specialist determines that it will be more cost effective or clinically effective than the alternatives


  • Drug costs for emergency use in other hospitals will be reimbursed through the Specialist Centre
    07.04.05 Constrictor rings for erectile dysfunction  Hospital initiation only.

    DCHFT: Not Pharmacy.
    06.01.06 Contour® Test Strips 
    05.01.08 Co-trimoxazole IV Septrin®
    05.01.08 Co-trimoxazole oral Septrin®
    08.01.05 Crisantaspase 
    08.01.05 Crizotinib Xalkori®

    Commissioned by CDF in line with CDF criteria and NICE TA529 and NHS England in line with NICE TA406 and TA422.

    13.02.02 Cutimed Protect Cream® 
    • Protects wound margins and peri-wound skin from external factors including wound exudate, incontinence and friction, caused by urinary and/or faecal incontinence
    • Preserves and maintains intact or irritated skin by building a moisture barrier with good permeability to oxygen and water vapour
    • Prevention of incontinence dermatitis
    • Prevents maceration by providing up to 96 hours of moisture barrier action
    • Effective adjunctive skin therapy during treatment of chronic wounds  e.g. venous or arterial, diabetic foot or pressure ulcers, or whenever skin requires a protective shield
    13.02.02 Cutimed Protect Spray® 

    Enables easy, even application over a wide area to protect peri-wound and irritated skin.

    Alcohol and irritant free, non-stinging solution

     

    A5.03 Cutimed Sorbact Gel Dressings 

    Cutimed Sorbact gel dressings reduce bacterial load in a wound by combining Cutimed Sorbact swab with an amorphous hydrogel to support moist wound healing in lower exuding or sloughy wounds. 

    Available as 7.5cm x 15cm and 7.5cm x 7.5cm

     

    A5.03 Cutimed Sorbact Ribbon 

    Cutimed Sorbact can be used for all contaminated, colonised and infected, exuding wounds such as pressure, diabetic foot and venous leg ulcers. Also suitable for traumatic and post-operative wounds.

    Available as 5cm x 200cm and 2cm x 50cm

    A5.03 Cutimed Sorbact Swabs 

    All sizes approved for addition to the Joint Wound Formulary April 2018

    A5.02.02 C-View®  

    Conformable, self-adhesive film which provides a water and bacteria proof barrier for wounds with little or no exudate.

    All sizes are on the formulary

    04.06 Cyclizine  Tablets.
    Antihistamine option.
    21 Cyclizine  
    04.06 Cyclizine Injection  Formulary status does not apply for palliative care indications.
    11.05 Cyclopentolate Hydrochloride drops 0.5%  Not RBCH
    11.05 Cyclopentolate Hydrochloride drops 1% 
    08.01.01 Cyclophosphamide 
    10.01.03 Cyclophosphamide  IV and oral
    18 Cyproheptadine Periactin® Anticholinergic (antimuscarinic) antihistamine used in serotonin syndrome.

    RBCH: kept in EDC and pharmacy
    06.04.02 Cyproterone Acetate 
    08.03.04.02 Cyproterone Acetate 
    08.01.03 Cytarabine 
    02.08.02 Dabigatran Pradaxa® Capsules.
  • For prevention of stroke or systemic embolism in patients with AF within NICE TA249 and local guidance, as per licensed indications.

  • 02.08.02 Dabigatran Pradaxa® Capsules.
  • For the prevention of venous thromboembolism after hip or knee replacement surgery in adults, in accordance with NICE TA157.
  • RBCH:1st line option is dalteparin.
  • DCHFT: 1st line option is enoxaparin.


  • 02.08.02 Dabigatran  Pradaxa ® For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE TA327
    02.08.02 Dabigatran Pradaxa®

    Red

    • In accordance with NICE TA for prevention of VTE in patients undergoing hip or knee replacement surgery, as per licensed indications.
      • Note routine 1st line option at RBCH and DCH is LMWH

    Green

    • For prevention of stroke or systemic embolism in patients with AF within NICE TA and local guidance, as per licensed indications.
    • For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE TA. 

     

    08.01.05 Dabrafenib Tafinlar®

    Commissioned by NHS England in line with NICE TA321 and TA396.

    Commissioned by CDF in combination with trametinib for adjuvant treatment of resected BRAF V600 positive malignant melanoma as per CDF criteria and NICE TA544.

    08.01.05 Dacarbazine 
    05.03.03.02 Daclatasvir Daklinza®

    Treatment of hepatitis C commissioned in line with latest rate card from NHS England.

    08.01.02 Dactinomycin 
    13.04 Daktacort® cream  Cream, hydrocortisone 1%, miconazole nitrate 2%
    Potency: mild
    Excipients include butylated hydroxyanisole, disodium edetate
    13.04 Daktacort® ointment  Ointment, hydrocortisone 1%, miconazole nitrate 2%
    Potency: mild
    13.10.02 Daktarin®  Cream, miconazole nitrate 2%
    Excipients include butylated hydroxyanisole
    05.01.07 Dalbavancin 

    PHFT: 

    For treatment of cellulitis when approved by microbiology

    For treatment of bone and joint infections (including spinal abscess, discitis, osteomyelitis and septic arthritis) when approved by microbiology and who are suitable for discharge and:

    • Compliance with daily IV or oral antibiotics is likely to be an issue and are therefore at risk of treatment failure and readmission
    • Discharge with an IV cannula is likely to be a risk e.g. IVDU
    • Is likely to decline treatment / self-discharge and therefore likely to have repeated readmissions
    • Are identified as suitable for early discharge in which oral antibiotics would not be appropriate and were not requiring any other medical/therapy interventions.
    09.06.07 Dalivit® 

    RBCH Tube-fed /Swallowing difficulites who would otherwise require Sanatogen A-Z

    02.08.01 Dalteparin Fragmin®

    Green for DVT in patients who are intravenous drug users.

    Specialist initiation:

    Amber Please use in accordance with the relevant local shared care guidance.

    Red for specialist indications, e.g. prevention of clotting in the extracorporeal circuit during haemodialysis, not listed above

     

    • RBCH and PGH.
    • DCHFT: Dalteparin not routinely used.

     

     

    02.08.01 Danaparoid Orgaran® Injection.
    For consultant use only on haematological advice.
    06.07.02 Danazol 
    19.01 Dansac EasiSpray™ adhesive remover  Dansac Ltd
    Product Reference Code 083-01
    Approved Pack Size 50ml
    19.01 Dansac non-sting adhesive remover spray™  Dansac Ltd
    Product reference code 082.01
    Approved pack size 50ml
    18 Dantrolene IV  For malignant hyperthermia, neuroleptic malignant syndrome (NMS). Other drug related pyrexia seek NPIS advice.

    RBCH: Kept in ITU and Theatres
    10.02.02 Dantrolene sodium  Specialist use.

    DCHFT: Specialist / Consultant use only.
    15.01.08 Dantrolene sodium Dantrium Intravenous® Injection.
    06.01.02.03 Dapagliflozin Forxiga®

    Green When used with oral hyperglycaemics in patients with Type 2 Diabetes
     
     Amber When used with insulin in patients with Type 2 Diabetes

    05.01.10 Dapsone 
    05.01.07 Daptomycin Cubicin® On microbiology advice only
    08.01.05 Daratumumab DARZALEX®

    For use as monotherapy in line with CDF recommendations and NICE TA510 only.

    Not recommended for use in combination with lenalidomide and dexamethasone in accordance with NICE TA454.

    09.01.03 Darbepoetin Aranesp®

    Commissioned by NHS England (for dialysis-induced anaemia including via outpatients and only as per NICE CG114) and Trust Guidelines.

    07.04.02 Darifenacin 
    05.03.01 Darunavir Prezista® Commissioned by NHS England for use in HIV in combination with other antiretrovirals as per BHIVA Guidelines.
    05.03.01 Darunavir & Cobicistat Rezolsta® Commissioned by NHS England (HIV in combination with other anti-retrovirals)
    05.03.03.02 Dasabuvir Exviera®

    Treatment of hepatitis C commissioned in line with latest rate card from NHS England.

    08.01.05 Dasatinib Sprycel®

    Commissioned by NHS England in line with NICE TA425 and TA426.

    08.01.02 Daunorubicin  DCHFT: Daunorubicin 20mg injection and daunorubicin lipid formulation (liposomal) DaunoXome® 50mg injection listed on formulary.
    09.03 Decan®  Not DCHFT.
    09.01.03 Deferasirox Exjade®

    Commissioned by NHS England for iron chelation in thalassaemia and sickle cell - policy in progress.

    09.01.03 Deferiprone Ferriprox® Commissioned by NHS England for iron chelation in thalassaemia and sickle cell - policy in progress.
    08.03.04.02 Degarelix Firmagon® Consultant urologist use for a SINGLE DOSE in naive prostate cancer that present with emergencies such as:
  • Spinal cord compression.
  • Severe uraemia due to malignant ureteric obstruction.
  • Impending long bone pathological fracture.

    OR

    in accordance with NICE TA404
  • 06.05.02 Demeclocycline  Restricted Item  RBCH: Needs Endocrine CONSULTANT approval
    06.06.02 Denosumab 120mg XGEVA® In accordance with NICE TA265 for the prevention of skeletal-related events in patients with bone metastases from breast cancer and from solid tumours other than prostate.
    06.06.02 Denosumab 60mg Prolia® In accordance with NICE TA204 and local shared care guideline for the prevention of fragility fractures.
    13.08 DEPIGMENTING lotion 50ml  unlicensedunlicensed

    Not DCHFT.
    07.03.02.02 Depo-Provera®  Injection (aqueous suspension), medroxyprogesterone acetate 150 mg/mL

    DCHFT: Restricted Item  Family planning only.
    07.02.02 Dequalinium chloride 10mg vaginal tablets Fluomizin®

    Nov 18: Approved for use at RBCH as 2nd line agent - application for Green status is pending DMAG approval. 

    13.10.04 Derbac-M®  Liquid, malathion 0.5% in an aqueous basis
    Excipients include cetostearyl alcohol, fragrance, hydroxybenzoates (parabens)
    13.02.01 Dermatonics Heel Balm® 

    An alternative to Flexitol® with 25% Urea content

    13.09 Dermax®  Shampoo, benzalkonium chloride 0.5%
    13.02.01.01 Dermol 200®  Shower Emollient, benzalkonium chloride 0.1%, chlorhexidine hydrochloride 0.1%, liquid paraffin 2.5%, isopropyl myristate 2.5%

    Excipients include cetostearyl alcohol
    13.02.01.01 Dermol 600®  Bath Emollient, benzalkonium chloride 0.5%, liquid paraffin 25%, isopropyl myristate 25%
    Excipients include polysorbate 60
    13.02.01 Dermol® 500 

    Lotion, benzalkonium chloride 0.1%, chlorhexidine hydrochloride 0.1%, liquid paraffin 2.5%, isopropyl myristate 2.5%

    Excipients include cetostearyl alcohol

    13.04 Dermovate 60% and propylene glycol 40%  Extemporaneous product
    Hospital only
    13.04 Dermovate®  Cream, clobetasol propionate 0.05%
    Potency: very potent
    Excipients include beeswax (or beeswax substitute), cetostearyl alcohol, chlorocresol, propylene glycol

    Ointment, clobetasol propionate 0.05%
    Potency: very potent
    Excipients include propylene glycol
    13.04 Dermovate®  Scalp application, clobetasol propionate 0.05%, in a thickened alcoholic basis
    Potency: very potent
    18 Desferrioxamine  For iron poisoning.

    RBCH: kept in ED resus and Pharmacy
    09.01.03 Desferrioxamine Mesilate  Commissioned by NHS England for iron chelation in thalassaemia and sickle cell - policy in progress.
    15.01.02 Desflurane Suprane® Anaesthetic.
    06.05.02 Desmopressin Injection DDAVP® or Octim® RBCH: Octim® brand where required as a single dose immediately before surgery or after trauma for patients with mild to moderate haemophilia and von Willebrand's disease. Haematologist only.
    06.05.02 Desmopressin oral/intranasal/sublingual  Octim® nasal spray is non-formulary
    06.03.02 Dexamethasone  For specific indications
    10.01.02.02 Dexamethasone 
    11.04.01 Dexamethasone drops 0.1% Maxidex®
    11.04.01 Dexamethasone for ocular injection  Not DCHFT.
    11.04.01 Dexamethasone intravitreal implant Ozurdex®

    Commissioned by CCG for use in accordance with NICE TA229, TA 349 and TA460.

    04.04 Dexamfetamine  Tablets.
    For ADHD in children. Refer to local shared care guideline.

    DCHFT: Restricted Item  Consultant psychiatrist only.
    15.01.04.04 Dexmedetomidine  Dexdor® RED - Critical care use only at PHT
    08.01 Dexrazoxane Cardioxane®, Savene® Commissioned by NHS England - use in accordance with agreed Trust Guidelines, for the treatment of anthracycline extravasation.

    Not routinely commissioned by NHS England for anthracycline cardiotoxicity.
    06.01.04 Dextrogel®  Not at RBCH
    Not at DCHFT
    04.07.02 Diamorphine 

    Injections.


    Stock update (5mg and 10mg injections) 14/8/2018

    Accord are still out of stock of diamorphine 5mg and 10mg injection, but have advised that new stock of both strengths will be available during the w/c 27th August. There are further deliveries scheduled for both strengths through September, October and the coming months. Wockhardt still have supplies available, but as previously advised they cannot support the full demand for primary and secondary care.

    Therefore, it is expected that this supply issue should hopefully be resolved by early September. Until this time therefore please continue with the management plan as previously stated – primary care and drug misuse centres will be able to continue to order diamorphine in line with historical demand.

    Recommended local action - primary care - Although you will be able to access diamorphine as per historical demand, we would encourage prescribers to be aware of the supply issues and reduce prescribing where appropriate. Please order responsibly during this time, in line with historical demand and do not stock pile to avoid lengthening the stock shortage. In the case that diamorphine cannot be accessed, please refer to the clinical guidance issued by UKMI which provides more information on suggested alternatives to diamorphine.

    15/6/17
    The medicines team has been made aware of shortages of some strengths of Diamorphine ampoules, in some areas. 

    In order that patients are able to access essential palliative care medicines, it is recommended that prescribers and palliative care staff check availability with local pharmacies before sending patients or relatives to collect prescriptions.
    Where possible and appropriate, prescriptions should be written to order the strengths that are available. Prescribers may need to amend prescriptions accordingly. The diamorphine prescription may need to be written on a separate prescription to other palliative care medicines. 

    Nurses and carers are reminded to carefully check ampoule strengths if doses need to be made up from smaller amps, or where wastage of parts of larger amps needs to occur, following best practice when wasting part amps.

    If diamorphine is unavailable, then prescribers are advised to convert to Morphine, using the conversion tables in the front of the BNF or on bnf.org
    Seek the advice of local pharmacies and the listed palliative care pharmacies in the out of hours period. 

    04.01.02 Diazepam  See Primary care protocol for anxiety disorders.
    10.02.02 Diazepam 
    15.01.04.01 Diazepam  Tablet, oral solution, injection.
  • Red - when used as a premedication. See section 4.1.2 for other uses.
  • 04.08.02 Diazepam IV 
    04.08.02 Diazepam rectal solution 
    06.01.04 Diazoxide Eudemine® Specialist initiation only
    11.03.01 Dibrompropamidine Isetionate ointment 0.15% Brolene® Acanthamoeba keratitis (unlicensed indication)

    DCHFT: Consultant use only. Not routinely stocked.
    10.01.01 Diclofenac 
    10.01.01 Diclofenac Injection Voltarol®
    11.08.02 Diclofenac Sodium unit dose drops 0.1% Voltarol® Ophtha
    18 Dicobalt edetate IV  For severe cyanide poisoning.

    RBCH: kept in Emergency Drug Cupboard
    01.02 Dicycloverine hydrochloride 

    Tablets, syrup.

    05.03.01 Didanosine Videx® Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.
    08.03.01 Diethylstilbestrol  Hospital initation
    13.06.01 Differin®  Cream, adapalene 0.1%
    Excipients include disodium edetate, hydroxybenzoates (parabens)

    Gel, adapalene 0.1%
    Excipients include disodium edetate, hydroxybenzoates (parabens), propylene glycol
    02.01.01 Digoxin  Tablets, Elixir, (Injection - secondary care only)
    Bioavailabilities are approximately: Injection 100%, Liquid 80%, Tablets 70%.
    02.01.01 Digoxin specific antibody fragments DigiFab ® Specific manufacturers - refer to www.toxbase.org
    18 Digoxin specific antibody fragments Digifab® For digoxin overdose - see Dorset-wide guideline.
    04.07.02 Dihydrocodeine  Tablets, elixir.
    Short-term use only.
    04.07.02 Dihydrocodeine Injection 
    02.06.02 Diltiazem 60mg Tablets 
  • Although the means of formulation has called for the strict designation ‘modified-release’ the duration of action corresponds to that of tablets requiring administration 3 times daily.
  • 02.06.02 Diltiazem Modified Release  Modified release capsules/tablets.
  • Once daily slow release (Slozem®) at RBCH and PGH.

  • DCHFT: Slozem® and Adizem-SR® on formulary.

  • Different versions of modified-release preparations containing more than 60 mg diltiazem hydrochloride may not have the same clinical effect. To avoid confusion between these different formulations of diltiazem, prescribers should specify the brand to be dispensed.

  • 08.02.04 Dimethyl fumarate Tecfidera®

    Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA320.

    13.05.02 Dimethyl fumarate  Skilarence®
    07.04.04 Dimethyl sulfoxide Bladder Instillation 50% and 90%  DCHFT: 50% only.
    13.07 Dinitrochlorobenzene (DNCB)  Used at Poole Hospital NHS Foundation Trust
    07.01.01 Dinoprostone 
    13.07 Diphenycyclopropenone (DCPN)  Used at Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
    In a variety of strengths ranging from 0.0010% to 7%

    DCHFT: Some interest shown by Dermatologists in using. Awaiting formulary application (Dec 2014). Not currently stocked.
    13.02.01 Diprobase® 

    Cream, cetomacrogol 2.25%, cetostearyl alcohol 7.2%, liquid paraffin 6%, white soft paraffin 15%
    Ointment, liquid paraffin 5%, white soft paraffin 95%,
    Excipients include cetostearyl alcohol, chlorocresol

    DCHFT: Ointment not stocked.

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition. 

    13.04 Diprosalic®  Ointment, betamethasone (as dipropionate) 0.05%, salicylic acid 3%
    Potency: potent
    13.04 Diprosalic®  Scalp application, betamethasone (as dipropionate) 0.05%, salicylic acid 2%, in an alcoholic basis, net price 100 mL = Ł10.10. Label: 28, counselling, application.
    Potency: potent
    Excipients include disodium edetate
    02.09 Dipyridamole MR capsules Persantin® Retard Modified release capsule.
  • Specialist initiation.
  • Use in accordance with NICE TA210.

  • 11.99.99.99 Disodium Edetate 0.37%   unlicensedUnlicensed
    Preservative free
    06.06.02 Disodium Pamidronate  For multiple myeloma and treatment of hypercalcaemia.
    02.03.02 Disopyramide  Capsule, Tablet MR (Injection - secondary care only).
    Hospital initiation.
  • DCHFT: Not routinely stocked.
  • 04.10.01 Disulfiram  Tablets.
    13.05.02 Dithranol in zinc and salicylic acid Lassar's paste Extemporaneous product - made to orderunlicensedunlicensed
    0.1%, 0.2%, 0.5%, 1%, 3%, 4%, 5%


    13.05.02 Dithrocream®  Cream, dithranol 0.1%,
    Preparations not available for NHS prescription 2%
    Excipients include cetostearyl alcohol, chlorocresol

    DCHFT: 0.25% and 2% also stocked.
    02.07.01 Dobutamine  Injection.
    08.01.05 Docetaxel 
    01.06.02 Docusate sodium  Capsules, syrup, paediatric syrup.
  • Alternative prescribing option.
  • 05.03.01 Dolutegravir Tivicay® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs).
    04.06 Domperidone  Tablets, suppositories, suspension.
    MHRA/CSM advice Domperidone should only be used for the relief of the symptoms of nausea and vomiting;
  • Domperidone should be used at the lowest effective dose for the shortest possible duration (max. treatment duration should not normally exceed 1 week);

  • Domperidone is contra-indicated for use in conditions where cardiac conduction is, or could be impaired, or where there is underlying cardiac disease, when administered concomitantly with drugs that prolong the QT interval or potent CYP3A4 inhibitors, and in severe hepatic impairment

  • The recommended dose in adults and adolescents over 12 years and over 35 kg is 10 mg up to 3 times daily

  • The recommended dose in children under 35 kg is 250 micrograms/kg up to 3 times daily

  • Note This advice does not apply to unlicensed uses of domperidone (e.g palliative care)

    04.11 Donepezil film-coated tablets  Specialist initiation and use in accordance with NICE recommendations (TA217).

    Refer to local shared care guideline (see below).

    04.11 Donepezil orodispersible tablets  Alternative prescribing option
    02.07.01 Dopamine  Injection.
    02.07.01 Dopexamine Dopacard® Injection.
    03.07 Dornase Alfa Pulmozyme®

    Commissioned by NHS England for Cystic Fibrosis in line with policy A01/P/b.

    Amber Amber if provided by primary care for Cystic Fibrosis prior to April 2013.

    Red For patients initiated after April 2013, Dornase Alfa is restricted to supply from secondary care.

    • Adult patients: specialist centre only (University Hospital Southampton)
    • Paediatric patients: PHFT use in line with network arrangements with UHS.

    Not at DCH or RBCH.

    11.06 Dorzolomide 2% with timolol 0.5% Cosopt® Preservative free unit dose drops also amber
    11.06 Dorzolomide drops 2% Trusopt®
    11.06 Dorzolomide unit dose drops 2% Trusopt® Preservative free
    13.02.01 DoubleBase® 

    Gel, isopropyl myristate 15%, liquid paraffin 15%

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition. 

    13.05.02 Dovonex®  Ointment, calcipotriol 50 micrograms/g
    Excipients include disodium edetate, propylene glycol
    03.05.01 Doxapram  Injection.
    Hospital only.
    02.05.04 Doxazosin  Tablets.
  • MR formulation is non formulary.
  • 07.04.01 Doxazosin  modified-release preparations licensed for BPH
    13.03 Doxepin hydrochloride Xepin® Cream, doxepin hydrochloride 5%

    Excipients include benzyl alcohol

    Not at DCHFT.
    13.03 Doxepin hydrochloride  Unlicensed use of a licensed medicine
    08.01.02 Doxorubicin Hydrochloride 
    08.01.02 Doxorubicin Hydrochloride Caelyx®

    In accordance with NICE TA91 or CDF policy.

    05.01.03 Doxycycline  RBCH: Policy states to use higher doses than usual: 200mg stat then 100mg TWICE daily
    13.06.02 Doxycycline 
    13.12 Driclor® Aluminium salt

    Restrict to patients in exceptional circumstances, this is a Self Care Self Care Medicine

    Application, aluminium chloride hexahydrate 20% in an alcoholic basis

    Not stocked at RBCH

    02.03.02 Dronedarone Multaq® Tablets.
    In accordance with NICE TA197 and local shared care guideline.
    Hospital initiation.
    04.06 Droperidol Xomolix®

    RBCH : Restricted Item Consultant Anaesthetist only in Recovery areas for Intractable PONV.

    13.06.01 Duac® Once Daily 

    Gel, benzoyl peroxide 5%, clindamycin 1% (as phosphate) in an aqueous basis
    Excipients include disodium edetate

    For use within acne guideline when required in combination with antibiotics

    Self Care Self Care Medicine

    06.01.02.03 Dulaglutide Trulicity®
    04.03.04 Duloxetine Cymbalta® For depression second choice after SSRIs, also for neuropathic pain in accordance with local guidelines.

    04.07.03 Duloxetine Cymbalta® Capsules.
    For neuropathic pain in accordance with local guideline.

    Alternative prescribing option in diabetic neuropathic pain.
    07.04.02 Duloxetine Yentreve®

    Choice should be based on selecting the most cost-effective option.

    13.08.01 Dundee reflective sun creams Dundee Block® Where the patient is sensitive to visible light, most commonly solar urticaria and porphyrias, particularly erythropoietic protoporphyria
    A2.04.01.02 Duocal® Super Soluble 

    For paediatric patients. 

    13.05.03 Dupilumab Dupixent®

    For treating moderate to severe atopic dermatitis, in accordance with NICE TA534

    08.01.05 Durvalumab Imfinzi®

    PHT only: Only on direction of Consultant Oncologists, for adult patients with with stage 3 NSCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (cCRT).

    This is an unlicensed medicine supplied as part of an 'early access to medicines' (EAMS) scheme until NICE assessment. Prescribers must make patients aware of this & the implications for future funding. 

    06.04.02 Dutasteride Avodart®
    11.03.02 Econazole drops 1%  Preservative free
    unlicensedunlicensed
    Not RBCH
    DCHFT: On formulary but not stocked.
    07.02.02 Econazole nitrate pessaries/cream Gyno-Pevaryl
    09.01.03 Eculizumab Soliris®

    Commissioned by NHS England for aHUS as per NHS England Policy E03/PS(HSS)/a: On recommendation from Newcastle specialist centre only.

    Also commissioned by NHS England for paroxysmal nocturnal haemoglobinuria as per NHS National Specialised Commissioning Team (NSCT) Service Specification.

    13.02.01 Eczmol®  Cream, chlorhexidine gluconate 1 % in emollient basis
    Excipients include cetostearyl alcohol

    Not DCHFT and RBCH.
    02.08.02 Edoxaban Lixiana® As per NICE TA 354
    02.08.02 Edoxaban Lixiana® Recommended as an option in accordance with NICE TA355 for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation who have one or more risk factors, such as:
    •heart failure, high blood pressure or diabetes
    •had a stroke or transient ischaemic attack before
    •aged 75 years or older
    02.08.02 Edoxaban Lixiana®

    Green

    • For prevention of stroke or systemic embolism in patients with AF within NICE TA and local guidance, as per licensed indications.
    • For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE TA. 

     

    05.03.01 Efavirenz Sustiva® Commissioned by NHS England for HIV in combination with other anti-retroviral drugs as per BHIVA Guidelines.
    13.09 Eflornithine cream Vaniqa®

    Eflornithine 11.5% for facial hirsutism in women. Refer to local guideline.

    Excipients include cetostearyl alcohol, hydroxybenzoates, stearyl alcohol.

    13.08.01 Efudix®  Cream, fluorouracil 5%
    Excipients include hydroxybenzoates (parabens), polysorbate 60, propylene glycol, stearyl alcohol
    05.03.03.02 Elbasvir with Grazoprevir Zepatier®

    Treatment of hepatitis C commissioned in line with latest rate card from NHS England.

    A2.03.02 Elemental 028® 

    Paediatric and adult patients.

    If patient dislikes or does not tolerate Modulen IBD then trial of Elemental 028 extra can be considered

    Available in 2 flavours or the unflavoured one can be made more palatable using the flavour modjuls

    Use liquid E028 for patients who need to take product away from home or who dislike the taste of powdered E028

    Short bowel syndrome, intractable malabsorption, inflammatory bowel disease, bowel fistulae.

    A2.03.01 Elemental 028® Extra 

    If patient dislikes or does not tolerate Modulen IBD then trial of Elemental 028 extra can be considered

    Available in 2 flavours or the unflavoured one can be made more palatable using the flavour modjuls

    Use liquid E028 for patients who need to take product away from home or who dislike the taste of powdered E028

    Short bowel syndrome, intractable malabsorption, inflammatory bowel disease, bowel fistulae.

    09.08.01 Eliglustat Cerdelga®

    To be prescribed by specialist metabolic centres only in accordance with NICE HSTG 5 and NHS England Commissioning criteria. 

    Approved specialist adult metabolic centres are:
    „h Addenbrookes
    „h University Hospital Birmingham
    „h Salford Royal
    „h UCLH
    „h Royal Free Hospital

    06.04.01.01 Elleste-Duet ® 
    06.04.01.01 Elleste-Duet Conti ® 
    06.04.01.01 Elleste-Solo®  Estradiol only
    06.04.01.01 Elleste-Solo® MX  Patches, self-adhesive,
    13.04 Elocon®  Scalp lotion, mometasone furoate 0.1% in an aqueous isopropyl alcohol basis
    Potency: potent
    13.04 Elocon®  Cream, mometasone furoate 0.1%
    Potency: potent
    Excipients include beeswax

    Ointment, mometasone furoate 0.1%
    Potency: potent
    Excipients include beeswax, propylene glycol
    09.01.04 Eltrombopag Revolade® Commissioned by CCG: See commissioning statement

    Use in accordance with NICE TA293
    01.04.02 Eluxadoline Truberzi®

    In accordance with NICE TA

    02.11 Emicizumab Hemlibra®

    Commissioned by NHSE to prevent or reduce the frequency of bleeding episodes in people with haemophilia A who have factor VIII inhibitors in accordance with Clinical Commissioning Policy 170067/P via haemophilia comprehensive care centres only.

    06.01.02.03 Empagliflozin Jardiance®

    Green When used with oral hyperglycaemics in patients with Type 2 Diabetes
     
     Amber When used with insulin in patients with Type 2 Diabetes

    05.03.01 Emtricitabine Emtriva® Not routinely commissioned by NHS England for HIV in combination with other anti-retroviral drugs. Policy in progress.
    05.03.01 Emtricitabine & Tenofovir alafenamide fumarate Descovy® Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.
    05.03.01 Emtricitabine and tenofovir Truvada® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs) as per BHIVA guidelines.
    05.03.01 Emtricitabine, efavirenz and tenofovir  Atripla® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs) as per BHIVA Guidelines.
    05.03.01 Emtricitabine, Elvitegravir, Cobicistat, Tenofovir alafenamide fumarate Genvoya® Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.
    05.03.01 Emtricitabine, Rilpivirine hydrochloride & Tenofovir alafenamide fumarate Odefsey® Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.
    13.02.01.01 Emulsiderm®  Liquid emulsion, benzalkonium chloride 0.5%, liquid paraffin 25%, isopropyl myristate 25%

    Excipients include polysorbate 60
    13.02.01 Emulsifying Ointment BP 

    Ointment, emulsifying wax 30%, white soft paraffin 50%, liquid paraffin 20%

    Excipients include cetostearyl alcohol

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.

    02.05.05.01 Enalapril   Tablets.
  • Restricted Item Restricted for paediatric or diagnostic use only.
  • A2.03.01 Enfamil AR® 

    Pre-thickened feed for use in severe gastro-oesophageal reflux. 

    A2.03.01 Enfamil® O-Lac 

    For use in proven lactose intolerance (not suitable for use in cow's milk allergy).

    If used for temporary lactose intolerance after a bout of gastroenteritis, it should only be used for 6-8 weeks before titrating back onto standard infant formula. 

    05.03.01 Enfuvirtide Fuzeon® Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.

    02.08.01 Enoxaparin Clexane®, Inhixa® (biosimilar)

    Injection.
    Specialist initiation.


    Green for DVT in patients who are intravenous drug users.

    Amber for use in accordance with the relevant local shared care guidance.

    Red for specialist indications, e.g. prevention of clotting in the extracorporeal circuit during haemodialysis, not listed above.

    • DCHFT: Dalteparin not routinely used.



     

    A2.04.01.02 Enshake® 

    Generally use as a second choice to 1.5kcal/ml sip feeds as not nutritionally complete. However these supplements do provide more calories per ml approx. 600kcal in 250ml so useful for those with very high calorie needs (when reconstituted with whole milk) e.g. CF Patients

    A2.01.02.03 Ensure Compact 

    NICE CG32 (Feb 2006) Nutrition support in adults

    This has a smaller volume and more than 2kcals /ml these can very useful in those who struggle with a larger volume

    A2.02.02.01 Ensure Plus Savoury 

    NICE CG32 (Feb 2006) Nutrition support in adults www.nice.org.uk/page.aspx?o=cg032niceguideline

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)

    Adult sip feeds containing 1kcal/ml (Fresubin Original, Ensure, Fortimel, Clinutren ISO) should not be prescribed as they are less cost effective compared to 1.5kcal/ml sip feeds

    A2.02.02.02 Ensure® Plus Crčme 

    NICE CG32 Nutrition support in adults

    For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds

    A2.02.02.01 Ensure® Plus Fibre 

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Restrict use to those patients with bowel problems as slightly more expensive than 1.5kcal.ml sips without fibre.

    A2.02.01.02 Ensure® Plus Juce 

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Useful for those patients with preference to juice /dislike to milk. However note these are less cost effective in terms of calorie and protein content than milk based sips.

    These are not suitable for those with an allergy to cow’s milk.

    A2.02.02.01 Ensure® Plus Milkshake style 

    NICE CG32 (Feb 2006) Nutrition support in adults www.nice.org.uk/page.aspx?o=cg032niceguideline

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)

    Adult sip feeds containing 1kcal/ml (Fresubin Original, Ensure, Fortimel, Clinutren ISO) should not be prescribed as they are less cost effective compared to 1.5kcal/ml sip feeds

    A2.02.02.01 Ensure® Plus Yoghurt style 

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Useful for patients with taste changes e.g. as a side effect to cancer treatments

    A2.02.01.01 Ensure® Shake 

    Calories are based on a sachet made up with 200ml of full cream milk and contains approx 385 kcals.

    If patient likes milky drinks, prescribe as a supplement to diet 1-2 servings/day.

    Not suitable for patients with cow's milk intolerance or galactosaemia.

    Not nutritionally complete.

    If patient dislikes milk drinks, choose from the juice style supplements instead.

     

    A2.01.02.03 Ensure® TwoCal 

    Green  NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Amber Restrict use to those patients with increased protein requirement. Use only under direction of dietitian. Not to be used for those with renal insufficiency.

     

    04.09.01 Entacapone  Tablets.
    See shared care guideline for entacapone.

    Used as an adjunct to levodopa therapy in patients who cannot be stabilised, particularly those with 'end-of-dose' fluctuations.

    See local guidance on drug treatment of Parkinson's Disease and shared care guideline.
    05.03.03.01 Entecavir Generic, Baraclude®

    Generic product should be used where possible.

    15.01.02 Entonox®  50% nitrous oxide, 50% oxygen.
    08.03.04.02 Enzalutamide Xtandi® In accordance with NICE TAs.

    NICE TA 316: for metastatic hormone‐relapsed prostate cancer previously treated with a docetaxel‐containing regimen.

    NICE TA 377: for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (from April 16)
    13.02.01 Epaderm® 

    Cream, yellow soft paraffin 15%, liquid paraffin 10%, emulsifying wax 5%
    Excipients include cetostearyl alcohol, chlorocresol

    Ointment, emulsifying wax 30%, yellow soft paraffin 30%, liquid paraffin 40%
    Excipients include cetostearyl alcohol

    Not stocked at RBCH: use Hydromol ointment

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.

    02.07.02 Ephedrine  Injection.
    12.02.02 Ephedrine   Nasal drops 0.5% and 1%
    13.06.01 Epiduo® 

    Gel, adapalene 0.1%, benzoyl peroxide 2.5%
    Excipients include disodium edetate, polysorbate 80, propylene glyc

    For use within acne guideline when required in combination with antibiotics

    Self Care Self Care Medicine

    Not DCHFT and RBCH.

    08.01.02 Epirubicin hydrochloride 
    02.02.03 Eplerenone Inspra® Tablets.
  • Restricted Item Restricted. Specialist initiation.
  • 02.08.01 Epoprostenol Flolan® Injection.
  • Commissioned by NHS England for PAH, as per NHS England policy A11/PS/b.
  • Used for anticoagulant in dialysis circuits and CVVH (included in tariff).

  • 02.09 Eptifibatide Integrilin® Injection / infusion.
  • Cardiology consultant use only.
  • 09.06.04 Ergocalciferol injection 
    07.01.01 Ergometrine Maleate 
    07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®
    08.01.05 Eribulin Halaven®

    Commissioned in accordance with NICE TA423 and TA515.

    08.01.05 Erlotinib Tarceva® Commissioned by NHS England for cancer, policy in progress. See NICE TA162 and TA374.
    05.01.02.02 Ertapenem Invanz® On microbiology advice only.

    DCHFT: As per local guidelines or on microbiology advice only.
    13.06.02 Erythromycin 
    05.01.05 Erythromycin IV  Short-term as a prokinetic to improve gastric motility.
    05.01.05 Erythromycin oral  For COPD or bronchiectasis and GUM

    05.01.05 Erythromycin oral  For splenectomy prophylaxis
    04.03.03 Escitalopram  In the absence of a clinical rationale for a particular antidepressant the most cost-effective agent should be selected
    02.04 Esmolol IV Brevibloc® Injection.
    01.03.05 Esomeprazole 

    Capsules.

    • For use in Barrett's oesophagus only.

    GPs should consider discontinuing PPIs in patient with unexplained eGFR decline or substituting them with ranitidine if indicated.

    Such patients should be referred for specialist advice as per CKD NICE guidance i.e.

    • eGFR less than 30 ml/min/1.73m2
    • sustained decrease in eGFR of 25% or more within 12 months
    • sustained decrease in eGFR of 15 ml/min/1.73m2 or more within 12 months

    Alternatively, patients with AKI as defined in the AKI NICE guidance should be discussed with a nephrologist if interstitial nephritis is suspected, as soon as it is possible i.e. within 24 hours.ť

    01.03.05 Esomeprazole IV 
  • DCHFT: Not available as non-formulary item.
  • 07.02.01 Estring®  Vaginal ring, releasing estradiol approx. 7.5 micrograms/24 hours
    07.02.01 Estriol cream  0.1% and 0.01% available.
    Excipients include arachis (peanut) oil
    May damage latex condoms and diaphragms

    DCHFT: 0.1% routinely stocked only.
    07.02.01 Estriol pessaries 500 micrograms Ortho-Gynest® Excipients include butylated hydroxytoluene
    May damage latex condoms and diaphragms
    02.11 Etamsylate Dicynene®
  • Specialist initiation.
  • 10.01.03 Etanercept Benepali®, Enbrel®

    All products should be prescribed by brand. Biosimilar should be used where possible.

    NHSE Commissioned by CCG for:

    • Rheumatoid arthritis in accordance with NICE TA 375 and local pathway.
    • Ankylosing spondylitis in accordance with NICE TA383 and local pathway
    • Plaque psoriasis in accordance with NICE TA103
    • Psoriatic arthritis in accordance with NICE TA199 and local pathway

    NHSE Commissioned by NHS England for:

    • Juvenile idiopathic arthritis in line with NICE TA373.
    • Paediatric patients in line with adult NICE TAs.
    13.05.03 Etanercept Benepali®, Enbrel®

    All products should be prescribed by brand. Biosimilar should be used where possible.

    09.05.01.02 Etelcalcetide Parsabiv®

    Restricted Item  DCHFT renal consultants only.

    Commissioned by NHS England in line with NICE TA448 for treating secondary hyperparathyroidism via specialist centres only.

    Treatment must have prior approval on Blueteq®.

    05.01.09 Ethambutol  
    18 Ethanol (alcohol) injection  Orally or by injection for ethylene glycol (antifreeze) and methanol (methyl alcohol) poisoning as alternative to fomepizole.
    11.08.02 Ethanol 20% Eye Solution  Preservative-free


    Unlicensedunlicensed
    02.13 Ethanolamine oleate  Injection.
    08.03.01 Ethinylestradiol  Hospital initiation
    04.08.01 Ethosuximide  Capsules, liquid.
    Options based on licence.

    Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors.
    15.02 Ethyl Chloride Cryogesic® Spray Aerosol spray.
    10.01.01 Etodolac 
    15.01.01 Etomidate Hypnomidate® Injection.
    08.01.04 Etoposide 
    05.03.01 Etravirine Intelence® Commissioned by NHS England in HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.

    13.04 Etrivex®  Shampoo, clobetasol propionate 0.05%
    Potency: very potent

    Not at RBCH
    Not at DCHFT
    13.02.01 Eucerin® Intensive  Lotion, urea 10%

    Excipients include benzyl alcohol, isopropyl palmitate

    Not RBCH
    Not DCHFT
    Not stocked PGH
    13.04 Eumovate®  Cream, clobetasone butyrate 0.05%
    Potency: moderate
    Excipients include beeswax substitute, cetostearyl alcohol, chlorocresol

    Ointment, clobetasone butyrate 0.05%
    Potency: moderate
    18 European Viper Venom Antivenom  For European adder (Vipera berus) envenoming (bites).

    DCH: Kept in ED Fridge & Emergency Drugs Fridge.
    08.01.05 Everolimus Afinitor®

    Commissioned by NHS England in line with NICE TA recommendations.

    02.12 Evolocumab Repatha®

    RED, Initiation by lipid specialist – this can be by written or verbal approval to other secondary care consultant clinicians. A copy of any letters should be forwarded to the patient’s GP.

    Commissioned by CCG in accordance with NICE TA 394 for primary non-familial hypercholesterolaemia or mixed dyslipidaemia and primary heterozygous familial hypercholesterolaemia.

    Commissioned by NHS England via specialist centres only for homozygous familial hypercholesterolaemia.

    06.04.01.01 Evorel®  Patches, self-adhesive,

    RBCH: 50 microgram routinely stocked
    06.04.01.01 Evorel® Conti  patches, self-adhesive
    06.04.01.01 Evorel® Sequi  combination pack, self-adhesive patches
    08.03.04.01 Exemestane  In accordance with NICE TA112 and local shared care guideline. Also for advanced disease in postmenopausal women in whom anti-oestrogen therapy has failed.
    06.01.02.03 Exenatide prolonged release Bydureon® Use in accordance with NICE NG28 and local shared care guideline.

    Once weekly preparation:
    2mg once weekly, in combination with metformin and a
    sulphonylurea, or metformin and a thiazolidinedione.


    GREEN: When used with oral hyperglycaemics in patients with Type 2 Diabetes

    AMBER : When used with insulin in patients with Type 2 Diabetes

    DCHFT: Consultant diabetologist only.
    06.01.02.03 Exenatide standard release injection Byetta® Use with oral agents, in accordance with NICE NG28 recommendations for treatment of type 2 diabetes and local shared care guideline.

    Also when used as adjunctive therapy to basal insulin with or without metformin and/or pioglitazone in adults

    Give twice daily within 1 hour before 2 main meals (at least 6 hours apart)

    GREEN: When used with oral hyperglycaemics in patients with Type 2 Diabetes

    AMBER : When used with insulin in patients with Type 2 Diabetes

    DCHFT: Consultant diabetologist only.
    13.05.02 Exorex® 

    Restrict to where moderate to severe skin condition requires it

    Lotion, coal tar solution 5% in an emollient basis

    Excipients include hydroxybenzoates (parabens)

    Self Care Self Care Medicine

    02.12 Ezetimibe Ezetrol® Tablets.
  • Use of ezetimibe should only be considered for patients with primary hypercholesterolaemia, in line with licensed indications.
  • Use in accordance with NICE TA385.
  • 02.12 Ezetimibe Ezetrol® For use in combination with a statin for the secondary prevention of cardiovascular disease.
    02.11 Factor IX Fraction, Dried  Non pharmacy item please contact blood bank for details and availability.

    Commissioned by NHS England, as per BCSH guidelines.

    Available from CSL Behring (Mononine®), BPL (Replenine®-VF, Dried Factor IX Fraction), Grifols (AlphaNine®), Biotest UK (Haemonine®)

    Note Preparation of recombinant coagulation factor IX (nonacog alfa) available from Pfizer (BeneFIX®)

    02.11 Factor VII  Non pharmacy item please contact blood bank for details and availability.

    Commissioned by NHS England as per BCSH Guidelines.

    02.11 Factor VIIa (Recombinant) - eptacog alfa (activated) NovoSeven® Non pharmacy item please contact blood bank for details and availability.
    DCHFT: Currently held by Pharmacy (Nov 2014).

    Commissioned by NHS England as per BCSH Guidelines.

    02.11 Factor VIII Fc Fusion Protein  Non-pharmacy item. Please contact blood bank for details and availability.
    Commissioned by NHS England as per BCSH Guidelines.

    02.11 Factor VIII Fraction, Dried  Commissioned by NHS England as per BCSH Guidelines.

    Available from Biotest UK (Haemoctin®), CSL Behring (Haemate® P), BPL (Optivate®, High Purity Factor VIII and von Willebrand factor concentrate; 8Y®), Grifols (Alphanate®; Fanhdi®), Octapharma (Octanate®; Wilate®); Haemoctin®, Optivate®, Fanhdi®, and Octanate® are not indicated for use in von Willebrand’s disease

    Note Preparation of recombinant human coagulation factor VIII (octocog alfa) available from CSL Behring (Helixate® NexGen), Baxter (Advate®), Bayer (Kogenate® Bayer); preparation of recombinant human coagulation factor VIII (moroctocog alfa) available from Wyeth (ReFacto AF®); octocog alfa and moroctocog alfa are not indicated for use in von Willebrand's disease

    02.11 Factor VIII Inhibitor Bypassing Fraction FEIBA® Non-pharmacy item. Please contact blood bank for details and availability.

    Commissioned by NHS England as per BCSH Guidelines.

    02.11 Factor XIII Fraction, Dried Fibrogammin® P Non-pharmacy item. Please contact blood bank for details and availability.
    Commissioned by NHS England as per BCSH Guidelines.

    05.06 Faecal Microbiota Transplant 

    RBCH & PHT: Approved as a treatment option for patients with recurrent C. difficile infections that have failed to respond to antibiotics and other treatments on recommendation of Consultant Microbiologist and Gastroenterologist. 

    05.03.02.01 Famciclovir Famvir® RBCH: GUM only.
    DCHFT: Consultant only.
    10.01.04 Febuxostat Adenuric®

    For the management of hyperuricaemia in people with gout, in accordance with NICE TA 164 as a secondline treatment to allopurinol

    02.06.02 Felodipine  Fourth Line Choice.

    Option choices agreed for new initiations, existing patients will not be switched unless clinically appropriate.

    Modified release tablets.

    Alternative prescribing option.
    07.03.01 Femodene®  Ethinylestradiol 30 micrograms/gestodene 75 micrograms
    06.04.01.01 Femoston® 
    06.04.01.01 FemSeven Conti ®  Patches, self-adhesive
    06.04.01.01 FemSeven Sequi®  Combination pack, self-adhesive patches
    06.04.01.01 FemSeven®  Patches, self-adhesive
    02.12 Fenofibrate 

    Capsules / Tablets

    • Specialist initiation.
    15.01.04.03 Fentanyl  Injection.
    04.07.02 Fentanyl Injection/Infusion  Red status does not apply to palliative care settings.
    04.07.02 Fentanyl Patches  Pain team/palliative care initiation, where morphine is contra-indicated or not tolerated or where there is specific need for a non-oral route.

    For non-cancer pain, 75mcg/hour should be the maximum dose, if ineffective other causes for lack of response should be considered.
    04.07.02 Fentanyl sublingual tablets Abstral® For the management of breakthrough pain in adults using opioids for chronic cancer pain in the palliative care setting and where other short-acting opioids have been proved to be unsuitable.


    Recivit® - this has now been withdrawn from the UK market
    09.01.01.02 Ferric Carboxymaltose Ferinject® Choice according to local specialist policy

    Not at RBCH or PGH

    DCHFT: Restricted Item  3rd line for renal use only.
    09.01.01.01 Ferrous Fumarate  

    Syrup and Tablets

    09.01.01.01 Ferrous Gluconate 
    09.01.01.01 Ferrous Sulphate Tablets 
    07.04.02 Fesoterodine fumarate 

    Choice should be based on selecting the most cost-effective option.

    03.04.01 Fexofenadine  Tablets.
    Restricted Item Dermatology use only.
    DCHFT: 3rd line after cetirizine and loratadine.
    02.11 Fibrinogen Riastap® Non-pharmacy item. Please contact blood bank for details and availability.
    Commissioned by NHS England as per BCSH Guidelines.

    05.01.07 Fidaxomicin Dificlir®

    DCHFT & Poole ONLY: On advice of Consultant Microbiologist ONLY for the treatment of recurrent Clostridium difficile infection.

    09.01.06 Filgrastim e.g. Zarzio® Commissioned by NHS England for neutropenia according to Trust Guidelines. Use product with lowest acquisition cost.

    Commissioned by NHS England for Barth Syndrome at specialist centres only.
    13.06.01 Finacea®  Gel, azelaic acid 15%
    Excipients include disodium edetate, polysorbate 80, propylene glycol
    06.04.02 Finasteride 
    08.02.04 Fingolimod Gilenya®

    Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA254.

    23.09 Fixation Devices 
    Company Product Code Price Per Unit Comments
    Optium Ugo Gentle Code: 3004-Box of 5 2.47 Really gentle and moveable and re-sticks well
    Clinifix Code: 40-310 Box of 10 (110mmx25mm) 40-410 Box of 10 (140mm x 40mm) 1.71 Good size variety. Kind to skin and suitable for fragile skin
    Stat Loc Code FOLO102DT Box of 5 2.51 Sticks well but can be tough on skin

     

    13.10.01.01 Flamazine®  Cream, silver sulfadiazine 1%
    Excipients include cetyl alcohol, polysorbates, propylene glycol
    A5.03 Flaminal Forte Gel 

    alginate with glucose oxidase and lactoperoxidase, for moderately to heavily exuding wounds,

    A5.03 Flaminal Hydro Gel  

    alginate with glucose oxidase and lactoperoxidase, for lightly to moderately exuding wounds

    02.03.02 Flecainide Tambocor®, Tambocor® XL Tablets, (Injection - secondary care only).
    Hospital initiation.
    01.06.05 Fleet Phospho-soda®  Oral solution.
  • Choice to be determined by Trust.
  • 13.02.01 Flexitol® 

    Heel balm, urea 25%
    Excipients include benzyl alcohol, cetostearyl alcohol, fragrance, lanolin.

    Not RBCH.

    12.02.01 Flixonase Nasule®  Fluticasone propionate 400micrograms/unit doses
    12.02.01 Flixonase®  Fluticasone propionate 50micrograms/dose nasal spray
    05.01.01.02 Flucloxacillin IV 
    05.01.01.02 Flucloxacillin oral 
    07.02.02 Fluconazole  Oral treatment
    05.02.01 Fluconazole IV  Excellent oral bioavailability: use oral route where possible
    05.02.01 Fluconazole oral 
    05.02.05 Flucytosine Ancotil® For use on microbiology advice only.
    08.01.03 Fludarabine Phosphate 
    06.03.01 Fludrocortisone Florinef®
    15.01.07 Flumazenil Anexate® Injection.
    18 Flumazenil  For reversal of benzodiazepines.
    11.04.01 Fluocinolone acetonide intravitreal implant Iluvien® PbR excluded: Commissioned by CCG - Use in accordance with NICE TA301
    11.08.02 Fluorescein sodium injection  unlicensedUnlicensed
    For hospital use during surgical procedures

    DCHFT: 20% injection stocked.
    11.04.01 Fluorometholone FML®
    08.01.03 Fluorouracil 
    04.03.03 Fluoxetine 
    04.02.01 Flupentixol Depixol®, fluanxol® Hospital or specialist initiation.
    Option based on NICE guidance and licence.

    04.02.02 Flupentixol Decanoate  Depot injection

    Hospital initiation
    Option based on NICE guidance and licence

    200mg/ml low volume injection is more expensive so reserve for higher dose prescriptions (>250mg)

    04.02.02 Fluphenazine Decanoate  

    Hospital initiation
    Option based on NICE guidance and licence

    Discontinued in March 2018. Not to be prescribed for new patients

    08.03.04.02 Flutamide 
    03.02 Fluticasone Flixotide® Inhaler.
    Single agent - For combinations with Long-Acting Beta Agonists see separate entries
    03.02 Fluticasone furoate & vilanterol Relvar Ellipta® Inhaler.
    For both licensed indications, asthma and COPD.

    03.02.03 Fluticasone Furoate / Vilanterol / Umeclidinum Trelegy®

    For use within its licensed indication for COPD

    03.02 Fluticasone/Salmeterol Seretide®

    Inhalers.

    *prescribe by brand to ensure the patient receives the same inhaler at each dispensing*

    Seretide 250 Evohaler is now Non-Formulary for new initiations as per DMAG March 2018

    Seretide 250 and 500 Accuhaler are now Non-Formulary for new initiations as per DMAG March 2018

    02.12 Fluvastatin Lescol® Capsules.
    Existing patients only should not be newly initiated.
  • DCHFT: Held on formulary for renal patients only.
  • 09.01.02 Folic Acid 
    06.05.01 Follitropin Alfa  Gonal-F®
    06.05.01 Follitropin Beta Puregon®
    18 Fomepizole  unlicensedUnlicensed. Treatment of choice for methanol (methyl alcohol) and polyethylene glycol (antifreeze) poisoning. PbR excluded: Commissioned by CCG.

    There is an agreement that DCH, RBCH and PHT will keep initial doses of fomepizole to allow time for additional doses to be sourced from other trusts - contact Pharmacy to arrange supplies

    DCH: Available in Emergency Drugs Fridge.

    RBCH: Kept on ITU
    02.08.01 Fondaparinux Arixtra® Injection.
  • Treatment of unstable angina or non-ST-segment elevation myocardial infarction (i.e. Acute Coronary Syndrome.

  • RBCH: Treatment option for Muslim patients not wishing to be treated with LMWH (porcine derived) for VTE treatment or prevention.
  • A2.02.02.03 Foodlink® Complete 

    The calories are based on a sachet made up with 200ml of full cream milk and contain approx. 385 kcals.

    If your patient likes milky drinks prescribe as a supplement to diet 1-2 servings/day.

    Not suitable for patient with cow’s milk intolerance or galactosaemia.

    Not nutritionally complete.

    If your patient dislikes milky drinks choose from the juice style supplements instead.

    03.01.01.01 Formoterol   Inhalers.
    Long-acting beta2 agonist.
    A2.02.02.03 Forticreme® Complete 

    NICE CG32 Nutrition support in adults

    For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds

    A2.02.01.02 Fortijuce®  

    Nutritionally complete juice type sip feed.

    Useful for those patients with preference to juice /dislike to milk. However note these are less cost effective in terms of calorie and protein content than milk based sips.

    These are not suitable for those with an allergy to cow's milk.

    Adult patients

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)

    Paediatric patients

    For use in children over 1 year of age.

     

     

    A2.02.02.03 Fortini Compact Multifibre® 

    For use in children over 1 year of age. 

    A2.01.03.03 Fortini® 

    Nutritionally complete. 

    For use in children over 1 year of age.

    A2.01.03.03 Fortini®Multifibre 

    Includes Smoothie Multifibre.

    Nutritionally complete.

    For use in children over 1 year of age.

    A2.02.02.03 Fortisip® Compact 

    This has a smaller volume and more than 2kcals /ml these can very useful in those who struggle with a larger volume

    Adult patients

    NICE CG32 (Feb 2006) Nutrition support in adults

    Paediatric patients

    Paediatric patients: do not use in patients < 1 year of age, use with caution in children 1-5 years of age.

    A2.02.02.03 Fortisip® Compact Fibre 

    125ml volume with same nutritional value as 200ml bottle so useful for those who cannot manage a large volume

    Adult patients

    NICE CG32 Nutrition support in adults

    Paediatric patients

    Paediatric patients: do not use in patients < 1 year of age, use with caution in children 1-5 years of age.

    A2.02.02.01 Fortisip® Yoghurt Style 

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Useful for patients with taste changes e.g. as a side effect to cancer treatments

    A2.02.02.01 Fortisip® Bottle 

    Adult patients

    NICE CG32 (Feb 2006) Nutrition support in adults www.nice.org.uk/page.aspx?o=cg032niceguideline

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)

    Adult sip feeds containing 1kcal/ml (Fresubin Original, Ensure, Fortimel, Clinutren ISO) should not be prescribed as they are less cost effective compared to 1.5kcal/ml sip feeds

    Paediatric patients

    Do not use in patients < 1 year of age, use with caution in children 1-5 years of age.

     

    A2.02.02.01 Fortisip® Multi Fibre 

    Fortisip Multi Fibre comes in 200ml bottles and is available in 5 flavours: Orange, Strawberry, Banana, Vanilla and Chocolate.

    Adult patients

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Restrict use to those patients with bowel problems as slightly more expensive than 1.5kcal.ml sips without fibre.

    Paediatric patients

    Do not use in patients < 1 year of age, use with caution in children 1-5 years of age.

    A2.02.02.01 Fortisip® Multi Fibre Savoury flavours

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Restrict use to those patients with bowel problems as slightly more expensive than 1.5kcal.ml sips without fibre.

    Fortisip Savoury Multi Fibre comes in 200ml cups and in 2 flavours: Cream of Chicken and Cream of Tomato. To enjoy the great taste of Fortisip Savoury Mutli Fibre simply remove the aluminium lid and warm in the microwave or pour into a pan and heat gently.

    A2.02.02.03 Fortisip® 2kcal 

    Green NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)

    Amber Restrict use to those patients with increased protein requirement. Use only under direction of dietitian. Not to be used for those with renal insufficiency.

    A2.02.02.03 Fortisip® Compact Protein 

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Restrict use to those patients with increased protein requirement. Use only under direction of dietitian. Not to be used for those with renal insufficiency.

    05.03.01 Fosamprenavir Telzir® Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.

    11.03.03 Foscarnet intravitreal injection  unlicensedUnlicensed

    DCHFT: Not routinely stocked.
    05.03.02.02 Foscarnet Sodium Foscavir®

    Commissioned by NHS England (for cytomegalovirus) as per agreed Trust Guidelines.

    Hospital trusts are responsible for making the necessary arrangemenets for patients to receive intravenous treatment.

    05.01.07 Fosfomycin Intravenous Fomicyt® RBCH only: On microbiology advice only.

    DCHFT: Not stocked.

    05.01.13 Fosfomycin oral  Restricted Item On microbiology advice only for resistant urinary tract infection.

    Prescribe as the licensed product, Monuril™. This is available from all major wholesalers so community pharmacies can order directly and there should be no undue delay in the patient receiving the drug (pharmacies are unlikely to keep this as stock).

    Generic prescribing may lead to the dispensing of expensive specials.


    A5.06 Free Range larvae  Larvae300® On specialist advice only.
    Also have an antimicrobial effect

    Loose larvae are contained within a retention system
    06.01.06 FreeStyle Libre® Sensors 

    RED for the following patient groups only:

    1. Type 1 Diabetic adult patients who are pregnant
    2. Type 1 Diabetic adult patients with loss of hypoglycaemia awareness who have experienced a hypoglycaemic episode requiring assistance
    3. Type 1 Diabetic adult patients who require third parties to carry out monitoring and where conventional blood testing is not possible

    Patients will be required to agree to a patient contract for use of the device to maximise potential benefit and undertake training on how to use the device. Results will be shared for audits of effectiveness.

    02.11 Fresh Frozen Plasma  Available from Regional Blood Transfusion Services

    Note: A preparation of solvent/detergent treated human plasma (frozen) from pooled donors is available from Octapharma (OctaplasLG®)

    A2.02.02.03 Fresubin® 2 kcal Drink 

    NICE CG32 Nutrition support in adults

    A2.02.02.03 Fresubin® 2 kcal Fibre Drink 

    NICE CG32 Nutrition support in adults 125ml volume with same nutritional value as 200ml bottle so useful for those who cannot manage a large volume

    A2.04.01.01 Fresubin® 5 kcal Shot 

    NICE CG32 Nutrition support in adults

    (Modular energy supplements to be used under direction of Dietitian only)

    A2.02.02.01 Fresubin® Energy 
    A2.02.02.01 Fresubin® Energy Fibre 

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Restrict use to those patients with bowel problems as slightly more expensive than 1.5kcal.ml sips without fibre.

    A2.02.02.03 Fresubin® YOcreme 

    NICE CG32 Nutrition support in adults

    For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds

    A2.02.02.03 Fresubin® 2kcal Crčme 

    NICE CG32 Nutrition support in adults

    For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds

    A2.02.01.02 Fresubin® Jucy 

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Useful for those patients with preference to juice /dislike to milk. However note these are less cost effective in terms of calorie and protein content than milk based sips.

    These are not suitable for those with an allergy to cow’s milk.

    A2.02.02.01 Fresubin® Protein Energy Drink 

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Restrict use to those patients with increased protein requirement. Use only under direction of dietitian. Not to be used for those with renal insufficiency.

    A2.02.02.01 Fresubin® Thickened Stage 1 

    Should only be started under SLT guidance (dysphagia assessment needed)

    Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.

    Reduces risk of aspiration by removing potential for error

    A2.02.02.01 Fresubin® Thickened Stage 2  

    Should only be started under SLT guidance (dysphagia assessment needed)

    Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.

    Reduces risk of aspiration by removing potential for error

    A2.04.02 Fruitivits® 

    Vitamin, mineral, and trace element supplement in children 3 - 10 years with restrictive therapeutic diets

    13.04 Fucibet®  Cream, betamethasone (as valerate) 0.1%, fusidic acid 2%
    Potency: potent
    Excipients include cetostearyl alcohol, chlorocresol
    13.04 Fucidin H®  Cream, hydrocortisone acetate 1%, fusidic acid 2%
    Potency: mild
    Excipients include butylated hydroxyanisole, cetyl alcohol, polysorbate 60, potassium sorbate
    13.10.01.02 Fucidin®  Cream, fusidic acid 2%
    Excipients include butylated hydroxyanisole, cetyl alcohol

    Ointment, sodium fusidate 2%
    Excipients include cetyl alcohol, wool fat
    02.02.02 Furosemide  Tablets, Liquid, (Injection - secondary care only).
  • DCHFT: The 50mg/5mL and the 5mg/5mL (unlicensedunlicensed) oral solution is restricted to paediatrics only.
  • 21 Furosemide  
    11.03.01 Fusidic Acid m/r drops 1% 
    04.07.03 Gabapentin  Capsules.
    04.08.01 Gabapentin  Capsules.
    Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors.

    16.01 Gadoteric Acid Dotarem®
    16.01 Gadoxetic Acid Primovist®
    04.11 Galantamine  Tablet, modified release capsule, oral solution.
    Alternative prescribing option.

    Use in accordance with NICE recommendations TA217. Refer to local shared care guideline.

    09.08.01 Galsulfase  Commissioned by NHS England for mucopolysaccharidosis. as per NHS England Service Specification.

    For initiation by specialist centres only
    05.03.02.02 Ganciclovir Cymevene®

    Commissioned by NHS England (for Cytomegalovirus) as per agreed Trust Guidelines.

    Hospital trusts are responsible for making the necessary arrangements for patients to receive intravenous treatment.

    11.03.03 Ganciclovir gel 0.15%   Consultant only
    In patients intolerant of aciclovir.
    11.03.03 Ganciclovir intravitreal injection  unlicensedunlicensed

    DCHFT: Not routinely stocked.
    01.01.02 Gaviscon® Infant  Paediatrics.
    01.01.02 Gaviscon®Advance  Tablets on formulary at DCHFT.

    RBCH:
  • ENT use only for severe gastro-pharyngeal reflux causing ENT symptoms.
  • Mr Byrom using as an alternative to sucralfate (long-term shortage)to prevent reflux in patients who have had stomach and oesophageal resections
  • 08.01.05 Gefitinib Iressa® Commissioned by NHS England in line with TA192.
    09.02.02.02 Gelaspan® Gelatin DCHFT only.
    09.02.02.02 Gelatin Gelofusine®

    PHFT - for use by endocopy only

    12.03.01 Gelclair®  Oncology.
    Only at PHFT and RBCH: Haematology and Oncology.

    DCHFT: Oncology patients only. Can be used for palliative care patients at Joseph Weld Hospice.
    08.01.03 Gemcitabine  Only when used in accordance with NHS England criteria
    07.01.01 Gemeprost 
    08.01.05 Gemtuzumab ozogamicin MYLOTARG®

    Commissioned by CDF in line with CDF criteria and NICE TA545.

    13.10.01.02 Gentamicin 0.1% cream  Unlicensed medicine. Restricted use: Renal service for application to PD exit sites.
    11.03.01 Gentamicin drops 0.3% 
    12.01.01 Gentamicin drops 0.3% Genticin®
    11.03.01 Gentamicin drops 1.5%  Preservative free
    unlicensedunlicensed: Available as a manufactured special

    DCHFT: Both preservative free and with preservative available.
    05.01.04 Gentamicin Injection  DCHFT: Adult gentamicin prescribing guidelines - see link below.
    12.01.01 Gentisone® HC  Hydrocortisone acetate drops 1% with gentamicin 0.3%
    08.02.04 Glatiramer Acetate Copaxone®

    Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA32.

    05.03.03.02 Glecaprevir with Pibrentasvir Maviret®

    Treatment of hepatitis C commissioned in line with latest rate card from NHS England.

    06.01.02.01 Gliclazide 
    06.01.02.01 Gliclazide MR 
    06.01.02.01 Glimepiride  DCHFT: Consultant diabetologist only.
    06.01.02.01 Glipizide  DCHFT: Consultant diabetologist only.
    06.01.04 Glucagon GlucaGen® HypoKit
    18 Glucagon injection GlucaGen® Hypokit For treatment of hypoglycaemia due to insulin overdose and supportive off-label (unlicensed) treatment of beta-blocker overdose. Other indications e.g. calcium channel blockers, seek NPIS advice.

    Beta-blocker overdose requires large amounts of glucagon - contact Pharmacy to arrange supplies ASAP.
    08.01 Glucarpidase  Orphan drug

    High Cost Medicine: Commissioned by NHS England for urgent treatment of methotrexate-induced renal dysfunction in accordance with policy.

    Due to the cost of this antidote for methotrexate toxicity, it is not stocked at any hospital in the area. If a supply is needed it can be obtained on a named-patient basis from Clinigen Group 24 hours a day 7 days a week.
    Within office hours:
    Tel: 01283 494 340
    Fax: 01283 494 341
    Out of hours:
    Email: outofhours@clinigengroup.com
    Phone number: 07741 242858
    18 Glucarpidase  Orphan drug

    High Cost Medicine: Commissioned by NHS England for urgent treatment of methotrexate-induced renal dysfunction in accordance with policy.

    Due to the cost of this antidote for methotrexate toxicity, it is not stocked at any hospital in the area. If a supply is needed it can be obtained on a named-patient basis from Clinigen Group 24 hours a day 7 days a week.
    Within office hours:
    Tel: 01283 494 340
    Fax: 01283 494 341
    Out of hours:
    Email: outofhours@clinigengroup.com
    Phone number: 07741 242858
    22.01 Gluco Rx FinePoint 

    Size: 4mm/31g
    Size: 5mm/31g
    Size: 6mm/31g
     

    06.01.06 Gluco Rx Nexus Voice® 
    06.01.06 Gluco Rx Nexus® 
    09.02.01 Glucodrate®  For short bowel syndrome.

    ’Food for Special Medical Purpose’

    Approved for use at RBCH.
    06.01.04 GlucoGel® 
    06.01.06 GlucoMen® Areo Sensor Test Strips 
    13.02.01 GlucoRx Allpresan® diabetic foam cream 

    Allpresan diabetic foam cream Basic (5% urea) is a medical device for the specific treatment of dry and sensitive foot skin in patients with diabetes mellitus. Allpresan diabetic foam cream Basic reduces roughness, counteracts pressure marks and smoothes the skin.

    Allpresan diabetic foam cream Intensive (10% urea) is a medical device for the specific treatment for very dry to chapped foot skin in patients with diabetes mellitus. Allpresan diabetic foam cream Intensive counteracts pressure marks and helps prevent callouses

    Both Allpresan diabetic foam creams can be used on the entire foot, from heel to toe, including between the toes and around wound edges.

    09.02.02.01 Glucose Intravenous  5%, 10%, 20% and 50% IV infusions

    RBCH: 50% not available - use 20% to treat hyperkalaemia - see policy

    DCHFT: 5%, 10%, 15%, 20% and 50% available
    13.07 Glutarol® 

    Solution (= application), glutaraldehyde 10%

    DCHFT: Not routinely stocked.

    Used at RBH

    01.06.02 Glycerol (Glycerin)  Suppositories.
  • Alternative prescribing option.
  • 02.06.01 Glyceryl Trinitrate  Available as Tablet (S/L & Buccal), PUMP Spray, Patches, (Injection/infusion - secondary care only).
    01.07.04 Glyceryl Trinitrate 0.4% Rectogesic® Ointment.
    07.04.04 Glycine Irrigation Solution  Hospital only
    03.01.04 Glycopyrrolate/ indacaterol inhaler Ultibro Breezhaler®
    03.01.02 Glycopyrronium Seebri breezhaler® Inhaler.
    Long-acting option.
    15.01.03 Glycopyrronium  Injection.
    21 Glycopyrronium 
    13.12 Glycopyrronium 0.5% in 70%IMS Lotion  unlicensedUnlicensed
    13.12 Glycopyrronium 0.5% Lotion  unlicensedUnlicensed
    15.01.03 Glycopyrronium Bromide Sialanar®

    Indicated for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3-years and older with chronic neurological disorders

    01.05.03 Golimumab Simponi®
    10.01.03 Golimumab Simponi®

    Commissioned by NHS England for paediatric indications.

    • For psoriatic arthritis in accordance with NICE TAs and local pathway.
    • For Rheumatoid arthritis in accordance with NICE TAs and local pathway.
    • For ankylosing spondylitis in accordance with NICE TAs and local pathway.

     

    06.05.01 Gonadorelin 
    06.07.02 Goserelin Zoladex®, Zoladex® LA DCHFT: 3.6mg implant only.
    08.03.04.02 Goserelin Zoladex®, Zoladex® LA DCHFT: 3.6mg implant only.
    02.05.03 Guanethidine Monosulphate  Injection.
  • DCHFT: Restricted Item Restricted to Consultant use only.
  • 13.05.03 Guselkumab Tremfya® 100 mg solution for injection

    In accordance with NICE guidance

    07.03.03 Gygel®   Gel, nonoxinol ‘9’ 2%
    Excipients include hydroxybenzoates (parabens), propylene glycol, sorbic acid

    No evidence of harm to latex condoms and diaphragms
    Pregnancy toxicity in animal studies
    Breast-feeding present in milk in animal studies

    DCHFT: Not routinely stocked.
    13.04 Haelan® tape  Tape, polythene adhesive film impregnated with fludroxycortide 4 micrograms /cm2
    09.08.02 Haem Arginate Normasang® Commissioned by NHS England (for hepatic porphyria) according to NHS England Service Specification. For highly specialised criteria only.
    14.04 Haemophilus influenzae type B Menitorix®
    14.04 Haemophilus influenzae type B Combined Vaccine 
    03.01.05 Haleraid Haleraid® Cannot be prescribed on FP10
    04.02.01 Haloperidol  Hospital or specialist initiation.
    Baseline ECG is recommended prior to treatment in all patients.
    Option based on NICE guidance and licence.
    Maximum licensed daily dose is 20mg oral administration or 12mg by IM injection.
    04.02.02 Haloperidol  Hospital initiation
    Option based on NICE guidance and licence
    04.06 Haloperidol  Capsules, tablets, liquid.
    Palliative care.
    21 Haloperidol 
    04.06 Haloperidol Injection 
    13.10.04 Hedrin®  Lotion, dimeticone 4%
    Note Patients should be told to keep hair away from fire and flames during treatment
    02.08.01 Heparin  Injection.
  • RBCH: 5000unit in 0.2mL for SC use; 20 000unit in 20mL for IV infusion.
  • DCHFT:
    Heparin calcium 5000 units in 0.2mL.

    Heparin sodium 200 units in 2mL - Renal use only.
    Heparin sodium 5000 units in 5mL - Renal use only.
    Heparin sodium 25000 units in 5mL - Renal use only.

    Heparin sodium (for syringe pump) 1000 units per mL (10mL vial).
    Heparin sodium (for syringe pump) 1000 units per mL (20mL vial).

    Heparin sodium 1000 units per mL (1mL vial).
    Heparin sodium 5000 units per mL (1mL vial).

    Heparin sodium 10 units per mL (5mL vial). Restricted Item  Heparin flush restricted for CVP lines only.
  • 02.08.01 Heparinised saline flush  Heparin sodium 10 units per mL (5mL vial).
    Specialist initiation.
  • DCHFT: Restricted Item Heparin flush restricted for CVP lines only.

  • 14.04 Hepatitis A & B vaccines Twinrix Adult This vaccine is not available at NHS expense in Dorset for Overseas Travel : See Dorset Guidance on Prescribing for Overseas Travel
    14.04 Hepatitis A & B vaccines Twinrix Paediatric This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance on Prescribing for Overseas Travel
    14.04 Hepatitis A vaccine Havrix Junior Monodose DCHFT: Not routinely stocked.
    14.04 Hepatitis A vaccine Single Component Avaxim® DCHFT: Not routinely stocked.
    14.04 Hepatitis A vaccine Single Component Epaxal® DCHFT: Not routinely stocked.
    14.04 Hepatitis A vaccine Single Component Havrix Monodose® DCHFT: Not routinely stocked.
    14.04 Hepatitis A vaccine Single Component VAQTA® Paediatric DCHFT: Not routinely stocked.
    14.04 Hepatitis A vaccine with Hepatitis B vaccine  Twinrix®
    14.04 Hepatitis A vaccine with typhoid vaccine Hepatyrix® DCHFT: Not routinely stocked.
    14.04 Hepatitis A vaccine with typhoid vaccine ViATIM® DCHFT: Not routinely stocked.
    14.05.02 Hepatitis B immunoglobulin  Microbiology request only
    14.04 Hepatitis B vaccine Single Component Engerix B® This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance on Prescribing for Overseas Travel
    14.04 Hepatitis B vaccine Single Component Fendrix® DCHFT: Not routinely stocked.

    This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance for Prescribing for Overseas Travel
    14.04 Hepatitis B vaccine Single Component HBvaxPRO® DCHFT: 10mcg/mL and 40mcg/mL stocked.

    This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance on Prescribing for Overseas Travel
    07.04.04 Hexaminolevulinate 85mg for intravesical solution Hexvix®

    Restricted Item  RBCH approved: Diagnostic agent for patients undergoing blue light cystoscopy for investigation of the bladder to detect cancerous tumours.

    11.99.99.99 Histacryl Blue® Tissue Adhesive
    11.99.99.99 Holoclar® Viable autologous human corneal epithelial cells

    Only for use at Specialist Centres (University of Southampton and Oxford) in accordance with NICE TA 467.

    09.02.02.02 Human Albumin Solution  4.5% and 20% infusions

    DCHFT: Not stocked in Pharmacy - contact blood bank.
    14.05.03 Human Anti-D (Rh0) Immunoglobulin  For routine antenatal anti-D prophylaxis for RhD-negative women in accordance with NICE TA156.

    DCHFT: Not pharmacy.
    14.05.01 Human normal immunoglobulin  

    Commissioned by NHS England as per clinical guidelines for immunoglobulin use second edition update, July 2011.

    NHS England routinely commissions the following products:

    • 10% intravenous immunoglobulin: Gamunex®, Iqymune®, Intratect®, Privigen®, Octagam®, Kiovig®.
    • 5% intravenous immunoglobulin: Intratect®, FlebogammaDIF®, Octagam®.
    • Subcutaneous immunoglobulin: Cuvitru®, Gammanorm®.

    Note: Guidance from NHS England (October 2017) states that the recommended dose of IVIg for the treatment of ITP is a single dose of 1g/kg. A repeat dose of 1g/kg should only be considered at day 7 if there is a failure to achieve a haemostatically adequate platelet count (approval from the local immunoglobulin approval panel is required if earlier use is contemplated in cases of exceptional clinical circumstances such as active mucosal bleeding or the need for emergency surgery).

    14.04 Human papilloma virus vaccine Gardasil®
    06.01.01.01 Human soluble insulin Actrapid® For inpatient use - only available in 10ml vials
    06.01.01.01 Human soluble insulin Humulin® S Alternative prescribing option
    14.05.02 Human Tetanus immunoglobulin 
    11.99.99.99 Hyaluronidase Hyalase®
    02.05.01 Hydralazine IV  Injection - secondary care only.
  • DCHFT: Tablets stocked and listed as Amber Shared Care Guidelines.
  • 01.05.02 Hydrocortisone Colifoam®

    Foam enema.

    Jan 18: There is currently a shortage of of this product due to a change of manufacterer and it anticipated to remain unavailable until mid-2018. Budesonide foam enema can be used as an alternative for adults in the interim at a dose of 1 application daily ( Note this product is not licensed in under 18s).

    10.01.02.02 Hydrocortisone acetate Hydrocortistab®
    13.04 Hydrocortisone cream  Cream, hydrocortisone 0.5%, 1%, 2.5%
    Potency: mild
    12.03.01 Hydrocortisone mucoadhesive buccal tablets 2.5mg 
    13.04 Hydrocortisone ointment  Ointment, hydrocortisone 0.5%, 1%, 2.5%
    Potency: mild
    06.03.02 Hydrocortisone sodium phosphate Efcortesol®

    Amber Amber for patients with Hypoadrenalism e.g. Addison's Disease

    Red Red for all other indications

    As of May 2018 there are still on-going stock issues (see link below)

    06.03.02 Hydrocortisone sodium succinate Solu-Cortef®

    Amber Amber for patients with Hypoadrenalism e.g. Addison's Disease

    Red for all other indications

    Patients should be encouraged to register as a steroid-dependant patient with their local ambulance service as patient consent is required (see SWASFT form below)

    Please see the addisons.org.uk website for videos explaining how to give an emergency injection of hydrocortisone sodium succinate in the event of an adrenal crisis.

    06.03.02 Hydrocortisone tablets 
    13.11.06 Hydrogen Peroxide Crystacide® Cream.

    Not at DCHFT.
    12.03.04 Hydrogen peroxide mouthwash 3% and 6%  DCHFT: 3% only.
    13.11.06 Hydrogen Peroxide Solution BP  For Procedural Use
    13.02.01 Hydromol® 

    Cream, sodium pidolate 2.5%, liquid paraffin 13.8%
    Excipients include cetostearyl alcohol, hydroxybenzoates (parabens)

    Ointment, yellow soft paraffin 30%, emulsifying wax 30%, liquid paraffin 40%
    Excipients include cetostearyl alcohol

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition. 

     

    13.02.01 Hydrous ointment (oily cream) 

    Ointment, (oily cream), dried magnesium sulfate 0.5%, phenoxyethanol 1%, wool alcohols ointment 50%, in freshly boiled and cooled purified water.

    Not DCHFT and RBCH.

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition. 

    09.01.02 Hydroxocobalamin 
    18 Hydroxocobalamin Cyanokit® Can be considered for use in victims of smoke inhalation who show signs of significant cyanide poisoning.

    RBCH: 1 kept in ED; obtain further supplies from PHT
    08.01.05 Hydroxycarbamide  Hospital initiation. Use in accordance with local shared care guideline.
    09.01.03 Hydroxycarbamide  In essential thrombocythaemia
    13.05.03 Hydroxychloroquine   For rheumatoid arthritis in accordance with NICE CG79 recommendations.
    03.04.01 Hydroxyzine 

    Tablets.
    Sedating option.

    Alternative prescribing option to first line.

    A European review of the safety and efficacy of hydroxyzine has been undertaken following concerns of heart rhythm abnormalities associated with this medicine. The review concluded that hydroxyzine is associated with a small risk of QT interval prolongation and Torsade de Pointes, the link to the Drug Safety Update provides more information, click here

    01.02 Hyoscine butylbromide  Buscopan® Tablets, injection.
    21 Hyoscine butylbromide Buscopan ®
    04.06 Hyoscine Hydrobromide  Patches, tablets.
    For hypersalivation.
    15.01.03 Hyoscine Hydrobromide  Injection.
  • Amber: Some palliative care use.
  • 21 Hyoscine Hydrobromide  
    04.06 Hyoscine Hydrobromide Injection  Red status unless for palliative care.
    A5.07.03 Hypafix® Surgical Adhesive Tape 

    Dressing retention in particular of large post-operative wound dressings, gauze and absorbent compresses.

     

    • Skin friendly
    • Split liner for easy removal of release paper.
    • Large range of sizes fits: a large amount of uses.
    • Square frame printing on the release paper: guideline for cutting.

     

    03.07 Hypertonic sodium chloride MucoClear®3% Nebuliser solution.

    DCHFT only: Consultant paediatrician only.
    03.07 Hypertonic sodium chloride 7%  Nebuliser solution.
    11.08.01 Hypromellose drops 0.3%  Preserved or Preservative-free.

    Preservative-free - NOT RBCH- if admitted on this convert to alternative lubricant

    Other strengths of Hypromellose are considered non-formulary
    06.06.02 Ibandronate 50mg Tablets 

    Locally approved for use in post menopausal women with breast cancer in accordance with the local Shared Care Guideline and Pathway.

    06.06.02 Ibandronic Acid 

    150mg strength for use in osteoporosis

    DCHFT: Injection is 3rd line, used in rheumatology patients intolerant of oral bisphosphonates.

    08.01.05 Ibrutinib Imbruvica®

    In accordance with CDF policy and NICE TA429, TA491 and TA502.

    10.01.01 Ibuprofen 
    10.03.02 Ibuprofen 5 % gel  DCHFT: 5% and 10% stocked.
    03.04.03 Icatibant Firazyr® Commissioned by NHS England for Hereditary Angioedema and Acquired Angioedema for acute treatment or short-term prophylaxis prior to planned procedures. See NHS England Policy: B09/P/b.

    Restricted Item May only be initiated by (or on advice of) Specialist Centres where:
  • C1inh is unsuitable due to adverse effects or administration difficulties

  • the specialist clinician determines that Icatibant is the most suitable or cost-effective preparation for the patient


  • Drug costs for emergency use in other hospitals will be reimbursed through the Specialist Centre
    08.01.02 Idarubicin Hydrochloride Zavedos®
    02.08.03 Idarucizumab Praxbind®

    When rapid reversal of dabigatran is require for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

    On Consultant Haematologist advice only.

    RBCH: Stored in Haematology department.


    Commissioned by CCG.

    08.01.05 Idelalisib Zydelig®

    Commissioned in accordance with NICE TA359.

     But NOT in combination with ofatumumab in accordance with as per NICE TA469Black

    09.08.01 Idursulfase  Commissioned by NHS England (for mucopolysaccharidosis) according to NHS England Service Specification, for highly specialised criteria only.

    For initiation by specialist centres only
    08.01.01 Ifosfamide 
    02.05.01 Iloprost injection   Injection.
  • unlicensedUnlicensed.

  • Restricted Item  Restricted for peripheral vascular and rheumatology use.
  • DCHFT: Restricted Item Specialist use only.
  • 02.05.01 Iloprost nebules Ventavis® Only to be initiated by approved Tertiary Centres in accordance with NHS England commissioning policies for Pulmonary Hypertension.
    08.01.05 Imatinib Generic, Glivec®

    For haematology indications use generic drug, for gastrointestinal stromal tumours use Glivec® brand.

    09.08.01 Imiglucerase Cerezyme®

    Commissioned by NHS England (for Gaucher's disease), according to the NHS England Service Specification for highly specialised criteria only.

    For initiation by specialist centres only

    05.01.02.02 Imipenem  On microbiology advice only.

    DCHFT: Consultant only.
    04.03.01 Imipramine 

    Third line choice in line with the primary care protocol for depression

    Anxiety - second line recommended by NICE for Panic Disorder and within Primary Care Protocol

    07.04.02 Imipramine 
    A5.03.02 Inadine   Knitted viscose primary dressing impregnated with povidone–iodine ointment 10%
    03.01.01.01 Indacaterol Onbrez® Inhalers.
    Long-acting beta 2 agonist for COPD.
    02.02.01 Indapamide  Standard release formulation - tablet 2.5mg.
    (MR tablet 1.5mg - non formulary)
    16.01 INDIGO CARMINE Injection 0.8 %  unlicensedUnlicensed
    To aid with detection of colonic polyps/surveillance of ulcerative colitis
    05.03.01 Indinavir Crixivan® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs). See BHIVA Guidelines.
    11.08.02 Indocyanine green 25mg injection  unlicensedunlicensed

    DCHFT: Not routinely stocked.
    07.01.03 Indometacin  Not at RBCH
    10.01.04 Indometacin 
    13.11.01 Industrial Methylated Spirit BP 
    14.04 Infanrix hexa 

    Powder and suspension for suspension for injection.

    Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).

    Infanrix hexa is indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b.

    A2.03.01 Infatrini Peptisorb® 

    200ml bottle. 

    Nutritionally complete. 

    For use from birth to 8kg weight. 

    A2.01.03.02 Infatrini® 

    ACBS indication: disease related malnutrition and malabsorption, or growth failure. For use from birth to 18 months. 

    01.05.03 Infliximab Remsima®, Inflectra®, Remicade®, Flixabi®

    All products should be prescribed by brand. Biosimilars should be used where possible.

    RBCH: Preferred brand is Flixabi

    10.01.03 Infliximab Remsima®, Inflectra®,Remicade® All products should be prescribed by brand. Biosimilars should be used where possible.

    RBCH: Preferred brand is Remsima

    Commissioned by NHS England for paediatric indications (where adult TA available). According to adult TAs (TA130, TA134, TA140, TA143, TA163, TA199) for the range of arthritis-related indications. Also Crohn's disease in children (TA187).

  • For rheumatoid arthritis in accordance with NICE recommendations TA130 and TA195 and local pathway.
  • For ankylosing spondylitis in accordance with NICE TA145 and TA140 and local pathway.
  • For psoriatic arthritis in accordance with NICE TA199 and local pathway.
  • recommendations for acute exacerbations.
  • For psoriasis in accordance with NICE TA134.


  • Not routinely commissioned by NHS England for: connective tissue disease - interstitial lung disease, graft versus host disease, renal indications, sarcoidosis, uveitis or hidradenitis suppurativa. As per IFR approval.
    13.05.03 Infliximab Remsima®, Inflectra®, Remicade®

    All products should be prescribed by brand. All products should be prescribed by brand. Biosimilars should be used where possible.

    RBCH: Preferred brand is Remsima

    14.04 Influenza vaccine  



    14.04 Influenza vaccine (NASAL) Fluenz DCHFT: Not routinely stocked.

    Primary Care Only : Please note that flu vaccines for children should be ordered via IMMFORM and should NOT be reclaimed via NHS prescription services (PPA).
    13.08.01 Ingenol mebutate gel Picato® Use within the local guidance for Actinic Keratosis.

    Gel, ingenol mebutate 150 micrograms/g
    Excipients include benzyl alcohol

    Not stocked at RBCH
    DCHFT: Not routinely stocked.
    08.01.05 Inotuzumab ozogamicin BESPONSA®

    Commissioned by CDF in line with CDF criteria and NICE TA541.

    06.01.01 Insulin (continuous subcutaneous infusion)  Use in accordance with NICE recommendations for insulin pump therapy (TA151).
    06.01.01.01 Insulin 500 units in 1mL  Humulin R®

    unlicensedUnlicensed - RBCH & PHT: See policy. Only to be initiated by Diabetes Specialists. Patients should be initiated on the Humulin R Kwikpen.

     

    DCHFT: No new patients to be commenced without discussion with Formulary Pharmacist. NAMED PATIENT ONLY.

    Star HUMULIN R IS 5 TIMES THE STRENGTH OF OTHER INSULINS - TAKE GREAT CARE WHEN PRESCRIBING OR ADMINISTERING!

    06.01.01.01 Insulin Aspart Fiasp®

    Amber with Shared Care Guidelines for one year from November 2017, continued approval is subject to audit.

    For patients where Novorapid has been tried and proven to be ineffective and where patients are getting post meal hyperglycaemia.

    "The safety and efficacy of Fiasp in children and adolescents below 18 years of age has not been established" SPC

    06.01.01.01 Insulin Aspart  NovoRapid®
    06.01.01.02 Insulin degludec Tresiba®

    Type 1 patients as second line for adults and children.

    Type 2 patients as third line for adults.

    Initiation would be for:

    • Recurrent ketosis / ketoacidosis - use of insulin degludec in patients, particularly those with suspected poor compliance.
    • Adolescent / young adult type 1 diabetes population where there is a history of irregular administration of long-acting insulin.
    • Paediatric patient population already established on insulin degludec treatment reaching adulthood to continue on degludec treatment.
    • Type 1 diabetes population with reduced hypoglycaemia awareness and at risk of severe hypoglycaemic events, including those experiencing nocturnal hypoglycaemia.
    • For frail patients with type 1 or type 2 diabetes at risk of hypoglucaemia and the housebound population requiring administration of insulin from healthcare providers, where timing of insulin administration may vary on a day to day basis.
    06.01.01 Insulin Degludec with Liraglutide Xultophy®
    06.01.01.02 Insulin Detemir Levemir® Alternative prescribing option.
    Recommended option where a basal analogue is required, see NG17, 18 and NG28
    06.01.01.02 Insulin Glargine Lantus® In accordance with NICE NG17,18 and NG28. Refer to local guidance.
    06.01.01.02 Insulin glargine (biosimilar) Abasaglar® Formulary choice for new patients needing a basal analogue insulin.
    06.01.01.02 Insulin Glargine 300 UNITS/ML SOLUTION  Toujeo® Solostar® Amber, initiated by Diabetes Specialists only.
    For use in patients requiring greater than 100 units.


    Formulations of insulin glargine are not bioequivalent and require dosing changes. It is recommended prescriptions should state the brand name Toujeo® where prescribed.

    Advice on changing from glargine 100units/ml or other basal insulin to Toujeo see Drug Safety Update from April 2015 (link)
    06.01.01.01 Insulin Glulisine Apidra®
    06.01.01.01 Insulin Lispro Humalog®
    08.02.04 Interferon Alfa IntronA® Commissioned by NHS England for hepatitis B (TA96) and C (TA75).

    08.02.04 Interferon Beta-1a & Interferon Beta 1-b Avonex®, Rebif®, Extavia®

    Commissioned by NHS England (for Multiple sclerosis) in accordance with NICE TA527 and Department of Health guidance contained in health service circular 2002/004. See NHS England Policy: D04/P/b

    Note: Betaferon® is not recommended as per NICE TA527.

    09.03 Intralipid 20%  For severe local anaesthetic toxicity
    A5.03.02 Iodoflex  Paste, iodine 0.9% as cadexomer–iodine in a paste basis with gauze backing
    A5.03.02 Iodosorb  Ointment, iodine 0.9% as cadexomer–iodine in an ointment basis,
    Powder, iodine 0.9% as cadexomer–iodine microbeads
    16.01 Iohexol Omnipaque®
    16.01 Iopamidol Niopam®
    08.01.05 Ipilimumab YERVOY ®

    For use in accordance with NICE TA268 and TA319 recommendations.

    03.01.02 Ipratropium Atrovent

    Inhaler, nebuliser solution.
    Short-acting muscarinic agonist

    It is recommended that if patients are on a "triple therapy inhaler" and they are requiring ipratropium or similar medications including Combivent via a nebuliser for an acute episode that they should cease use of the triple inhaler short term due to the possible cardiac side effects (in particular arrhythmias). 

    Amber categorisation only applies to adult patients, for paediatric patients, this should be considered "green"

    03.01.04 Ipratropium bromide with salbutamol nebules Combivent®

    NB - less suitable for prescribing. Licensed for bronchospasm in patients with COPD. BNF states flexibility of dosing is lost with a compound bronchodilator but it may be appropriate for patients stabilised on the individual components in the same proportion.

    Amber categorisation only applies to adult patients, for paediatric patients, this should be considered "green"

    It is recommended that if patients are on a "triple therapy inhaler" and they are requiring ipratropium or similar medications including Combivent via a nebuliser for an acute episode that they should cease use of the triple inhaler short term due to the possible cardiac side effects (in particular arrhythmias).

     

    08.01.05 Irinotecan Hydrochloride 
    09.01.01.02 Iron Dextran CosmoFer® Choice according to local specialist policy
    09.01.01.02 Iron Isomaltoside 1000 Monofer® / Diafer® Choice according to local specialist policy

    Not at RBCH

    DCHFT: Restricted Item  2nd line in patients intolerant of iron dextran. In dialysis patients Diafer® is 1st line.
    09.01.01.02 Iron Sucrose Venofer® Choice according to local specialist policy
    05.02.01 Isavuconazole CRESEMBA®

    Commissioned by NHS England (for the treatment of fungal infections), as per agreed Trust Guidelines.

    Restricted Drug For use on microbiology/specialist mycology advice only.

    04.03.02 Isocarboxazid 

    Initiated on specialist advice only as per shared care

    15.01.02 Isoflurane  Anaesthetic.
    05.01.09 Isoniazid 
    06.01.01.02 Isophane Insulin Insulatard®
    06.01.01.02 Isophane Insulin Humulin® I
    06.01.01.02 Isophane Insulin Insuman® Basal DCHFT: Not stocked.
    02.07.01 Isoprenaline  Injection.
    unlicensedUnlicensed.
  • Available from special order manufacturers or specialist importing companies.
  • 13.02.01 Isopropyl Myristate 15% w/w, Liquid Paraffin 15% w/w Isomol Gel®

    Prescribe by brand name

    A highly moisturising gel for regular and frequent use in eczema, psoriasis and other dry skin conditions.

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.

    02.06.01 Isosorbide Mononitrate  Tablets - standard release or MR 60mg.
  • Short acting preparations should be prescribed asymmetrically to reduce the risk of nitrate tolerance.

  • MR tablet 40mg and MR capsules non-formulary.
  • 13.06.02 Isotretinoin  Capsules.
    Hospital or specialist use only
    Side effects require specialist supervision
    13.06.01 Isotrex® gel  Gel, isotretinoin 0.05%
    Excipients include butylated hydroxytoluene
    13.06.01 Isotrexin®  Gel, isotretinoin 0.05%, erythromycin 2% in ethanolic basis
    Excipients include butylated hydroxytoluene

    DCHFT: Not routinely stocked.
    01.06.01 Ispaghula Husk  Granules.
    05.02.01 Itraconazole  Suspension is significantly more expensive than the capsules
    02.06.03 Ivabradine Procoralan® Tablets.
  • Specialist initiation.

  • See commissioning statement.

  • See shared care guideline for ivabradine in heart failure.
  • See shared care guideline for ivabradine in angina.
  • DCHFT: Treatment may only be initiated by a consultant cardiologist in line with local commissioning or NICE guidance.

  • Use in accordance with NICE TA 267 as an option for treating chronic heart failure.
  • 13.06.03 Ivermectin Soolantra®
    08.01.05 Ixazomib Ninlaro®

    Commissioned by CDF in accordance with CDF policy and NICE TA505 for use in combination with lenalidomide and dexamethasone if the conditions of the managed access agreement are followed.

    13.05.03 Ixekizumab Taltz®

    In accordance with NICE guidance

    A5.08.08 K- Lite 

     

    • For the treatment of Venous Leg Ulcers (2nd layer of K-Four multilayer bandage system)
    • Light support for sprains and strains
    • Can be used for retention bandaging

     

    A5.08.08 K- Lite Long 

    Provides no compression
    2nd layer of multi-layer compression bandaging

     

    • For the treatment of Venous Leg Ulcers (2nd layer of K-Four multilayer bandage system)
    • Light support for sprains and strains
    • Can be used for retention bandaging

     

    A5.08.08 K-Band® 

    Knitted Polyamide and Cellulose Contour Bandage, BP 1988
    4 m stretched
    10cm and 15cm

    A5.02.04 KerraCel® Gelling Fiber Dressing 

    100% caboxmethyl celluose primary dressing for use on a variety of exuding wounds. Soft and conformable with high absorbency, and retains its integrity when removed from the wound/cavity.

    KerraCel dressings are designed to:

    • Lock in exudate to protect peri-wound skin from maceration

    • Form a soothing gel when wet

    • Contour to the wound bed to minimise dead space where bacteria can live

    • Sequester harmful components found in exudate (bacteria and MMPs)

    • Help maintain a moist healing environment

    • Be removed from the wound bed in one piece

    A5.03.03 KerraContact AG® 

    Silver wound dressing that is fast and powerful at killing bacteria, destroys biofilms and prevents reformation.

    Contains silver in its most active state

    A5.02.01 KerraLite Cool Dressings 

    KerraLite Cool is a soothing, debriding and moisturising dressing that provides the ideal environment for treating dry to lightly exuding sloughy wounds. It contains a strong, transparent hydrogel that is impermeable to bacteria but permeable to moisture, giving it the capacity to absorb or donate water, according to the needs of the wound.

    A5.01.02 Kerramax Care ® 

    Rationale for use should be based on clinical assessment

    • Highly absorbent for fewer dressing changes
    • Unique horizontal wicking layer increases capacity by distributing exudate
    • Retains exudate to help prevent maceration
    • Stackable to increase absorption for very wet wounds
    • Works under pressure with all forms of compression
    • Maintains integrity, even when fully soaked in exudate
    • Cost-effective compared with similar dressings
    • Locks away exudate so that outer layers remain dry

     

    15.01.01 Ketamine Ketalar® Injection.
  • Current supply problems with 10mg/mL and 50mg/mL. Unlicensed imported ketamine may be available from pharmaceutical wholesalers.
  • 15.01.04.02 Ketorolac Toradol® Injection.
    11.08.02 Ketorolac trometamol drops 0.5% Acular®
    06.01.06 Ketostix® 
    01.06.05 Klean-Prep®  Oral powder.
  • Choice to be determined by Trust.
  • 06.04.01.01 Kliofem® 
    06.04.01.01 Kliovance® 
    A5.08.08 Knit-Band®  

    Knitted Polyamide and Cellulose Contour Bandage, BP 1988

    For dressing retention
    Secondary care supply subject to NHS supply chain derivatives

    All sizes

    A5.08.08 Ko-Flex and Ko-Flex Long 

    4th layer of multi-layer compression bandaging
    10cm x 6m
    10cm x 7m

    A5.08.08 K-Plus Long 

    3rd layer of multi-layer compression bandaging.

    10cm x 10.25m Stretched

    A5.08.08 K-Plus® 

    3rd layer of multi-layer compression bandaging
    10cm x 8.7m stretched

    A5.08.07 K-Soft® and K-Soft Long 

    Padding, absorbent, 10cm x 3.5 m unstretched, 10 cm x 4.5 m unstretched,

    07.03.02.03 Kyleena® 
    02.04 Labetalol  Tablets, (Injection - secondary care only).
    Specialist initiation.
    02.06.02 Lacidipine Motens® 3rd Line Choice

    Option choices agreed for new initiations, existing patients will not be switched unless clinically appropriate.
    04.08.01 Lacosamide  

    Tablets, syrup.
    Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors.

    01.06.04 Lactulose  Solution.
  • Note: Lactulose may also be used for alternative indications e.g. hepatic encephalopathy.
  • 05.03.01 Lamivudine Generic, Epivir® Commissioned by NHS England (for HIV in combination with other anti-retrovirals).
    05.03.03.01 Lamivudine Zeffix® Commissioned by NHS England (for Hepatitis B). See NICE CG165.
    05.03.03.01 Lamivudine Generic, Zeffix®
    04.02.03 Lamotrigine 

    second line for mood stabilisation
    See NICE CG185 Bipolar Disorder

    04.08.01 Lamotrigine  Tablets, dispersible tablets.
    Options based on licence.

    When given for epilepsy: Category 2: base the need for continued supply of a particular manufacturer's product on clinical judgement and consultation with the patient and/or carer, taking into account factors such as seizure frequency and treatment history.

    08.03.04.03 Lanreotide Somatuline® Autogel®, Somatuline® LA

    Commissioned by NHS England, as per agreed Trust Guidelines. Use product with lowest procurement cost.

    • Neuroendocrine tumors (carcinoid syndrome).
    • Restricted Item RBCH only: Third line treatment for acromegaly (second line if patient is unfit for surgery). 
    • Restricted Item Specialist centres only: congenital hyperinsulinism - in line with highly specialised criteria.
    01.03.05 Lansoprazole 
    • Capsules first line.
    • Orodispersible tablets (i.e. Lansoprazole FasTabs) are restricted for use in adult patients with swallowing difficulties or with a feeding tube only.

    GPs should consider discontinuing PPIs in patient with unexplained eGFR decline or substituting them with ranitidine if indicated.

    Such patients should be referred for specialist advice as per CKD NICE guidance i.e.

    • eGFR less than 30 ml/min/1.73m2
    • sustained decrease in eGFR of 25% or more within 12 months
    • sustained decrease in eGFR of 15 ml/min/1.73m2 or more within 12 months

    Alternatively, patients with AKI as defined in the AKI NICE guidance should be discussed with a nephrologist if interstitial nephritis is suspected, as soon as it is possible i.e. within 24 hours.ť

    09.05.02.02 Lanthanum Fosrenol® Commissioned by NHS England (for adult renal dialysis only) as per Trust Guidelines. For hyperphosphataemia in renal patients, in accordance with local shared care guideline.

    09.08.01 Laronidase Aldurazyme® Commissioned by NHS England (for mucopolysaccharidosis)as per NHS England Service Specification, for highly specialised criteria only.

    For initiation by specialist centres only.
    11.06 Latanoprost 50micrograms/ml Single Use Drops Monopost® Preservative-free.

    RBCH: 1st line prostaglandin analogue for patients with preservative allergy.

    DCHFT: Consultant use only. 1st line prostaglandin analogue for patients with proven intolerance to preserved eye drops.
    11.06 Latanoprost drops 50micrograms with timolol 5mg/ml  Xalacom®
    11.06 Latanoprost drops 50micrograms/ml 
    19.03 LBF Sterile no sting barrier film wipes  CliniMed Ltd®
    Product reference code 3820
    Approved pack size 30
    10.01.03 Leflunomide  For third-line use in patients with active RA when treatment with sulphasalazine and methotrexate is contra-indicated or has been found to be ineffective or not tolerated. Treatment to be initiated by a consultant rheumatologist. In accordance with NICE recommendations (CG79) and local shared care guideline.

    DCHFT: Consultant Rheumatologist only.
    23.14 Leg Bag Support Straps 
    Company  Product Codes Price per unit Comments
    Unomedical 45-85-Ex 1.42 Box of 10 (straps last a week)
    Qufora 21100301 2.05 Box of 10
    Gret Bear 10622C-10 1.38 Box of 10

     

    08.02.04 Lenalidomide Revlimid®

    Commissioned by NHS England in line with NICE TA171 and TA322.

    09.01.06 Lenograstim Granocyte® Commissioned by NHS England for neutropenia according to Trust Guidelines. Use product with lowest acquisition cost.

    Commissioned by NHS England for Barth Syndrome according to highly specialised criteria only.
    08.01.05 Lenvatinib Kisplyx®, Lenvima®

    Kisplyx®:

    • Commissioned by NHSE in accordance with NICE TA498 for the treatment of previously treated renal cell carcinoma in combination with everolimus.

    Lenvima®:

    • Commissioned by NHSE in accordance with NICE TA535 for the treatment of differentiated thyroid cancer after radioactive iodine.
    • Commissioned by CDF in line with CDF criteria for first line treatment of Child Pugh A locally advanced or metastatic hepatocellular carcinoma.
    02.06.02 Lercanidipine  2nd Line Choice

    Option choices agreed for new initiations, existing patients will not be switched unless clinically appropriate.
    08.03.04.01 Letrozole  Use in accordance with NICE TA112 and local shared care guideline. Local criteria for use include for advanced disease in postmenopausal women (including those in whom other anti-oestrogen therapy has failed) and those women at high risk of early distant relapse.

    06.07.02 Leuprorelin acetate Prostap® SR DCS, Prostap® 3 DCS

    Acute trusts only stock the 3.75mg  (monthly) implant.

    Caution with brand when prescribing/dispensing:

    • Prostap® is the only brand licenced for the mangament of endometriosis, fibroids and precocious puberty.
    • Lutrate® is NOT licensed for the treatment of endometriosis, management of fibroids or precocious puberty. It is only licenced for prostate cancer. 
    08.03.04.02 Leuprorelin Acetate Prostap® SR DCS, Prostap® 3 DCS, Lutrate

    Acute Trusts: For prostate cancer, Lutrate® is the preferred brand as it is the most cost-effective option. 

    Note: Lutrate® is not licensed for endocrine/gynaecological indications.

     

    04.08.01 Levetiracetam  Tablets, oral solution.
    Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors.

    04.08.01 Levetiracetam IV  Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors.

    11.06 Levobunolol drops 0.5% and polyvinyl alcohol 1.4% Betagan®
    15.02 Levobupivacaine Chirocaine® 0.25% and 0.5% injections, 0.125% epidural infusion
    15.02 Levobupivacaine with Fentanyl  Fentanyl 2 micrograms per mL & levobupivacaine 0.1% Epidural infusions.
    09.08.01 Levocarnitine Carnitor®

    Commissioned by NHS England for carnitine deficiency when supplied in secondary care, as per NHS England service specification. For initiation by specialist centres only.

    May be supplied in primary care when adequate shared care with specialist centre is in place.

    Specialist centre to provide appropriate shared care agreement. 

    11.03.01 Levofloxacin 5mg/ml Eye Drops 

    Unit dose vials are preservative-free. Preserved formulations contain benzalkonium chloride 0.05 mg in 1 ml

    RBCH only: Acute microbial keratitis and corneal conditions where benzlkonium chloride is contra-indicated. Where avoidance of preservative is not necessary (e.g. in patients without pre-existing corneal epitheliopathy or small corneal ulcers [<1mm]) preserved G.ofloxacin / G.levofloxacin will be the agent of choice.

    For patients who might require treatment up to 6 months. Hospital consultant should advise GP of course length and stopping date. 

    05.01.12 Levofloxacin IV  Initial treatment for severe community acquired penumonia. DCH only - see guidelines for place in therapy.
    05.01.12 Levofloxacin oral  For severe community acquired pneumonia (after initial IV treatment). DCH only - see guidelines for place in therapy.
    13.03 Levomenthol cream Dermacool®

    Restrict to pruritic conditions where moderate to severe skin condition requires it

    Dermacool® 0.5%, Dermacool® 1%, Dermacool® 2%

    Aqua, White Soft Paraffin, Emulsifying Wax, Paraffinum Liquidum, Menthol (1%), Phenoxyethanol.

    Self Care Self Care Medicine

    04.02.01 Levomepromazine Nozinan® Oncology/palliative care use.
    21 Levomepromazine  
    04.06 LEVOMEPROMAZINE (METHOTRIMEPRAZINE)  

    Used in palliative care.

    07.03.05 Levonelle® 1500  Levonorgestrel 1.5 mg. Emergency contraception up to 72 hours after UPSI/contraceptive failure

    Not RBCH
    07.03.02.03 Levonorgestrel 13.5mg intrauterine delivery system Jaydess® Jaydess® should only be used if other alternatives have been considered but none is suitable, eg:

    For those who wish to use IUS and plan pregnancies for less than 5
    years.
    Previous failed fit with IUS because of malposition.
    IUS required and uterine cavity on sounding is between 5-7cm
    Amenorrhea associated with Mirena ® is unacceptable to patient
    Previous ovarian cysts
    Hormonal adverse effects with Mirena®; but IUS required (reduced dose of LNG in Jaydess® less likely to cause AE).
    06.02.01 Levothyroxine 
    02.03.02 Lidocaine  Injection.
    Minijet 2% (Not DCHFT).
    Lidocaine infusion in 5% glucose (Not DCHFT).
  • DCHFT: 1% and 2% injections (which can be used to prepare 0.1% or 0.2% in glucose 5% intravenous infusions).
  • 15.02 Lidocaine   Injection - various strengths.
  • DCHFT: 0.5%, 1% and 2% available.
  • 15.02 Lidocaine 2% with Chlorhexidine 0.25% Instillagel®
    15.02 Lidocaine 2.5% with Prilocaine 2.5% EMLA®
    15.02 Lidocaine 4% cream LMX 4® DCHFT - Paediatrics only. Cannulation in/for theatres.
    15.02 Lidocaine 5% and Phenylephrine 0.5%  Pump spray.
    15.02 Lidocaine 5% plasters  Restricted Item
    RBCH:
  • Rib Fracture Pain: - Max 5 days supply
  • Post-amputation pain: Acute Pain Consultant only:where other analgesics or anaesthetic techniques are contra-indicated or have limited benefit - Maximum 30 days supply. Patients must be informed that this treatment is short-term before commencing therapy.

    DCH: Rib Fracture Pain: - Max 5 days supply. Patients must be informed that this treatment is short-term before commencing therapy.

    PHT: Rib Fracture Pain:






  • 15.02 Lidocaine for Surface Anaesthesia  Topical anaesthetics are only marginally effective and cause sensitisation.

  • 5% Ointment

  • Laryngojet® 40mg/ml solution

  • Xylocaine® 10% spray

  • 15.02 Lidocaine with Adrenaline 
  • DCHFT: Lidocaine 1% and 2% with adrenaline (various strengths). Dental cartridges.
  • 13.02.01 Light Liquid Paraffin 63.4% Oilatum® Cream

    Prescribe by Brand

    Oilatum Cream is indicated in the treatment of contact dermatitis, atopic dermatitis, senile pruritus, ichthyosis and related dry skin conditions. 

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.

    01.06.07 Linaclotide Constella▼® Within local pathway for chronic constipation, and commissioning statement
    06.01.02.03 Linagliptin Trajenta® No dosing adjustment required in renal impairment

    Use in accordance with NICE NG28 i.e. if metformin is not tolerated, or in combination for first and second treatment intensification
    05.01.07 Linezolid   On microbiology advice only
    06.02.01 Liothyronine Injection

    For emergency treatment of hypothyroid coma, OR in patients exhibiting signs and symptoms of hypothyroidism following failure to administer/absorb usual oral replacement therapy (typically after 5-7 days).

    06.02.01 Liothyronine Tablets

    Black  (NOT RECOMMENDED) for new patients 

    Amber SCG Amber SCG  for existing patients (pending review with endocrinologist)

    08.01.05 Liposomal Cytarabine-Daunorubicin Vyxeos®

    Commissioned by CDF in line with CDF criteria for untreated, high risk, acute myeloid leukaemia.

    13.10.05 LiquiBand® Tissue Adhesive
    13.02.01 Liquid and White Soft Paraffin Ointment  

    Ointment, liquid paraffin 50%, white soft paraffin 50%

    Self Care Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.

    11.08.01 Liquid Paraffin ointment  VitA-POS® or Xailin®

    For night time use.
    A2.04.01.02 Liquigen® 

    Liquigen is an emulsion consisting of approximately 50% MCT oil and 50% water.

    Liquigen may be used in conditions requiring high energy where fat absorption is impaired and where a high MCT intake is indicated.

    Liquigen can be used as part of the MCT ketogenic diet.

    Liquigen can be used to fortify a wide variety of drinks and foods and is also useful as an energy enhancer in tube and sip feeds.

    Liquigen is suitable from birth.

    06.01.02.03 Liraglutide Victoza® Use in accordance with NICE TA 203 and local shared care guideline. For GLP-1 agonists use in accordance with NICE NG28.

    GREEN: When used with oral anti diabetic agents in patients with Type 2 Diabetes

    AMBER : When used with insulin in patients with Type 2 Diabetes

    04.04 Lisdexamfetamine Elvanse® Second/third line option for younger patients and those unable to swallow tablets. Refer to shared care guidance.

    DCHFT: Restricted Item  Consultant psychiatrist only.
    02.05.05.01 Lisinopril  Tablets.
    04.02.03 Lithium Carbonate 

    Hospital initiation. Prescribers should be aware of the brand and form of lithium each patient is taking and ensure all prescribing is branded. Local practice, prescribing guidance, formulary restrictions and shared care guideline should be considered when initiating lithium.

    The Preferred Brand for DHC is Priadel

    04.02.03 Lithium Citrate liquid 

    Hospital initiation. Prescribers should be aware of the brand and form of lithium each patient is taking and ensure all prescribing is branded. Local practice, prescribing guidance, formulary restrictions and shared care guideline should be considered when initiating lithium.

    July 2018: Sanofi have confirmed that there is very limited stock available currently of Priadel oral solution ( Lithium Citrate oral solution 520 mg/5 mL). Due to the issues with switching formulations / brands of lithium expert advice is available at this link 

    https://www.sps.nhs.uk/articles/shortage-of-priadel-lithium-citrate-520mg-5ml-liquid/

    06.01.02.03 Lixisenatide Lyxumia® As an option alongside exenatide and liraglutide. When initiating a GLP-1 agonist choice should be on clinical indication and consideration to use the most cost effective product, first line. Refer to shared care guideline.

    GREEN: When used with oral hyperglycaemics in patients with Type 2 Diabetes

    AMBER : When used with insulin in patients with Type 2 Diabetes

    13.04 Locoid®  Cream, hydrocortisone butyrate 0.1%
    Potency: potent
    Excipients include cetostearyl alcohol, hydroxybenzoates (parabens)

    Ointment, hydrocortisone butyrate 0.1%
    Potency: potent
    12.01.01 Locorten-Vioform®  Flumetasone pivalate drops 0.02% and clioquinol 1%
    11.04.02 Lodoxamide drops 0.1%  Second choice for
  • Adults

  • Seasonal allergies

  • Not at DCHFT.
    07.03.01 Loestrin 20®  Ethinylestradiol 20 mcg / norethisterone 1mg
    07.03.01 Loestrin 30®  Ethinylestradiol 30 micrograms/ Norethisterone acetate 1.5mg
    04.03.01 Lofepramine 
    04.10.03 Lofexidine BritLofex® For Specialist Use only
    01.04.02 Loperamide  Capsules, syrup.
    05.03.01 Lopinavir and Ritonavir Kaletra® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs), as per BHIVA Guidelines.
    03.04.01 Loratadine  Tablets, syrup.
    04.01.02 Lorazepam  See Primary care protocol for anxiety disorders.
    04.01.02 Lorazepam injection 4mg/ml 

    For status epilepticus or rapid tranquilisation.

    By intramuscular or slow intravenous injection (into a large vein)

    Note: Only use intramuscular route when oral and intravenous routes not possible

    For intramuscular injection it should be diluted with an equal volume of water for injections or physiological saline (but only use when oral and intravenous routes not possible)

    See NICE NG10: Violence and Aggression: Short Term Management in Mental Health, Health and Community Settings

    04.08.02 Lorazepam IV 4mg/ml  By slow intravenous injection (into large vein)
    21 Lorazepam Tablets  Genus® Can be used sublingually
    02.05.05.02 Losartan  Tablets.
  • For hypertension.
  • 11.04.01 Loteprednol  Not at DCHFT.
    13.04 Lotriderm®  Cream, betamethasone dipropionate 0.064% (≡ betamethasone 0.05%), clotrimazole 1%
    Potency: potent
    Excipients include benzyl alcohol, cetostearyl alcohol, propylene glyco
    01.06.07 Lubiprostone Amtiza® Capsules.
  • In accordance with the requirements of NICE TA318 (Lubiprostone for treating chronic idiopathic constipation).
  • Licensed for a two week course of treatment. If treatment is not effective after 2 weeks, re-examine and consider the benefit of continuing treatment.
  • Also see local commissioning statement for further details.
  • DCHFT: For gastroenterology consultant initiation only in line with NICE TA318.


  • 08.01.05 Lutetium (177Lu) oxodotreotide Lutathera®

    Commissioned by CDF in line with CDF criteria and NICE TA539.

    05.01.03 Lymecycline Tetralysal® 300 For dermatology use only.
    13.06.02 Lymecycline  DCHFT: Dermatology use only.
    01.06.04 Macrogols  Oral powder.
  • Alternative prescribing option.

  • Available as various brands including Laxido®, Movicol®.

  • Restricted Item  DCHFT: Consultant use only and, restricted indications (i) one-off use in faecal impaction or (ii) patients intolerant or unresponsive to lactulose and magnesium hydroxide suspension. It is envisaged that very few patients will be discharged from hospital on this medication.
  • 18 Macrogols Klean-Prep® or similar For gut decontamination of agents not bound by activated charcoal (e.g. iron & lithium).
    01.06.04 Macrogols Paediatric   Oral Powder
    First line in paediatric patients.

    To avoid confusion this should be prescribed by brand and prescribers are asked to use the most cost effective option. Brands available (DM&D 21/11/16) include:
    • CosmoCol® Paediatric
    • Laxido® Paediatric plain
    • Macilax® Paediatric
    • Molative® Paediatric
    • Movicol® Paediatric Chocolate
    • Movicol® Paediatric Plain
    09.05.01.03 Magnesium Aspartate Magnaspartate®
    09.05.01.03 Magnesium citrate  Not at RBCH
    Not at DCHFT

    See primary care Magnesium guidelines
    09.05.01.03 Magnesium Glycerophosphate  Oral

    See primary care magnesium guidelines
    09.05.01.03 Magnesium Glycerophosphate NeoMag®

    Second line: for patients who cannot tolerate magnesium aspartate

    01.06.04 Magnesium Hydroxide   Mixture.
    09.05.01.03 Magnesium Hydroxide Mixture BP  
    09.05.01.03 Magnesium Sulfate  Injection / Infusion
    01.01.01 Magnesium Trisilicate Mixture BP 
    23.06 Male drainage pouch 
    Company Code Price Comment

    Hollister

    Urinary pouch
    Code: GVC000

    £2.86

    Specialist Item.
    Retractable penis – area would need to be shaved.

    23.05 Male urinals 
    Company Code Price Comment

    Beambridge
    Medical

    Male Funnel (6–35)

    Male Mini Funnel (6–35 M)

    £13.07

    £13.07

    For men who Spray when passing urine. Mini will fit in pocket. One Supplied.

    02.02.05 Mannitol  Infusions.
    03.07 Mannitol  Bronchitol ®

    Commissioned by NHS England for use in CF as per policy A01/P/b and NICE TA266.

    Adult patients: specialist centre only (University Hospital Southampton)

    Paediatric patients: PHFT use in line with network arrangements with UHS.

    Not at DCH or RBCH.

    05.03.01 Maraviroc Celsentri® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs) as per BHIVA Guidelines.

    A2.04.01.01 Maxijul® Super Soluble 

    (Modular energy supplements to be used under direction of Dietitian only)

    Adult patients

    NICE CG32 Nutrition support in adults

    Paediatric patients

    Flavoured carbohydrate supplements are not suitable for children under 1 year of age, dilute liquid supplements forfore use in children under the age of 5. 

    11.04.01 Maxitrol®  Eye drops, dexamethasone 0.1%, neomycin sulfate 3500 units /g, polymyxin B sulfate 6000 units/mL

    Eye ointment, dexamethasone 0.1%, neomycin sulfate 3500 units/g, polymyxin B sulfate 6000 units/g
    14.04 Measles, mumps and rubella vaccine MMRVAXPRO
    05.05.01 Mebendazole 
    01.02 Mebeverine Hydrochloride  Tablets, liquid.
    06.07.04 Mecasermin Increlex® Commissioned by NHS England (for growth failure) as per NHS England Policy: E03/P/a.
    A5.03.01 Medihoney Antibacterial Apinate Dressings 

    creates a micro-environment that supports healing and provides an antibacterial barrier.

    INDICATIONS

    • Acute and chronic wounds
    • Infected and malodorous wounds
    • Necrotic and sloughy wounds 
    • Pressure sores
    • Surgical, post op wounds, donor sites and recipient graft sites
    • Leg ulcers (venous, arterial and mixed aetiology ulcers) and diabetic foot ulcers
    • 1st and 2nd degree burns
    A5.03.01 Medihoney Antibacterial Wound Gel 

    Medihoney Antibacterial Wound Gel is formulated from 100%. Medical Grade Manuka Honey combined with 20% natural plant waxes in a single patient sealable, reusable tube.

    INDICATIONS

    • Acute and chronic wounds
    • Infected and malodorous wounds
    • Necrotic and sloughy wounds 
    • Pressure sores
    • Surgical, post op wounds, donor sites and recipient graft sites
    • Leg ulcers (venous, arterial and mixed aetiology ulcers) and
    • diabetic foot ulcers
    • 1st and 2nd degree burns
    A5.03.01 Medihoney Tulle  

    Medihoney® Antibacterial Honey Tulle Dressing protects the wound by creating a barrier against wound pathogens, including antibiotic resistant strains, and therefore reducing the risk of infection. The osmotic action produces an outflow of body fluid which assists the removal of wound bacteria, endotoxins, debris and slough, providing a cleaner wound, rapidly removing malodour and helping to reduce the inflammatory response, oedema and exudate levels. Granulation and epithelialisation are enhanced through provision of the optimal healing environment.

    INDICATIONS

    • Leg/foot ulcers
    • Pressure ulcers
    • Infected wounds
    • Sloughy wounds
    • Necrotic wounds
    • Malodorous wounds
    • Donor and recipient graft sites
    • Burns
    • Surgical wounds
    • Diabetic wounds
    • Abrasions
    13.02.02 Medihoney® Barrier Cream 

    Medihoney barrier cream contains only natural products with the addition of 30% active 100% Pure Medical Grade Manuka Honey.

    INDICATIONS

    • Protects at risk skin from breakdown associated with incontinence. Can be used under incontinence pads

    • Can be used around wound edges to protect skin from irritation
      and breakdown caused by wound exudate

    • Suitable for injured skin or areas that are inflamed or excoriated

    • Suitable for all ages including paediatrics and neonates

    A5.03.01 Medihoney® Gel Sheet Dressing 

    Medihoney Gel Sheet is a sterile, non-adherent wound dressing made from Medihoney Antibacterial Honey (80%w/w) and Sodium Alginate for wound care (20%w/w).

    The gel sheet is helpful in treating a wide variety of mild to moderately exudating wounds

    Indications:

     

    • Leg and foot ulcers.
    • Pressure ulcers.
    • Infected wounds.
    • Burns.
    • Sloughy wounds.
    • Malodorous wounds.
    • Donor and recipient graft sites.

     

    A5.03.01 Medihoney® HCS  

    Medihoney® HCS is an all in one dressing combining the unique properties of medical grade Manuka honey with a hydrogel sheet containing superabsorbent polymers.

    INDICATIONS

    • Diabetic Foot Ulcers
    • Leg Ulcers (venous, arterial and mixed aetiology ulcers)
    • Pressure Ulcers 1st and 2nd degree burns
    • Donor sites
    • Traumatic Wounds
    • Surgical and post op wounds
    • Skin tears
    • Suitable for neonatal and paediatric patients
    06.01.06 Medi-Test® Glucose Test Strips 
    06.04.01.02 Medroxyprogesterone Acetate Provera® Climanor®
    07.03.02.02 Medroxyprogesterone acetate as Sayana Press®

    08.03.02 Medroxyprogesterone Acetate Provera®
    10.01.01 Mefenamic Acid 
    05.04.01 Mefloquine Lariam® BNF caution: mefloquine and driving - dizziness or a disturbed sense of balance may affect performance of skilled tasks e.g. driving; effects may occur and persist upto several months after stopping mefloquine.

    DCHFT: Not stocked.
    08.03.02 Megestrol Acetate Megace®
    04.01.01 Melatonin SR Circadin ® When used for licensed indication only: for short-term treatment of insomnia in adults over 55 years, for up to 13 weeks.
    A5.01.01 Melolin 

    A low-adherent absorbent dressing used for the management of a wide variety of light to moderately exuding wounds including clean sutured wounds, abrasions, lacerations and minor burns.

    10.01.01 Meloxicam 
    08.01.01 Melphalan Alkeran®
    04.11 Memantine  Tablets, oral drops.
    For moderate to severe Alzheimer's disease. In accordance with NICE recommendations (TA217). Specialist initiation. Refer to local shared care guideline.

    09.06.06 Menadiol Sodium Phosphate  For malabsorption syndrome
    14.04 Meningococcal A, C, W135, and Y conjugate vaccine Menveo® Menveo powder and solution for solution for injection

    Meningococcal Group A, C, W135 and Y conjugate vaccine

    DCHFT: Not routinely stocked.

    This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance for Prescribing for Overseas Travel
    14.04 Meningococcal group B Vaccine Bexsero®

    Meningococcal group B Vaccine (rDNA, component, adsorbed)

    14.04 Meningococcal group C conjugate vaccine Menjugate Kit®
    14.04 Meningococcal Group C conjugate vaccine NeisVac-C
    14.04 Meningococcal polysaccharide A, C, W135 and Y vaccine ACWY Vax® DCHFT: Not routinely stocked.

    This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance for Prescribing for Overseas Travel
    14.04 Meningococcal Quadrivalent A, C, W135 & Y conjugate vaccine Nimenrix ® DCHFT: Not routinely stocked.

    This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance for Prescribing for Overseas Travel
    06.05.01 Menotrophin Menopur ®, Merional®, Human Menopausal Gonadotrophin
    A5.02.03 Mepitel  

    Soft silicone, semi-transparent/transparent wound contact dressing

    All Sizes

    For the management of life threatening acute skin disorders such as toxic epidermal necrolysis (TEN), bullous pemphigoid and vasculitis.

    15.02 Mepivacaine Scandonest Plain® Injection.
    03.04.02 Mepolizumab Nucala®

    Commissioned by NHS England in accordance with NICE TA431 at specialist centres only.

    09.08.01 Mercaptamine Cystagon® Commissioned by NHS England (for nephropathic cystinosis) as per NHS England Service Specification according to highly specialised criteria.

    For initiation by specialist centres only
    01.05.03 Mercaptopurine  Unlicensed special - see entry above
    01.05.03 Mercaptopurine  Tablets only.
  • Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults unlicensedUnlicensed for these indications but in line with national guidelines.
  • See also Chapter 8 section 8.1.3
  • unlicensedUnlicensed 10mg capsules may be available as a special. At RBCH, the capsules are Consultant Gastroenterologist for Crohn's disease in conjunction with allopurinol only.

  • 08.01.03 Mercaptopurine  Also see BNF chapter 1 section 1.5.3.
    01.05.03 Mercaptopurine 20mg in 1mL Suspension 

    unlicensedUnlicensed
    RBCH: Consultant Gastroenterologist for Crohn’s disease where patients are unable to swallow capsules

    07.03.01 Mercilon®  Ethinylestradiol 20mcg / desogestrel 150mcg
    05.01.02.02 Meropenem Meronem® On microbiology advice only.

    RBCH:On microbiology advice or in accordance with neutropenic sepsis policy.

    DCHFT: Consultant only or as per local guidelines.
    01.05.01 Mesalazine 

    Retention enema, foam enema, suppositories.

    • To be initiated in secondary care.
    • Only Asacol® foam enemas are licensed for 2g doses to treat disease in the descending colon.

    Crohns patients prescribed mesalazine should undergo a specialist review given the updated guidance from the Gastroenterology working group: "There is almost no convincing evidence of any therapeutic benefit for the use of any form of mesalazine in Crohns. All patients with Crohns currently receiving mesalazine should be reviewed with consideration of the aim of stopping this treatment.

    01.05.01 Mesalazine 

    Tablets, m/r tablets, sachets.

    • There is no evidence to show that any one oral preparation of mesalazine is more effective than another; however, the delivery characteristics of oral mesalazine preparations may vary. It is recommended that mesalazine is prescribed by brand name (Asacol®, Asacol® MR, Ipocol®, Mezavant® XL, Octasa®, Pentasa®, or Salofalk®).
    • If it is necessary to switch a patient to a different brand of mesalazine, the patient should be advised to report any changes in symptoms.
    • Initiate all non-oral mesalazine products in secondary care.
    • Give Octasa® for all newly initiated patients. Patients on Asacol® can safely be switched to Octasa®. Routine switching of brands is not expected.
    • Patients prescribed mesalazine require 6 monthly or annual blood tests for renal function when treatment is stable.

    Crohns patients prescribed mesalazine should undergo a specialist review given the updated guidance from the Gastroenterology working group: "There is almost no convincing evidence of any therapeutic benefit for the use of any form of mesalazine in Crohns. All patients with Crohns currently receiving mesalazine should be reviewed with consideration of the aim of stopping this treatment." 

    01.05.01 Mesalazine Octasa®

    All new initiations should be for the Octasa® brand

    08.01 Mesna  DCHFT: Injection and tablets available.
    18 Mesna  For cyclophosphamide toxicity.

    RBCH: IV kept in Pharmacy Aseptic Unit
    13.02.02 Metanium® 

    Ointment, titanium dioxide 20%, titanium peroxide 5%, titanium salicylate 3% in a basis containing dimeticone, light liquid paraffin, white soft paraffin, and benzoin tincture

    This product is indicated for use in Paediatrics and is not included in the Moisture Pathway.

    02.07.02 Metaraminol  Injection.
    06.01.02.02 Metformin 
    06.01.02.02 Metformin modified release  DCHFT: Restricted Item  In accordance with NICE guidelines - for patients in whom gastrointestinal tolerability prevents patients continuing with standard release metformin.
    04.10.03 Methadone hydrochloride 

    Now categorised as a "red drug" for substance misuse. DMAG March 2018

    03.09.01 Methadone linctus 2mg/5ml  Oral solution for palliative care only (not substance misuse).
    05.01.13 Methenamine Hippurate Hiprex®

    May be used as a third-line prophylactic agent if no renal or hepatic impairment.

    For prophylaxis of UTIs only in line with the SCAN Guidelines

    01.05.03 Methotrexate  Tablets.
  • 2.5mg tablets preferred as per Dorset CCG policy.
  • There are a number of different indications for methotrexate. Please see
    here for other indications.
  • Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults unlicensedUnlicensed for these indications but in line with national guidelines.
  • 08.01.03 Methotrexate 
    10.01.03 Methotrexate 

    Hospital initiation for rheumatoid arthritis in accordance with shared care guidelines, NICE recommendations CG79 and NPSA patient safety alert.

    Do not prescribe 10mg tablets. See the Policy for Prescribing Methotrexate for further information.

    Where using a Pre-Filled Syringe, patients should be maintained on the product they were initiated / trained on. Brands available include Nordimet® and Metoject®

    13.05.03 Methotrexate 

    For severe psoriasis unresponsive to conventional therapy.

    DCHFT: Restricted Item  Consultant use only.

    09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera®
    13.05.02 Methoxypsoralen Gel/Bath Lotion  Not DCHFT.
    01.06.01 Methylcellulose 450 0.5% liquid  Liquid.
  • Radiology use for MRI enteroclysis.

  • RBCH UL medicines risk assessment: LOW risk

  • 02.05.02 Methyldopa  Tablets.
  • For use during pregnancy.
  • 04.04 Methylphenidate  Tablets, modified release capsules and tablets.
    Use in accordance with NICE TA98 and local shared care guidelines for use in children and adults.

    Modified release preparations are shared care. Concerta, Matoride and Xenidate are the options available. Prescribers are asked to consider the most cost effective option taking into consideration the strengths and release profiles available. Prescribers should specify the specific name of the preparation and these should not be switched.

    DCHFT: Modified release formulations are second line when compliance with standard release form is a significant problem.
    06.03.02 Methylprednisolone 
    10.01.02.02 Methylprednisolone Acetate Depo-Medrone®,
    10.01.02.02 Methylprednisolone Acetate with Lidocaine Depo-Medrone® with Lidocaine DCHFT: Not routinely stocked.
    18 Methylthioninium chloride injection methylene blue unlicensedUnlicensed. For treatment of methaemoglobinaemia and as a diagnostic aid for fistula detection.

    RBCH: kept in ITU and Theatres
    04.06 Metoclopramide  Tablets, syrup.
    MHRA/CSM advice Aug 13:
  • In adults over 18 years, metoclopramide should only be used for prevention of postoperative nausea and vomiting, radiotherapy-induced nausea and vomiting, delayed (but not acute) chemotherapy-induced nausea and vomiting, and symptomatic treatment of nausea and vomiting, including that associated with acute migraine (where it may also be used to improve absorption of oral analgesics

  • Metoclopramide should only be prescribed for short-term use (up to 5 days)

  • Usual dose is 10 mg, repeated up to 3 times daily; max. daily dose is 500 micrograms/kg

  • Note This advice does not apply to unlicensed uses of metoclopramide (e.g. palliative care)
    04.06 Metoclopramide Injection  Red formulary status does not apply to palliative care.

    MHRA/CSM advice Aug 13:
  • In adults over 18 years, metoclopramide should only be used for prevention of postoperative nausea and vomiting, radiotherapy-induced nausea and vomiting, delayed (but not acute) chemotherapy-induced nausea and vomiting, and symptomatic treatment of nausea and vomiting, including that associated with acute migraine (where it may also be used to improve absorption of oral analgesics

  • Metoclopramide should only be prescribed for short-term use (up to 5 days)

  • Usual dose is 10 mg, repeated up to 3 times daily; max. daily dose is 500 micrograms/kg

  • Note This advice does not apply to unlicensed uses of metoclopramide (e.g. palliative care)
    02.02.01 Metolazone  Tablets.
    For refractory heart failure.
    unlicensedUnlicensed, available from special order manufacturers or specialist importing companies.
    02.04 Metoprolol  Tablets, (Injection - secondary care only).
  • Modified release tablet is non formulary.
  • Alternative prescribing option to first line agents.
  • 13.04 Metosyn®  FAPG cream, fluocinonide 0.05%
    Potency: potent
    Excipients include propylene glycol

    Ointment, fluocinonide 0.05%
    Potency: potent
    Excipients include propylene glycol, wool fat

    Not RBCH
    Not DCHFT
    13.10.01.02 Metrogel®  Gel, metronidazole 0.75%
    Excipients include hydroxybenzoates (parabens), propylene glycol

    For rosacea
    05.04.02 Metronidazole 
    05.04.03 Metronidazole 
    05.04.04 Metronidazole 
    07.02.02 Metronidazole 0.75% Vaginal Gel 

    1st line treatment for bacterial vaginosis. 

    05.01.11 Metronidazole IV 
    05.01.11 Metronidazole oral/rectal 
    13.08.01 Metvix®  Hospital use only
    Methyl-5-Aminolevulinate
    Used in photodyamic therapy
    06.07.03 Metyrapone Metopirone® Hospital initiation
    02.03.02 Mexiletine  Capsules, injections.
  • unlicensedUnlicensed: Available from special order manufacturers or specialist importing companies.
  • DCHFT: Restricted Item 
  • Restricted to specialist use only. Not routinely stocked.
    05.02.04 Micafungin Mycamine®

    Commissioned by NHS England (for fungal infection treatment). Use as per Trust Guidelines.

    DCHFT: Not routinely stocked.

    07.02.02 Miconazole Gyno-Daktarin®
    11.03.02 Miconazole drops 1%  Preservative free
    unlicensedunlicensed

    DCHFT: On formulary but not stocked.
    05.02.02 Miconazole oral gel Daktarin®
    12.03.02 Miconazole oral gel 24mg/ml Daktarin® Not at RBCH
    07.03.01 Microgynon 30®  Ethinylestradiol 30mcg / levonorgestrel 150mcg
    15.01.04.01 Midazolam Hypnovel® Injection.
  • DCHFT: Higher strength products (2mg/mL or 5mg/mL) are restricted to critical care areas only.
  • 21 Midazolam 
    04.08.02 Midazolam buccal liquid Buccolam® and Epistasus®

    For use in status epilepticus in accordance with local shared care guidelines for use in children and adults. Buccolam® is licensed for use in status epilepticus in children (3months up to 18 years). Epistasus® is licensed for ages 10-18years.

    DCHFT: Buccolam® 2.5mg in 0.5mL, 5mg in 1mL, 7.5mg in 1.5mL stocked.

    For adult patients (> 18 years of age) there is no licensed version of buccal midazolam for this age group.



    DCHFT: Epistatus 10mg in 1mL stocked. unlicensedunlicensed.

    04.08.02 Midazolam IV 
    02.07.02 Midodrine 

    Tablets.

    • DCHFT: 2.5mg and 5mg tablets stocked.

     

    08.01.05 Midostaurin Rydapt®

    Commissioned by NHSE in line with NICE TA523 recommendations.

    08.02.04 Mifamurtide Mepact ®
    07.01.02 Mifepristone  DCHFT: CD CD. Restricted Item  Medical termination of pregnancy in accordance with local protocol.
    09.08.01 Miglustat Zavesca® Commissioned by NHS England (for Gaucher's disease/Niemann-Pick) as per NHS England Service Specification according to highly specialised criteria only.

    For initiation by specialist centres only.
    02.01.02 Milrinone Primacor® Injection.
    Secondary care only. Specialist use for severe heart failure.
    11.05 Minims® Atropine Sulfate drops 1%  Preservative-free
    11.05 Minims® Cyclopentolate Hydrochloride drops 0.5%  Preservative-free

    RBCH only: For in-patient/clinic use.
    DCHFT: On local formulary and stocked.
    11.05 Minims® Cyclopentolate Hydrochloride drops 1%  Preservative-free
    11.05 Minims® Phenylephrine Hydrochloride drops 10%  Preservative-free
    11.05 Minims® Phenylephrine Hydrochloride drops 2.5%  Preservative-free
    11.06 Minims® Pilocarpine 2%  Preservative-free
    11.05 Minims® Tropicamide drops 0.5%  Preservative-free
    11.05 Minims® Tropicamide drops 1%  Preservative-free
    11.03.01 Minims®Chloramphenicol drops 0.5%  Preservative free
    11.08.02 Minims®Fluorescein Sodium drops 1%  DCHFT: 2% on local formulary.
    11.07 Minims®Lidocaine Hydrochloride 4% with Fluorescein 0.25%  Preservative free
    11.07 Minims®Oxybuprocaine Hydrochloride 0.4% 
    11.04.01 Minims®Prednisolone drops 0.5%  Preservative free
    11.07 Minims®Proxymetacaine Hydrochloride 0.5% 
    11.07 Minims®Tetracaine Hydrochloride(Amethocaine hydrochloride 0.5% and 1% 
    03.01.05 Mini-Wright®  Available as low range peak flow meter and standard range peak flow meter.
    05.01.03 Minocycline  For dermatology use only.
    13.06.02 Minocycline  Minocycline should not be used routinely for acne as there are safety risks and it is an expensive treatment.
    Minocycline can cause gastrointestinal and dermatological adverse reactions.
    Minocycline has also been associated with hyperpigmentation and systemic lupus erythematosus (SLE) and autoimmune hepatitis. The BNF advises that if treatment continues beyond six months, GPs should monitor patients every three months for hepatotoxicity, pigmentatiion and SLE.
    02.05.01 Minoxidil Loniten® Tablets.
    Restricted Item Restriction: For renal use only.
    07.04.02 Mirabegron  Choice should be based on selecting the most cost-effective option. Use within NICE TA 290 and local commissioning statement.
    07.03.02.03 Mirena®  Intra-uterine system, T-shaped plastic frame (impregnated with barium sulfate and with threads attached to base) with polydimethylsiloxane reservoir releasing levonorgestrel 20 micrograms/24 hours
    04.03.04 Mirtazapine  Second choice after SSRIs
    01.03.04 Misoprostol Cytotec® Tablets.
    07.01.01 Misoprostol  RBCH use licensed oral tablets for vaginal administration (off-label)
    08.01.02 Mitomycin Mitomycin C Kyowa®
    11.99.99.99 Mitomycin C Eye Drops 0.02% and 0.04%  unlicensedUnlicensed.

    For ocular surface neoplasms.

    DCHFT: Not routinely stocked.
    08.01.05 Mitotane Lysodren®
    08.01.02 Mitoxantrone  
    15.01.05 Mivacurium Chloride Mivacron® Injection.
    04.03.02 Moclobemide 
    04.04 Modafinil Provigil® Tertiary care initiation only
    A2.03.01 Modjul® Flavour System Nutricia

    If patient dislikes or does not tolerate Modulen IBD then trial of Elemental 028 extra can be considered

    Available in 2 flavours or the unflavoured one can be made more palatable using the flavour modjuls

    Use liquid E028 for patients who need to take product away from home or who dislike the taste of powdered E028

    Short bowel syndrome, intractable malabsorption, inflammatory bowel disease, bowel fistulae.

    A2.03.02 Modulen IBD®  

    Paediatric and adult patients.

    Short bowel syndrome, intractable malabsorption, inflammatory bowel disease, bowel fistulae.

    03.03.02 Montelukast  Tablets, chewable tablets, granules.

    For use in asthma in accordance with British Thoracic Society Guidelines
    04.07.02 Morphine  Solution, concentrated solution, modified release tablets and capsules.
    For non-cancer pain, strong opioids should be considered only when they are used as part of a programme of supported rehabilitation, with the goal of helping patients to manage pain-related disability. There is no evidence of superior clinical analgesic effect of other opioids over morphine.
    04.07.02 Morphine Injection/Infusion 

    There is no evidence of superior clinical analgesic effect of other opioids over morphine.

    Red status does not apply for palliative care use.

    12.03.04 Mouthwash solution tablets  Not stocked at RBCH
    01.06.05 Moviprep®  Oral powder.
  • Choice to be determined by Trust.

  • Restricted Item DCHFT: For patients with co-morbidities only.
  • 05.01.12 Moxifloxacin 

    Restricted indications: 

    PGH respiratory

    DCH GUM only

    Osteomyelitis in patients with diabetes, on advice of consultant microbiologist ONLY

    11.03.01 Moxifloxacin 0.5% Eye Drops 

    Contans boric acid as a preservative

    RBCH only: Acute microbial keratitis and corneal conditions where benzlkonium chloride is contra-indicated. Based on clinical review of eye this may be more cost effective than preservative free G.levofloxacin. Boric acid is less toxic to the cornea than benzalkonium chloride, and is more suitable for short- to medium-term use.

    For patients who might require treatment up to 6 months. Hospital consultant should advise GP of course length and stopping date.

    02.05.02 Moxonidine  Tablets.
  • For renal use only.
  • 13.10.01.01 Mupirocin 2% Cream / Ointment Bactroban®

    Cream; mupirocin (as mupirocin calcium) 2%

    Excipients include benzyl alcohol, cetyl alcohol, stearyl alcohol

    DCHFT: Cream, indicated for the topical treatment of secondary infected traumatic lesions such as small lacerations, sutured wounds or abrasions [up to 10cm in length or 100cm square in area], due to susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. Treatment should not exceed 10 days.

    Ointment; mupirocin 2% no excipients

    DCHFT: Ointment, indicated for the treatment of skin infections by susceptible organisms, e.g. impetigo, folliculitis and furunculosis. Treatment should not exceed 10 days.

    12.02.03 Mupirocin nasal ointment 2%  Bactroban®

    Nasal ointment; mupirocin 2% (as calcium salt) in white soft paraffin basis

    08.02.01 Mycophenolate mofetil 

    Red

    • Commissioned by NHS England (for transplant immunosuppression only). 
      Renal transplant under the care of Dorset County Hospital or Portsmouth Hospitals Trust – RED (where GPs are still prescribing immunosuppressants, in these cases please inform the CCG Medicines Management team)

    Amber 

    • Renal or other organ transplant by tertiary centre other than Dorset County Hospital or Portsmouth Hospitals Trust – AMBER drug with shared care guideline (Trust specific). GPs are expected to continue supplies for existing patients only until repatriation occurs, no dates yet confirmed by NHS England.
    13.05.03 Mycophenolate mofetil 

    Hospital use only - unlicensed

    08.02.01 Mycophenolic acid (as Mycophenolate sodium) Myfortic®

    Red

    • Commissioned by NHS England (for transplant immunosuppression only). Renal transplant under the care of Dorset County Hospital or Portsmouth Hospitals Trust – RED (where GPs are still prescribing immunosuppressants in these cases please inform the CCG Medicines Management team)

    Amber

    • Renal or other organ transplant by tertiary centre other than Dorset County Hospital or Portsmouth Hospitals Trust – AMBER drug with shared care guideline (Trust specific). GPs are expected to continue supplies for existing patients only until repatriation occurs, no dates yet confirmed by NHS England. 
    11.05 Mydricaine No. 2 injection  Compound preparation containing procaine, atropine and adrenaline.

    Unlicensed special.

    DCHFT: Consultant only.
    22.02 Mylife Clickfine AutoProtect 

    Size: 5mm/31g


    22.01 Mylife Penfine Classic 

    Size: 4mm/32g
    Size: 6mm/32g
     
     

    06.01.06 MyLife® Pura Test Strips 
    06.01.06 MyLife® Unio Test Strips 
    06.07.02 Nafarelin Synarel® Hospital only, for in vitro fertilisation.
    02.06.04 Naftidrofuryl Oxalate  Capsules.
  • For use in accordance with NICE TA223.
  • Possible manufacturers supply problem for unknown duration.


  • 04.10.01 Nalmefene  Tablets

    It is very important that both the services who will be providing the psychosocial support and the GP who will be prescribing communicate closely to ensure that the drug is used in accordance with its licence and the NICE guidance (TA 325). A patient should not continue to receive the drug if they drop out of the support structure. Whilst the drug is categorised as “amber” all prescribing including the initial supply will be the responsibility of the GP and the shared care is in place as the prescribing and support will be coming from different providers who need to communicate closely. Providers of psychosocial support are listed in the shared care guidance and accompanying flow diagram. Patients should be encouraged to self-refer to these services following their initial discussion with their GP. GPs should not initiate prescriptions until they have received communications from the support service.
    01.06.07 Naloxegol  As per nice TA 345
    18 Naloxone injection  For emergency treatment of opioid overdose.
    04.10.01 Naltrexone 
    04.10.03 Naltrexone Liquid 5mg/ml

    RBCH & PHFT: Consultant dermatologist use for treatment of Hailey-Hailey disease only.

    04.10.03 Naltrexone Tablets

    As an adjunct to prevent relapse in detoxified, formerly opioid-dependent patients, in accordance with NICE TA115, shared care guideline and where supporting infrastructure is available to primary care.

    10.01.01 Naproxen 
    10.01.04 Naproxen  or alternative NSAID
    12.02.01 Nasacort®  Triamcinolone acetonide 55micrograms/dose nasal spray
    12.02.03 Naseptin®  Chlorhexidine hydrochloride drops 0.1% and neomycin sulfate 0.5%

    Contains arachis oil: avoid in peanut or soya allergy
    12.02.01 Nasonex®  Mometasone furoate 50micrograms/dose nasal spray
    08.02.04 Natalizumab Tysabri®

    Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA127.

    11.03.02 Natamycin drops 5% 

    unlicensedunlicensed


    DCHFT: On formulary but not stocked.

    02.04 Nebivolol  Tablets.
    Specialist initiation. Usually restricted to patients intolerant of other beta-blockers, bisoprolol usual first line choice. Note for patients requiring a 2.5mg dose, halve 5mg tablets where possible.
  • DCHFT: Restricted Item Restricted for heart failure patients intolerant of other beta-blockers. Must be initiated by consultant cardiologist or heart failure specialists (including Nurse Prescribers).

  • 08.01.03 Nelarabine Atriance®

    Commissioned by CDF (for cancer) as per CDF policy.

    A2.03.01 Neocate Junior® 

    Neocate Junior is a rarely used product. It is for use in children with severe ongoing allergies who have difficulty maintaining adequate nutritional intake and are usually prescribed for children with a complex clinical picture.

    A2.03.01 Neocate LCP®  On advice of dietitian or hospital specialist, for cow's milk protein allergy and other ACBS indications
    A2.03.01 Neocate Spoon® 

    Neocate Spoon is a weaning aid suitable for short term use by infants who are unable to take adequate amounts of specialised infant formula to meet their nutritional requirements for calcium. Its ongoing use should be closely monitored.

    05.01.04 Neomycin Sulphate 
    10.02.01 Neostigmine  Specialist initiation
    15.01.06 Neostigmine  Injection.
    15.01.06 Neostigmine with Glycopyrronium  Injection.
    04.06 Netupitant / Palonosetron Akynzeo®

    Single dose for the following indications:

    1. Prophylactic use in all chemotherapy regimens containing initial doses of cisplatin ≥ 70mg/m2 (highly emetogenic). E.g Pemetrexed+Cisplatin and Vinorelbine+Cisplatin for lung cancer.
    2. Prophylactic use in all chemotherapy regimens that are deemed moderately emetogenic (FEC 100)
    3. Replacing aprepitant or palonosetron as secondary prophylaxis of chemotherapy induced nausea and vomiting.
    05.03.01 Nevirapine 

    Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs) as per BHIVA Guidelines.

    Generic products should be used where available.

    07.03.02.02 Nexplanon®  Implant, containing etonogestrel 68 mg in radiopaque flexible rod
    For use by doctors with appropriate training and up-to-date documentary evidence of competency from the Faculty of Family Planning

    DCHFT: Restricted Item  Family planning only.
    02.06.03 Nicorandil  Tablets.
    04.10.02 Nicotine 
    07.01.03 Nifedipine  Not at RBCH
    02.06.02 Nifedipine capsules  Capsules.
    For Raynaud's phenomenon only.
    02.06.02 Nifedipine Modified-Release  Once daily long acting preparations:
  • Coracten XL® 30mg, 60mg.

  • Adalat® LA 20mg (DCHFT: 30mg also on formulary/stocked).


  • Twice daily sustained release:
  • Coracten SR® (except maternity - Adalat® Retard.)
  • 08.01.05 Nilotinib Tasigna®

    Commissioned by NHS England in line with NICE TA241 and TA251.

    19.02 Niltac Sting Free medical adhesive remover wipes™  ConvaTec Ltd
    Product reference code TR102
    Approved pack size 30
    02.06.02 Nimodipine Nimotop® Tablets, Injection.
    03.11 Nintedanib Ofev®

    Commissioned by NHS England for idiopathic pulmonary fibrosis as per TA379 via specialist centres only.

    08.01.05 Nintedanib  Vargatef®, Ofev®

    Vargatef®:

    • Commissioned by NHS England in line with NICE TA347 for non-small-cell lung cancer.

    Restricted Item Ofev®: 

    • Commissioned by NHS England in line with NICE TA379 for idiopathic pulmonary fibrosis via specialist centres only.
    08.01.05 Niraparib Zejula®

    Commissioned by CDF in line with CDF criteria and NICE TA528.

    09.08.01 Nitisinone Orfadin® Commissioned by NHS England (for alkaptonuria and tyrosinaemia), as per NHS England Service Specification for highly specialised criteria only.

    For initiation by specialist centres only.
    02.05.01 Nitric oxide (inhaled)  Commissioned by NHS England (for Pulmonary Arterial Hypertension of the newborn mostly) as per agreed Trust Guidelines.
    05.01.13 Nitrofurantoin 
    15.01.02 Nitrous oxide  Anaesthetic.
    08.01.05 Nivolumab Opdivo®

    Commissioned in line with CDF criteria and NICE technology appraisal reccomendations.

    13.09 Nizoral® 

    Restrict to where moderate to severe skin condition requires it

    Shampoo, ketoconazole 2%

    Self Care Self Care Medicine

    13.10.02 Nizoral®  Cream, ketoconazole 2%
    Excipients include cetyl alcohol, polysorbates, propylene glycol, stearyl alcohol
    02.07.02 Noradrenaline / Norepinephrine  Injection, pre-filled syringe.
  • RBCH: 4mg/8mg/16mg in 50mL prefilled syringes for Critical Care unlicensedUnlicensed.

  • DCHFT: 4mg/4mL injection. 8mg in 50mL prefilled syringes for Critical Care unlicensedUnlicensed.
  • 06.04.01.02 Norethisterone 
    08.03.02 Norethisterone 
    05.01.12 Norfloxacin  For microbiology use only. Not at DCH.
    07.03.02.01 Norgeston®  Levonorgestrel 30 micrograms
    07.03.02.01 Noriday®  Norethisterone 350 micrograms
    06.01.01.01 NovoRapid® PumpCart®  For patients using Accu-Chek Insight insulin pump only.
    A2.02.02.02 Nutilis Fruit Stage 3 

    NICE CG32 Nutrition support in adults

    For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds

    A2.05.02 Nutilis® Clear 

    Should only be started under SLT guidance (dysphagia assessment needed). These tend to be better tolerated

    For a syrup thick consistency per 200ml costs are as follows

    • Nutilis  = 14-21p
    • Nutilis Clear = 14.5p 
    • Thick & easy = 20p 
    • Thick & easy Clear = 20p 
    • Resource Thicken up = 18p 
    • Resource Thicken up clear = 16p
    A2.02.02.03 Nutilis® Complete Stage 1 

    Should only be started under SLT guidance (dysphagia assessment needed)

    Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.

    Reduces risk of aspiration by removing potential for error

    A2.05.02 Nutilis® Powder 

    For adult and paediatric patients.

    Should only be started under speech and language therapist guidance (dysphagia assessment needed).

    Not stocked at RBCH - use Nutilis Clear

    A2.02.02.03 Nutilis® Complete Stage 2  

    Should only be started under SLT guidance (dysphagia assessment needed)

    Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.

    Reduces risk of aspiration by removing potential for error

    A2.02.02.03 Nutilis® Complete Stage 3 

    Should only be started under SLT guidance (dysphagia assessment needed)

    Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.

    Reduces risk of aspiration by removing potential for error

    A2.03.01 Nutramigen 1 with LGG ® 

    First line choice for cow's milk protein allergy in infants under 6 months of age

    A2.03.01 Nutramigen 2 with LGG ® 

    First line choice for cow's milk protein allergy in infants over 6 months of age

    A2.03.01 Nutramigen PURAMINO® 

    On advice of dietitian or hospital specialist, for cow’s milk protein allergy and other ACBS indications

    A2.01.01.01 Nutricomp® Standard 

    NICE CG32 (Feb 2006) Nutrition support in adults www.nice.org.uk/page.aspx?o=cg032niceguideline

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)

    Adult sip feeds containing 1kcal/ml (Fresubin Original, Ensure, Fortimel, Clinutren ISO) should not be prescribed as they are less cost effective compared to 1.5kcal/ml sip feeds

    A2.02.02.02 Nutricrem® 

    NICE CG32 Nutrition support in adults

    For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds

    A2.01.03.01 Nutriprem 2  

    For promoting catch up growth in pre-term and small for gestational age infants. Use up to 6 months corrected age. 

    09.03 Nutryelt ® 
    07.03.01 NuvaRing®  To be initiated under specialist advice

    Vaginal ring, releasing ethinylestradiol approx. 15 micrograms/24 hours and etonogestrel approx. 120 micrograms/24 hours,
    13.10.02 Nystaform®  Cream, nystatin 100 000 units/g, chlorhexidine hydrochloride 1%
    Excipients include benzyl alcohol, cetostearyl alcohol, polysorbate 60
    05.02.03 Nystatin Nystan®
    12.03.02 Nystatin 100,000 units/ml oral suspension  Use Nystin brand (Ł1.80) compared with generic (Ł20)
    01.09.01 Obeticholic acid Ocaliva®

    Commissioned by NHS England in accordance with NICE TA443 at specialist hepatobiliary centres only.

    Commissioned specialist centres in South region:

    • University Hospital Southampton NHS Foundation Trust
    • Portsmouth Hospitals NHS Trust
    • Oxford University Hospitals NHS Foundation Trust
    • University Hospitals Bristol NHS Foundation Trust
    • Royal Surrey County Hospital NHS Foundation Trust
    08.02.03 Obinutuzumab  Gazyvaro®

    In accordance with NICE TA343 in combination with chlorambucil for untreated chronic lymphocytic leukaemia.

    In accordance with NICE TA472 in combination with bendamustine for treating rituximab-refactory follicular lymphoma (CDF).

    In accordance with NICE TA513 for untreated advanced follicular lymphoma.

    13.07 Occlusal® 

    Cutaneous solution, salicylic acid 26% in polyacrylic solution

     

    Used by DCH

    11.08.02 Ocriplasmin  PbR excluded: Commissioned by CCG - See commissioning statement and NICE TA297.
    13.11 Octenisan®   For MRSA decolonisation

    2nd line at PHT & those with sensitivity to chlorhexidine.
    08.03.04.03 Octreotide 

    For the short term management of high output stomas and fistulas and in palliative care.

    08.03.04.03 Octreotide Sandostatin® LAR®

    Commissioned by NHS England, as per agreed Trust Guidelines. Use product with lowest procurement cost.

    • Neuroendocrine tumors (carcinoid syndrome).
    • Restricted Item RBCH only: Third line treatment for acromegaly (second line if patient is unfit for surgery). 
    • Restricted Item Specialist centres only: congenital hyperinsulinism - in line with highly specialised criteria.
    18 Octreotide injection  For sulphonylurea overdose.
    06.04.01.01 Oestrogel® 
    08.02.03 Ofatumumab Arzerra®

    In accordance with NICE TA344 in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia

    05.01.12 Ofloxacin  For microbiology use only. Not at PGH.

    RBCH: GUM

    DCHFT: Restricted Item  In accordance with PID guidelines only and second line for chronic prostatitis. Urology or Microbiology consultant only, or on Urology or Microbiologist advice in patients with chronic prostatitis who haven't responded to ciprofloxacin.
    11.03.01 Ofloxacin drops 0.3%  DCHFT: Consultant use only.
    13.02.01.01 Oilatum® Plus  Bath additive, benzalkonium chloride 6%, triclosan 2%, light liquid paraffin 52.5%

    Excipients include acetylated lanolin alcohols, isopropyl palmitate
    13.02.01.01 Oilatum® Emollient 

    Reserved for patients with severe eczema and infants under the age of 1 year. 

    Emollient bath additive
    Light liquid paraffin 63.4%
    Excipients include acetylated lanolin alcohols, isopropyl palmitate, fragrance

    DCHFT: Scalp application also on local formulary.

    Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation.

    Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required

    01.07.03 Oily Phenol Injection BP  5% injection.
    04.02.01 Olanzapine (oral) 

    In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of schizophrenia (CG178) and local shared care guideline.
    In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of biolar disorder NICE CG185
    To be initiated on specialist advice only for schizophrenia, mania and preventing recurrence in bipolar disorders.

    DCHFT: Orodispersible tablets (Velotabs) limited to use when compliance is a problem.

    04.02.02 Olanzapine Embonate ZypAdhera® Hospital use only
    See olanzapine LAI guidelines
    Can be considered as a treatment option for psychoses with appropriate risk management arrangements
    04.02.01 Olanzapine injection 

    UNLICENSED Can be considered as a short term treatment option for psychoses with appropriate risk management arrangements.

    08.01.05 Olaparib Lynparza® NHSE commissioned for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy in accordance with NICE TA381.
    08.01.05 Olaratumab Lartruvo®

    Commissioned in line with Cancer Drug Fund and NICE TA465 recommendations.

    03.01.01.01 Olodaterol Striverdi Respimat®
    11.04.02 Olopatadine drops 1mg/ml  Children
    Antihistamine and mast cell stabiliser combined and has advantage of twice daily application
    Second choice for
  • Adults

  • Seasonal allergies
  • 03.04.02 Omalizumab Xolair®

    Commissioned by NHS England (for uncontrolled asthma) in accordance with NICE TA278.

    Patients must be assessed and approved for a 16 weeks trial by MDT decision at the Wessex Severe Asthma Centre. Trial outcome to be assessed at regional MDT to decide if ongoing treatment is appropriate. Blueteq registration and approval is necessary for all new initiations and continuations.

    13.05.03 Omalizumab Xolair®

    Commissioned by CCG (for chronic spontaneous urticaria) in accordance with NICE TA339 and local commissioning statement.

    05.03.03.02 Ombitasvir with Paritaprevir and Ritonavir Viekirax®

    Treatment of hepatitis C commissioned in line with latest rate card from NHS England.

    01.03.05 Omeprazole 
    • First line PPI at RBCH.
    • Capsules first line.
    • Omeprazole MUPS: Restricted use Paediatrics only
    • Update from the Cardiology Working Group July 2017: The interaction of omeprazole on the antiplatelet efficacy of clopidogrel is no longer considered clinically significant.

    GPs should consider discontinuing PPIs in patient with unexplained eGFR decline or substituting them with ranitidine if indicated.

    Such patients should be referred for specialist advice as per CKD NICE guidance i.e.

    • eGFR less than 30 ml/min/1.73m2
    • sustained decrease in eGFR of 25% or more within 12 months
    • sustained decrease in eGFR of 15 ml/min/1.73m2 or more within 12 months

    Alternatively, patients with AKI as defined in the AKI NICE guidance should be discussed with a nephrologist if interstitial nephritis is suspected, as soon as it is possible i.e. within 24 hours.ť

    01.03.05 Omeprazole IV 
  • DCHFT:IV infusion (unlicensedUnlicensed) used only in accordance with local protocol.
  • Not available at RBCH.
  • 1st line PHT
  • 04.06 Ondansetron  Tablets, sublingual tablets, injections.
    Hospital use only.

    DCHFT information: Ondansetron is licensed for moderately emetogenic chemotherapy for up to 5 days duration. It is also used for post-operative nausea and vomiting for just three doses. Long term treatment is rarely justified or necessary.
    06.01.06 OneTouch® Select Plus Test Strips 
    19.05 Orabase Paste®   ConvaTec Ltd
    Product reference code S103
    Approved pack size 30g

    AMBER -For protective paste for Peristomal or Mucosal Ulceration or Mucocutaneous Separation . Should only be a recurring item for patients with prolapsed stoma.
    19.10 Orahesive powder®   ConvaTec Ltd
    Product reference code S106
    Approved pack size 25g

    AMBER – only to be initiated by stoma nurse; Protective powder for broken skin or Mucocutaneous Separation.
    09.02.01.02 Oral Rehydration Salts  For oral rehydration therapy (ORT)
    12.03.05 Oralieve® oral gel  Carbomer, hydroxyethylcellulose, lactoferrin, lactoperoxidase, glucose oxidase, sorbitol, xylitol and other ingredients.
    04.05.01 Orlistat Xenical® Capsules.
    For use in accordance with NICE CG43.
    04.09.02 Orphenadrine  *DISCONTINUED DECEMBER 2015*

    See guidance for alternative antimuscarinics and dose equivalence
    05.03.04 Oseltamivir Tamiflu® For influenza prophylaxis in accordance with NICE TA158 and NICE TA168.

    For the treatment of influenza in adults and children if all the following circumstances apply:

    •national surveillance schemes indicate that influenza virus A or B is circulating
    •the person is in an 'at-risk' group as defined in the guidance
    •the person presents with an influenza-like illness and can start treatment within 48 hours (or within 36 hours for zanamivir treatment in children) of the onset of symptoms as per licensed indications.

    Vaccination, particularly targeting "high risk" patients, remains the mainstay of influenza management.
    08.01.05 Osimertinib Tagrisso®

    In accordance with Cancer Drugs Fund (CDF) and NICE TA recommendations.

    19.03 OstoGuard no sting protective skin barrier film sachets  OstoMart Ltd
    Product reference code RMC3
    Approved pack size 30
    19.07 Ostomy cohesive seal large  Pelican Healthcare Ltd
    Product size: 98mm. Product reference code:839001
    Pack size:10
    19.11 OstoSorb gel 3g sachets  OstoMart Ltd
    Product reference code PFW. Approved pack size 30
    Product reference code PFW6. Approved pack size 150


    AMBER – only to be initiated by stoma nurse
    Thickens liquid output to aid management.
    19.09 OstoZyme Multi Odour Neutralising Lubricating Gel  OstoMart Ltd
    Product reference code TCB6
    Approved pack size 300ml

    Amber only after a trial of baby oil or alternative simple measures
    12.01.01 Otomize®  Dexamethasone ear spray 0.1% with neomycin sulfate 3250 units/ml and glacial acetic acid 2%
    11.08.02 Otrivine®  Xylometazoline paediatric nasal drops
    For hospital use during surgical procedures
    08.01.05 Oxaliplatin 
    04.08.01 Oxcarbazepine Trileptal®
    07.04.02 Oxybutynin hydrochloride 

    Not for frail older women (NICE CG171)

    07.04.02 Oxybutynin hydrochloride patch 

    Not for frail older women (NICE CG171).

    For those unable to take oral medicines.

    04.07.02 Oxycodone (oral)  Solution, concentrated solution, capsules, modified release tablets.
    Pain team/palliative care initiation.

    Oxycodone is included only for patients where morphine is contra-indicated or not tolerated. Available data does not provide any evidence of oxycodone's superiority to morphine.

    DCHFT: Used in post-operative pain in patients with eGFR <60mL/min.

    RBCH: 1st line modified release opioid for Derwent patients for in-patient use only.
    04.07.02 Oxycodone Injection/Infusion 

    Pain team/Palliative Care initiation.

    Red categorisation does not apply to palliative care setting.


    Oxycodone is included only for patients where morphine is contra-indicated or not tolerated. Available data does not provide any evidence of oxycodone's superiority to morphine.

    09.01.03 Oxymetholone   Restricted Item RBCH only: Consultant Haematologist prescription
    13.06.02 Oxytetracycline 
    07.01.01 Oxytocin 
    09.06.02 Pabrinex®  IV high potency injection
    IM high potency injection
    08.01.05 Paclitaxel 
    08.01.05 Paclitaxel - Albumin Bound Formulation (Nab-paclitaxel) Abraxane®

    Commissioned by NHS England in line with NICE TA476 in combination with gemcitabine for untreated metastatic pancreatic cancer.

    A2.01.03.03 Paediasure Peptide® 

    For use from age 1 - 10 years and 8-30 kg body weight.

    A2.02.01.02 Paediasure Plus Juce® 

    Nutrionally complete.

    For children 1-10 years of age, and 8-30kg in weight.

    A2.04.02 Paediatric Seravit®  
    08.01.05 Palbociclib IBRANCE®

    Commissioned in accordance with NICE TA495 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

    Patients inititated on the free of charge patient access programme should continue on free of charge treatment so long as they derive benefit.

    04.02.02 Paliperidone prolonged release suspension for injection Xeplion® Hospital Use only

    See paliperidone long-acting injection prescribing guidelines.
    05.03.05 Palivizumab Synagis®

    Commissioned by NHS England (for RSV prophylaxis) as per JCVI Guidelines and PHE specification. See Green Book Chapter 27a.

    04.06 Palonosetron Aloxi® Injection.
    Hospital use only.

    In accordance with locally agreed protocol for the prevention of nausea and vomiting induced by moderately and severely emetogenic chemotherapy.
    01.09.04 Pancreatin 

    Capsules, granules, tablets, powder.

    • Brand choice to be determined by Trust.
    • Brands include; Creon®, Pancrex®, Pancrex V®, Nutrizym®, Pancrease HL®.
    • DCHFT: Only Creon® routinely kept in stock.

     

    • RBCH: Creon® for licensed indications; Pancrex V® powder for unblocking enteral tubes (in-patient use only)


    • Restricted Item Restricted use: High Strength preparations. See BNF advice for advice regarding high strength preparations (e.g. Pancrease HL®, Nutrizym 22®, Creon 25000®, Creon 40000®).



    Dec 2016: Creon 40,000 is available in limited quantities therefore should be restricted to those patients requiring more than 100,000 lipase units per meal or in those on lower doses where it is necessary to reduce pill burden

    08.01.05 Panitumumab Vectibix®

    For use in accordance with NICE TA439.

    08.01.05 Panobinostat Farydak® Commissioned by NHSE for treating multiple myeloma after at least 2 previous treatments in accordance with NICE TA380
    13.06.01 PanOxyl® 

    Aquagel (= aqueous gel), benzoyl peroxide 2.5%
    Excipients include propylene glycol

    Cream, benzoyl peroxide 5% in a non-greasy basis
    Excipients include isopropyl palmitate, propylene glycol

    Gel, benzoyl peroxide 10% in an aqueous alcoholic basis
    Excipients include fragrance

    Wash, benzoyl peroxide 10% in a detergent basis
    Excipients include imidurea

    For use within acne guideline when required in combination with antibiotics

    Self Care Self Care Medicine

    Not RBCH

    01.03.05 Pantoprazole 

    Tablets.

    GPs should consider discontinuing PPIs in patient with unexplained eGFR decline or substituting them with ranitidine if indicated.

    Such patients should be referred for specialist advice as per CKD NICE guidance i.e.

    • eGFR less than 30 ml/min/1.73m2
    • sustained decrease in eGFR of 25% or more within 12 months
    • sustained decrease in eGFR of 15 ml/min/1.73m2 or more within 12 months

    Alternatively, patients with AKI as defined in the AKI NICE guidance should be discussed with a nephrologist if interstitial nephritis is suspected, as soon as it is possible i.e. within 24 hours.

    04.07.01 Paracetamol 

    Tablets, suspensions (various strengths), suppositories.
    See RBCH guideline for paracetamol

    Soluble tablets are considered 2nd Line.

    04.07.01 Paracetamol IV Perfalgan®
    04.08.02 Paraldehyde enema 
    06.06.01 Parathyroid Hormone Preotact® Commissioned by NHS England (for specialist endocrinology conditions), as per agreed Trust Guidelines.
    04.03.03 Paroxetine 

    For use in line with the Primary Care Protocol for Anxiety

    08.01.05 Pazopanib Votrient® Commissioned by NHS England as per NICE TA215.
    14.04 Pediacel®  Suspension for injection in pre-filled syringe

    Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)
    08.01.05 Pegaspargase Oncaspar® In accordance with NICE guidance.
    08.02.04 Peginterferon Alfa Pegasys® ; ViraferonPeg® Commissioned by NHS England (for Hepatitis B and C), as per NICE TA75, TA96, TA106, TA200, TA300 and CG165.

    08.02.04 Peginterferon beta-1a Plegridy®

    Commissioned by NHS England for Multiple Sclerosis as per SSC1534: Multiple Sclerosis: First line disease modifying agents

    06.05.01 Pegvisomant Somavert® Commissioned by NHS England as third line treatment for acromegaly at specialist centres only in line with commissioning policy 16050/P
    08.01.05 Pembrolizumab Keytruda®

    Commissioned by the CDF in line with CDF criteria and NICE TA519, TA522 and TA540 recommendations.

    Commissioned by NHSE in line with NICE TA357, TA366, TA428 and TA531 recommendations.

    08.01.03 Pemetrexed Alimta®

    Commissioned by NHS England as per NICE guidance.

    BlueTeq prior approval required for use in line with NICE TA402 for the maintenance treatment of non-squamous NSCLC after pemetrexed and cisplatin. 

    10.01.03 Penicillamine  For rheumatoid arthritis in accordance with NICE recommendations (CG79).
    18 Penicillamine Distamine®
    05.04.08 Pentamidine Isetionate  Intravenous and nebulised
    08.01.05 Pentostatin Nipent®
    02.06.04 Pentoxifylline  Modified release tablet.
  • Gastroenterology use only unlicensedOff label indication.
  • 01.01.02 Peptac®  Note: Individual trusts may use a different alginate of choice.
    A2.03.02 Peptamen®  

    Short bowel syndrome, intractable malabsorption, inflammatory bowel disease, bowel fistulae.

    04.08.01 Perampanel Fycompa®
    02.05.05.01 Perindopril  Tablets. Erbumine salt.
    Alternative prescribing option to first line ACE inhibitors.
    01.05 Peristeen®  Included on formulary as amber in conjunction with the locally agreed pathway. Patients need to be referred to the Dorset Bladder and Bowel continence service who will support the patient in the training and introduction of the product and review initially for benefit before passing prescribing responsibility to primary care.
    13.10.04 Permethrin  Cream, permethrin 5%
    08.01.05 Pertuzumab Perjeta®

    For use in accordance with NICE TA424 and TA509 recommendations.

    04.07.02 Pethidine  Hospital use only.
    04.03.02 Phenelzine Nardil®

    Initiated on Specialist Advice only as per shared care guidance

    02.08.02 Phenindione  Tablets.
  • Specialist initiation.
  • 04.08.01 Phenobarbital  Tablets, elixir, alcohol-free & sugar free suspension.
    Category 1: ensure patient is maintained on a specific manufacturer's product.
    04.08.02 Phenobarbital 
    02.05.04 Phenoxybenzamine Hydrochloride Dibenyline® Capsules.
  • Supply problems with injection
  • DCHFT: Restricted Item  Restricted to Consultant use only.
  • 05.01.01.01 Phenoxymethylpenicillin 
    02.05.04 Phentolamine  Injection.
  • unlicensedUnlicensed.
  • Shortage since July 2014, currently no imported products available (Nov 2014).
  • 18 Phentolamine injection  For digital ischemia due to accidental injection of epinephrine (adrenaline) and resistant hypertension related to sympathomimetic drugs of abuse, MAOIs and clonidine.
    10.01.01 Phenylbutazone  Rheumatology
    02.07.02 Phenylephrine  Injection.
    04.08.01 Phenytoin  Capsules, suspension.
    Options based on licence.

    Category 1: ensure patient is maintained on a specific manufacturer's product.
    04.08.02 Phenytoin IV 
    09.05.02.01 Phosphate Polyfusor® 
    01.06.04 Phosphates (Rectal)  Enema.
  • Alternative prescribing option.
  • 09.05.02.01 Phosphate-Sandoz® 
    02.08.03 Phytomenadione Vitamin K Injection may be used orally.
    09.06.06 Phytomenadione  DCHFT: Various formulations available (inlcuding unlicensed 1mg capsules). Note:Paediatric injection may be given orally.
    18 Phytomenadione Vitamin K1 For reversal of warfarin and other coumarin anticoagulants (vitamin K1 antagonists).
    01.06.05 Picolax® Sodium picosulfate and magnesium citrate Oral powder.
  • Choice to be determined by Trust.

  • DCHFT: Used instead of CitraFleet®.
  • 11.06 Pilocarpine  Drops 1%, 2% and 4%
    12.03.05 Pilocarpine hydrochloride tablets 5mg Salagen®

    For patients with Sjogren's syndrome

    13.05.03 Pimecrolimus Elidel® Use in accordance with NICE recommendations for the use of tacrolimus and pimecrolimus for atopic eczema (TA82) and local shared care guideline.

    Cream, pimecrolimus 1%
    Excipients include benzyl alcohol, cetyl alcohol, propylene glycol, stearyl alcohol
    06.01.02.03 Pioglitazone Actos® Use in accordance with NICE NG28.
    05.01.01.04 Piperacillin and Tazobactam IV  RBCH: On microbiology advice only unless for treatment of neutropenic sepsis
    05.05.01 Piperazine Pripsen®
    03.11 Pirfenidone Esbriet®

    Commissioned by NHS England for idiopathic pulmonary fibrosis as per TA504 via specialist centres only.

    05.01.13 Pivmecillinam Selexid®

    Second line option for use in accordance with the SCAN Guidelines

    08.01.02 Pixantrone Pixuvri®
    04.07.04.02 Pizotifen  Tablets, elixir.

    Sanomigran range being discontinued: stock of 0.5mg tablets and elixir now depleted. Stock of 1.5mg tablets expected to be depleted by June 2015, so prescribing of generic is advised.
    09.02.02.02 Plasma-lyte 148  DCHFT only.
    09.01.07 Plerixafor Mozobil®

    Commissioned by NHS England (for stem cell mobilisation), as per NHS England policy: B04/P/2.

    14.04 Pneumoccocal Polysaccharide Vaccine - 23 valent PPV 

    Pneumococcal Polysaccharide Vaccine - PPV23
     
    Contains the following 23 pneumococcal polysaccharide serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F

    Primary Care:  at NHS expense for patients in accordance with the national immunisation programme. Adults over 65 years and at risk groups, as listed in the Green Book, chapter 25. Use practice stock and claim on FP34 appendix form. 

    14.04 Pneumococcal polysaccharide conjugate vaccine (adsorbed) Prevenar 13®

    Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - PCV13

    Primary Care:  at NHS expense for infants as part of the routine childhood immunisation programme (order free of charge via Immform)

    11.03.01 Polihexanide Eye Drops  unlicensedUnlicensed
    Preservative free

    RBCH: 0.02%

    Not DCHFT.
    A2.04.01.01 Polycal®  

    NICE CG32 Nutrition support in adults

    (Modular energy supplements to be used under direction of Dietitian only)

    13.10.01.01 Polyfax®  Ointment, polymyxin B sulfate 10 000 units, bacitracin zinc 500 units/g
    A5.02.05 Polymem 

    For specialist Prescribing.

    PolyMem dressings are designed to facilitate healing, relieve pain and reduce inflammation in a unique way. Each PolyMem dressing includes a hydrophilic polyurethane matrix with a mild, tissue-friendly wound cleanser, a soothing moisturizer, a superabsorbent, and a semi-permeable film backing. This patented formulation of ingredients works synergistically to provide unrivaled benefits for clinicians and patients.

    14.04 Polysaccharide Typhoid Vaccine Typherix® DCHFT: Not routinely stocked.
    14.04 Polysaccharide vaccine for injection Typhim Vi® DCHFT: Not routinely stocked.
    09.02.01.01 Polystyrene Sulfonate Resins Calcium Resonium® For management of hyperkalaemia
    13.05.02 Polytar Emollient®  Bath additive, coal tar solution 2.5%, arachis (peanut) oil extract of coal tar 7.5%, tar 7.5%, cade oil 7.5%, light liquid paraffin 35%

    Excipients include isopropyl palmitate
    13.09 Polytar Plus®  Liquid, tar blend 1%
    Excipients include arachis (peanut) oil, fragrance, imidurea, polysorbate 80
    13.09 Polytar®  Liquid, tar blend 1%
    Excipients include arachis (peanut) oil, fragrance, imidurea, polysorbate 80
    08.02.04 Pomalidomide Imnovid®

    Commissioned by NHS England in line with NICE TA427.

    08.01.05 Ponatinib Iclusig®

    Commissioned by NHS England in line with NICE TA451.

    03.05.02 Poractant Alfa Curosurf® Commissioned by NHS England (for Respiratory Distress Syndrome in neonates). Use product with lowest procurement cost in line with Trust guidelines. Hospital only.
    05.02.01 Posaconazole Noxafil®

    Commissioned by NHS England (for prophylaxis and treatment of fungal infections), as per agreed Trust Guidelines.

    For microbiology and haematology use only.

    11.08.02 Potassium ascorbate drops 10%  Preservative free
    unlicensedUnlicensed
    09.02.01.01 Potassium Chloride Slow-K® Modified release tablets only to be prescribed if effervescent tablets or liquid preparations are inappropriate.

    As branded product has been discontinued only specials are available to order - these my be expensive.

    Additional Note:
    Can cause oesophageal burning -Only suitable for patients who are able to sit upright and take a full glass of water after dose.
    09.02.01.01 Potassium Chloride Sando-K® Effervescent tablets
    09.02.02.01 Potassium Chloride and Glucose Intravenous Infusion   Use ready-prepared solutions: consult local Trust policy
    09.02.02.01 Potassium Chloride and Sodium Chloride Intravenous Infusion  Use ready-prepared solutions: consult local Trust policy
    09.02.02.01 Potassium Chloride Concentrate (Sterile)  Use ready-prepared solutions: consult local Trust policy

    RBCH: Critical Care only
    DCHFT: Ordered as Controlled drug. Critical care only.

    09.02.01.01 Potassium Chloride syrup Kay-Cee-L® Contains sorbitol: May cause osmotic diarrhoea
    1mmol/mL each of K+ and Cl-
    09.02.01.01 Potassium Chloride syrup Kay-Cee-L® Paediatric use
    1mmol/mL each of K+ and Cl-
    09.02.02.01 Potassium Chloride, Sodium Chloride and Glucose Intravenous Infusion  Use ready-prepared solutions: consult local Trust policy
    07.04.03 Potassium Citrate Mixture BP 

    Oral solution, potassium citrate 30%, citric acid monohydrate 5% in a suitable vehicle with a lemon flavour.

    DCHFT: Not stocked. Effercitrate effervescent tablets available as alternative.

    13.11.06 Potassium Permanganate Permitabs®
    13.11.04 Povidone-Iodine Betadine® DCHFT: Variety of products and strength stocked.
    10% alcoholic solution.
    10% alcoholic paint.
    10% aqueous solution.
    7.5% surgical scrub.
    2.5% spray powder.
    18 Pralidoxime chloride 
    18 Pralidoxime chloride Protopam® For use as an adjunct to atropine in the treatment of poisoning by organophosphorus insecticides or nerve agents. ‘NAAS pods’ containing pralidoxime chloride can be obtained through the Ambulance Service from the National Blood Service — see NPIS or TOXBASE for list of designated centres.

    RBCH is a designated regional holding site - kept in ED Resus
    04.09.01 Pramipexole  Tablets.
    See shared care guideline for dopamine agonists

    Use in accordance with local guidance on drug treatment of Parkinson's Disease and the shared care guideline for dopamine agonists used in Parkinson's Disease.

    Includes modified release formulation
    04.09.04 Pramipexole 

    Immediate release formulations only. 


    For use in line with the NICE CKS pathway on restless leg syndrome

    02.09 Prasugrel Efient ® Tablets.
  • Specialist initiation.
  • Use in accordance with NICE TA 182. In patients with ST elevation and diabetes requiring a stent who are unable to receive treatment with ticagrelor.


  • 02.12 Pravastatin   Tablets.
  • Alternative to 2nd choice.
  • 05.05.05 Praziquantel 

    If clinically appropriate a GP may prescribe on advice of a tertiary centre outside of Dorset. If local microbiologists wish to prescribe this must be via outpatients at their Trust and they should not ask primary care to prescribe

    unlicensedUnlicensed Medicine

    02.05.04 Prazosin  Tablets.
    Alternative prescribing option to first line agent.
    07.04.01 Prazosin 
    01.05.02 Prednisolone  

    Tablets, soluble tablets (expensive), retention enema, foam enema (expensive), suppositories.

    • Rectal formulations are active in different areas of the GI tract so may not be interchangeable - see BNF for details.
    06.03.02 Prednisolone  For swallowing difficulties or administration via feeding tubes

    Soluble prednisolone tablets are a costly choice and their use should be reserved for only when absolutely necessary. The standard tablets can be dispersed in water in two to five minutes (enteric coated tablets are not suitable to be used in this way). Please note dispersing standard prednisolone tablets is considered an “off label “use.”
    06.03.02 Prednisolone 
    10.01.02.01 Prednisolone  For swallowing difficulties or administration via feeding tubes

    RBCH: Non-formulary - plain tablets disperse readily in water. Soluble tablets cost 35 x the price of plain tablets.

    Soluble prednisolone tablets are a costly choice and their use should be reserved for only when absolutely necessary. The standard tablets can be dispersed in water in two to five minutes (enteric coated tablets are not suitable to be used in this way). Please note dispersing standard prednisolone tablets is considered an “off label “use.”
    10.01.02.01 Prednisolone 
    10.01.02.02 Prednisolone Acetate Deltastab®
    11.04.01 Prednisolone drops 0.1%  Preservative free
    unlicensedunlicensed
    Not RBCH

    DCHFT: Both preservative free and 'with' preservative available.
    11.04.01 Prednisolone drops 0.5% Predsol®
    11.04.01 Prednisolone drops 1% Predforte®
    12.01.01 Prednisolone sodium phosphate drops 0.5% Predsol®
    04.03.04 Pregabalin  Licensed for Generalised Anxiety Disorder. See local guidance.
    04.07.03 Pregabalin  Capsules.
    For neuropathic pain in accordance with local guidance.

    For 3rd line use in generalised anxiety in accordance with local guidance.

    Amber in epilepsy.
    04.08.01 Pregabalin  Capsules.
    Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors.
    06.04.01.01 Premarin® 
    06.04.01.01 Premique® 
    06.04.01.01 Prempak-C® 
    15.02 Prilocaine Hydrochloride Prilotekal® Injection.
  • Restricted Item  DCHFT: Day case and enhanced recovery patients only in accordance with local guideline.

    RBCH for short procedures in patients suitable for same day surgery by Consultant Anaesthetists only.
  • 15.02 Prilocaine Hydrochloride  Injection.
  • 0.5% is unlicensedunlicensed.
  • 15.02 Prilocaine Hydrochloride Citanest® Injection.
    15.02 Prilocaine Hydrochloride with Felypressin Citanest with Octapressin® Dental cartridge.
    05.04.01 Primaquine  unlicensedUnlicensed
    Second line therapy for PCP infection (Pneumocystis jirovecii pneumonia)if patients intolerant of co-trimoxazole/constituents/ first line treatment failure
    04.08.01 Primidone  Tablets.
    Category 1: Ensure patient is maintained on a specific manufacturer's product.
    05.01.01.01 Procaine Penicillin G Injection   For GUM
    A2.04.01.02 Procal MCT® 

    MCT Procal is a medicine containing the active ingredient(s) triglycerides medium chain formula.

    A2.04.01.02 Pro-Cal®  

    Energy supplement.

    To be used under direction of dietitian only.

    Paediatric patiens: not suitable in children under the age of 3, use with caution in children aged 3-6 years. 

    A2.04.01.02 Pro-Cal® Shot 

    Energy supplement.

    To be used under direction of dietitian only.

    Paediatric patients: not suitable in children under the age of 3, use with caution in children aged 3-6 years. 

    08.01.05 Procarbazine 
    04.06 Prochlorperazine  Tablets, buccal tablets, suppositories, syrup.
    Phenothiazine option.
    04.06 Prochlorperazine Injection  Red status unless palliative care
    01.07.02 Proctosedyl®  Ointment, suppositories

    More expensive option
    04.09.02 Procyclidine  Tablets, syrup, injection.
    18 Procyclidine injection  For dystonic reactions.

    RBCH: kept in Emergency Drug Cupboard, ED resus and AMU
    06.04.01.02 Progesterone  Crinone® (vaginal gel)
    Cyclogest® (vaginal or rectal pessaries)
    Gestone® (injection)
    Lubion® (Injection)
    Utrogestan® (Oral capsules,Vaginal capsule)
    05.04.01 Proguanil Hydrochloride  DCHFT: Not stocked.
    05.04.01 Proguanil Hydrochloride with Atovaquone 
    03.04.01 Promethazine  Tablets, elixir.
    Sedating option.

    Alternative prescribing option to first line.
    04.06 Promethazine   Tablets, liquid.
    Antihistamine option.
    04.01.01 Promethazine Hydrochloride 

    Specialist mental health inpatients service use only for rapid tranquilisation. See NICE NG10
    Violence and aggression: short-term management in mental health, health and community settings

    A5.03 Prontosan Wound Irrigation Solution  

    Aqueous solution containing betaine surfactant and polihexanide

    A5.03 Prontosan X Wound Gel 50ml Previously named - Prontosan Wound Gel

    Hydrogel containing betaine surfactant and polihexanide

    02.03.02 Propafenone Arythmol® Tablets.
    Hospital initiation.
    11.03.01 Propamidine Isetionate drops 0.1% Brolene®

    Acanthamoeba keratitis (unlicensed indication)



    DCHFT: Consultant use only. Not routinely stocked.

    01.02 Propantheline bromide Pro-Banthine® Tablets.
  • Alternative prescribing option.


  • 15.01.01 Propofol  Injection.
  • RBCH: 1% only
  • DCHFT: 1% only
  • 02.04 Propranolol  Tablets, MR Capsule, Liquid, (Injection - secondary care only).
  • DCHFT: Injection is non formulary.

  • Alternative prescribing option to first line agents.

  • 11.08.01 Propylene Glycol 0.6% and Hydroxypropyl Guar Systane Balance® Licensed for MGD only
    11.08.01 Propylene Glycol and Polyethylene Glycol Drops Systane® Preserved or Preservative-Free
    06.02.02 Propylthiouracil  For use in pregnancy
    A2.04.01.02 ProSource®  
    A2.04.01.02 Prosource® Jelly 
    A2.04.01.02 Prosource® Plus 
    02.08.03 Protamine Sulfate  Injection.
    18 Protamine Sulphate  For emergency reversal of heparin based anticoagulants.
    02.11 Protein C Concentrate Ceprotin® See commissioning and funding guidance from NHS England.
    02.11 Prothrombin complex Beriplex® P/N, Octaplex® Commissioned by NHS England as per BCSH Guidelines.
    Blood-related product.

    DCHFT: Held by Pharmacy (Nov 2014).

    A2.02.01.02 ProvideXtra® Juice Drink 

    Not nutritionally complete.

    Paediatric patients only. Not suitable for patients <1year, use with caution in patients 1-5 years of age.

    01.06.07 Prucalopride Resolor ® Tablets.
  • In accordance with the requirements of NICE TA211.
  • DCHFT: Gastroenterology consultant initiation only and in accordance with NICE TA211.
  • 13.05.02 Psoriderm®  Bath emulsion, coal tar 40%
    Excipients include polysorbate 20

    DCHFT and RBCH: Not routinely stocked.
    13.05.02 Psoriderm®  Cream, coal tar 6%, lecithin 0.4%
    Excipients include isopropyl palmitate, propylene glycol

    DCHFT: Not routinely stocked.
    13.09 Psoriderm®  Scalp lotion (= shampoo), coal tar 2.5%, lecithin 0.3%
    05.01.09 Pyrazinamide Zinamide®
    10.02.01 Pyridostigmine Bromide  For Myasthenia gravis
    09.06.02 Pyridoxine Hydrochloride  50mg tablets
    09.06.02 Pyridoxine Hydrochloride  RBCH only: 10mg tablets to prevent isoniazid-related toxicity

    DCHFT: 10mg tablets available.
    18 Pyridoxine injection  For isoniazid toxicity.
    05.04.07 Pyrimethamine Daraprim®

    On recommendation by Consultants in Sexual Health, Ophthalmology or Microbiology for treatment of toxoplasmosis.

    05.04.01 Pyrimethamine with Sulfadoxine Fansidar® 'Special order' manufacturers or specialist-importing companies.
    04.02.01 Quetiapine 

    Hospital or specialist initiation. In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of schizophrenia (CG178) and local shared care guideline. Tablet formulation.

    In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of bipolar disorder CG185

    To be initiated on specialist advice only for:
    -schizophrenia.
    -treatment of mania and major depressive episodes associated with bipolar disorder.
    -preventing relapse in schizophrenia and preventing recurrence in bipolar disorder in patients whose have responded to quetiapine treatment.

    04.02.01 Quetiapine modified release 

    N.B.Higher cost preparation

    When Quetiapine is prescribed to patients under the care of the Dorset Perinatal Mental Health Service, the immediate release formulation should be used.  If this causes sedation severe enough to interfere with parenting, Quetiapine modified release can be prescribed.  The responsible prescriber in the perinatal mental health team should discontinue Quetiapine modified release before the patient is discharged or transferred to another service, if necessary replacing it with Quetiapine immediate releases or a different anti-psychotic drug.

    01.05 Qufora®  Included on formulary as amber in conjunction with the locally agreed pathway. Patients need to be referred to the Dorset Bladder and Bowel continence service who will support the patient in the training and introduction of the product and review initially for benefit before passing prescribing responsibility to primary care.
    05.04.01 Quinine sulphate Malaria treatment
    10.02.02 Quinine sulphate 

    Where cramps cause regular disruption to sleep - not for routine use.
    Reassess benefit regulary as per MHRA advice

     

    200mg quinine sulphate is equivalent to 300mg quinine bisulphate

    14.05 Rabies immunoglobulin  Human Rabies Immunoglobulin, not less than 150 IU/mL solution for injection


    Microbiology request only.

    DCHFT: Not routinely stocked.
    06.02.02 Radioactive iodine-131 capsules  Hospital only.
    DCHFT: Consultant only.
    06.04.01.01 Raloxifene Hydrochloride Evista® For secondary prevention of osteoporosis in accordance with NICE TA161.

    Not recommended by NICE for primary prevention of osteoporosis (TA160).
    05.03.01 Raltegravir Isentress ® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs), as per BHIVA Guidelines.
    08.01.03 Raltitrexed Tomudex®

    NICE CG131: Consider raltitrexed only for patients with advanced colorectal cancer who are intolerant to 5-fluorouracil and folinic acid, or for whom these drugs are not suitable.

    02.05.05.01 Ramipril  Capsules.
    11.08.02 Ranibizumab Lucentis® PbR excluded: Commissioned by CCG -In accordance with NICE TAs 155, 274, 283, 298.Ophthalmology consultant only.

  • Macular degeneration
  • Macular oedema(diabetic)
  • Macular oedema(retinal vein occlusion)
  • Choridal neovascularisation


  • 01.03.01 Ranitidine  Tablets, syrup, injection.
    02.06.03 Ranolazine Ranexa® Modified release tablets.
  • Specialist initiation.
  • For symptomatic stable angina pectoris in accordance with local shared care guidance.
  • 04.09.01 Rasagiline 
    10.01.04 Rasburicase Fasturtec® Commissioned by NHS England (for hyperuricaemia) as per agreed Trust Guidelines.

    DCHFT: Consultant use only.
    09.01.03 Recombinant human erythropoietins (all variants) Commissioned by NHS England (for dialysis-induced anaemia only including via outpatients and only as per NICE CG114) and Trust Guidelines.

    Use product with lowest procurement cost.

    Prescriber must specify which epoetin is required.


    DCHFT:
  • Darbopoetin (Aranesp®) First line. Home delivery only.

  • Epoetin beta (NeoRecormon®) Second line if patient allergic to or intolerant of darbopoetin.

  • Methoxy polyethylene glycol-epoetin beta (Mircera®) Second line if patient allergic to or intolerant of darbopoetin.
  • 09.01.03 Recombinant human erythropoietins  Prescriber must specify which epoetin is required.


    For use in patients in accordance with NICE TA323 or local commissioning statement for patients with symptomatic anaemia due to low-risk MDS.
    Choice of agent dependent on Trust and procurement costs.

    RBCH: Epoetin alfa (Eprex®) for Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy

    RBCH: Epoetin alfa (Eprex®) 40,000 units for pre-operative anaemia prior to elective orthopaedic surgery (1 year funding from June 2014)
    08.01.05 Regorafenib Stivarga®

    Commissioned in line with NICE TA488.

    15.01.04.03 Remifentanil Ultiva® Injection.
    14.04 Repevax®  suspension for injection, in pre-filled syringe

    Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content)
    03.04.02 Reslizumab Cinqaero®

    Commissioned by NHS England in accordance with NICE TA479 at specialist centres only.

    A2.05.02 Resource® ThickenUp Clear 

    Should only be started under SLT guidance (dysphagia assessment needed). These tend to be better tolerated

    For a syrup thick consistency per 200ml costs are as follows „h

    • Nutilis  = 14-21p „h
    • Nutilis Clear = 14.5p „h
    • Thick & easy = 20p „h
    • Thick & easy Clear = 20p „h
    • Resource Thicken up = 18p „h
    • Resource Thicken up clear = 16p
    A2.02.01.02 Resource® Fruit 

    NICE CG32 Nutrition support in adults

    Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool) 

    Useful for those patients with preference to juice /dislike to milk. However note these are less cost effective in terms of calorie and protein content than milk based sips.

    These are not suitable for those with an allergy to cow’s milk.

    A2.04.02 Resource® Optifibre®  

    For adult and paediatric patients. 

    A2.05.02 Resource® Thickened Drink 

    Should only be started under SLT guidance (dysphagia assessment needed)

    Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.

    Reduces risk of aspiration by removing potential for error

    23.11 Retaining Straps 
    Company Product Codes and Sizes Price per unit Comments
    Great Bear

    Short

    Adult

    Abdominal

    Adjustable

    2.79 short / adult

     

    2.99 Abdominal

    3.52 Adjustable

    Good variety of sizes
    Optimum

    Ex-short - 35cm

    Short - 45cm

    Medium - 80cm

    Long - 130cm

    Ex-long - 180cm

    2.50 small / short

     

    2.76 med

    3.36 long

    3.76 Ex-long

    Comes with good instructions and wash bag

     

    04.08.01 Retigabine  Tablets.
    Category 2: base the need for continued supply of a particular manufacturer's product on clinical judgement and consultation with the patient and/or carer, taking into account factors such as seizure frequency and treatment history.

    DCHFT: Restricted Item : In accordance with NICE TA232.

    Healthcare professionals have been advised of the withdrawal of retigabine (Trobalt) from the market in June 2017 due to limited and declining use. The advice is that treatment should be withdrawn using gradual dose reduction over at least 3 weeks. See link below
    14.04 Revaxis®  Suspension for injection in pre-filled syringe

    Diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
    05.03.03.02 Ribavirin 

    Treatment of hepatitis C commissioned in line with latest rate card from NHS England.

    05.03.05 Ribavirin 
    08.01.05 Ribociclib Kisqali®

    Commissioned in accordance with NICE TA496 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

    05.01.09 Rifampicin 
    05.01.09 Rifampicin and Isoniazid Rifinah®
    05.01.09 Rifampicin and Isoniazid and Pyrazinamide Rifater®
    05.01.07 Rifaximin Targaxan®

    DCHFT: unlicensedUnlicensed indication. Locally agreed as 3rd line agent for pouchitis. Consultant gastroenterologist only.

    05.03.01 Rilpivirine Edurant® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs), as per BHIVA Guidelines.
    04.09.03 Riluzole Rilutek® Tablets.
    For motor neurone disease. Use in accordance with NICE TA20. Refer to local shared care guideline.
    12.02.02 Rinatec®  Ipratropium bromide 21micrograms/dose nasal spray
    09.02.02.01 Ringer's Solution for Injection  Compound sodium chloride IV infusion
    02.05.01 Riociguat Adempas® Only to be initiated by approved Tertiary Centres in accordance with NHS England commissioning policies for Pulmonary Hypertension.
    06.06.02 Risedronate   For patients who do not tolerate Alendronic Acid

    For Paget's disease and osteoporosis.

    DCHFT: 2nd line, used in accordance with NICE TA160 & 161.
    04.02.01 Risperidone  Red when used in children with neurodevelopmental disorders (oral preparation).

    Red - risperidone injection.

    DCHFT: Orodispersible tablets restricted to paediatric use only.
    04.02.01 Risperidone 

    In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of schizophrenia (CG178) and local shared care guideline. Tablet or liquid formulation.

    In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of bipolar disorder CG185

    To be initiated on specialist advice only for:

    • schizophrenia.
    • treatment of manic episodes in bipolar disorder.
    • short term use for persistent aggression in patients with moderate to severe Alzheimer’s dementia.


    Refer to local dementia guidelines. Prescribing guidance to accompany request to prescribe.

    Generic risperidone remains one of the least expensive oral atypicals.

    Doses above 8-10mg daily may not increase therapeutic benefit but may result in extrapyramidal side effects.

    04.02.02 Risperidone LAI Risperdal Consta® no new patients to intitiate risperidone long acting injection
    see paliperidone LAI
    05.03.01 Ritonavir Norvir® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs), as per BHIVA Guidelines.
    08.02.03 Rituximab Truxima®, MabThera® All products should be prescribed by brand. Biosimilars should be used for new patients where possible.

    NHS England states:
    Where NICE has already recommended the originator biological medicine, the same guidance will normally apply to a biosimilar of the originator. Continuing development of biological medicines, including biosimilar medicines, creates increased choice for patients and clinicians, increased commercial competition and enhanced value propositions for individual medicines.
    The decision to prescribe a biological medicine for an individual patient whether an originator or biosimilar medicine, rests with the responsible clinician in consultation with the patient. At the time of dispensing, a biosimilar medicine should not be automatically substituted for the originator by the pharmacist. In line with MHRA guidelines, biological medicines, including biosimilar medicines must be prescribed by brand name to support on-going pharmacovigilance of the individual products.
    NHS England supports the appropriate use of biosimilars which will drive greater competition to release cost efficiencies to support the treatment of an increasing number of patients and the uptake of new and innovative medicines.

    For splenic marginal zone lymphoma - not recommended for first-line use. May be considered on an individual patient basis in the second-line setting.

    May be considered in autoimmune haematological disorders as a third-line option for patients who have failed steroids and splenectomy or as a second-line option where a splenectomy is not indicated.

    10.01.03 Rituximab  MabThera® ; Truxima®

    Biosimilars - prescribe by BRAND!

    In accordance with NHS England policies for:

    • paediatric rheumatology indications where adult TA is available (TA195).
    • ANCA-positive vasculitis as per NICE TA308 and NHS England Policy: A13/P/a.
    • SLE as per NHS England Policy: A13/PS/a.
    • Dermatomyositis and polymyositis.
    • Neuromyelitis optica, as per specification.
    • ABO-incompatible kidney transplants, as per specification.
    • Myasthenia gravis as per NHSE policy 170084P (Restricted Item specialist centres only, local centre is UHS).


      Black Traffic Light 
      Not routinely commissioned by NHS England for: connective tissue disease - policy in progress, haemophilia, graft versus host disease and nephritis. As per IFR approval.
    13.14 Rituximab MabThera®; Truxima® Must be prescribed by BRAND - these are biosimilar medicines!


    In accordance with NHS England policies for
  • Immunobullous disease unlicensedunlicensed
  • 10.01.03 Rituximab biosimilar Truxima® Commissioned by NHS Dorset CCG and NHS England within SPC indications and as per the originator product above.
    NHS England states:
    Where NICE has already recommended the originator biological medicine, the same guidance will normally apply to a biosimilar of the originator. Continuing development of biological medicines, including biosimilar medicines, creates increased choice for patients and clinicians, increased commercial competition and enhanced value propositions for individual medicines.
    The decision to prescribe a biological medicine for an individual patient whether an originator or biosimilar medicine, rests with the responsible clinician in consultation with the patient. At the time of dispensing, a biosimilar medicine should not be automatically substituted for the originator by the pharmacist. In line with MHRA guidelines, biological medicines, including biosimilar medicines must be prescribed by brand name to support on-going pharmacovigilance of the individual products.
    NHS England supports the appropriate use of biosimilars which will drive greater competition to release cost efficiencies to support the treatment of an increasing number of patients and the uptake of new and innovative medicines.
    02.08.02 Rivaroxaban Xarelto®

    Red

    • Prophylaxis in Superficial Thrombosis - refer to Anticoagulation policy. 6 week course unlicensedUnlicensed
    • In accordance with NICE TA for prevention of VTE in patients undergoing hip or knee replacement surgery, as per licensed indications.
      • Note routine 1st line option at RBCH and DCH is LMWH


    Amber 

    • Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. As per NICE TA335.
      • For initiation by Consultant Cardiologist only. See shared care guideline for further details. 


    Green

    • For prevention of stroke or systemic embolism in patients with AF within NICE TA and local guidance, as per licensed indications.
    • For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE TA.
    02.08.02 Rivaroxaban Xarelto® For the treatment of DVT/PE and long term secondary prevention of DVT/PE in accordance with NICE TAs 287, 261

    Please note the commissioning statement is currently under review and will be updated shortly.
    02.08.02 Rivaroxaban Xarelto® N.B. NOTE INDICATION
    Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. As per NICE TA335.

    For initiation by Consultant Cardiologist only. See shared care guideline for further details.
    02.08.02 Rivaroxaban Xarelto®

    RBCH: Prophylaxis in Superficial Thrombophlebitis - refer to Anticoagulation policyunlicensed Unlicensed

    6 week course.

    02.08.02 Rivaroxaban  Tablets.
  • For prevention of VTE in patients undergoing hip or knee replacement surgery, in accordance with NICE TA170.
  • RBCH: 1st line option is dalteparin.

  • DCHFT: 1st line option is enoxaparin.
  • 02.08.02 Rivaroxaban Xarelto® Tablets.
  • FOR PREVENTION OF STROKE OR SYSTEMIC EMBOLISM IN PATIENTS WITH AF in accordance with NICE TA256 and local guidance. As per licensed indications.
  • 04.11 Rivastigmine  Capsules, oral solution and patches.
    For mild to moderate Alzheimer's disease. In accordance with NICE recommendations (TA217). Refer to local shared care guideline.

    15.01.05 Rocuronium Bromide Esmeron® Injection.
    03.03.03 Roflumilast Daxas®
    09.01.04 Romiplostim Nplate® Commissioned by CCG: Use in accordance with NICE TA221
    04.09.01 Ropinirole 

    Tablets, modified release tablets.

    First line in accordance with local guidance on drug treatment of Parkinson's Disease and the shared care guideline for dopamine agonists used in Parkinson's Disease.

    04.09.04 Ropinirole 

    Immediate release formulations only. 


    For use in line with the NICE CKS pathway on restless leg syndrome

    15.02 Ropivacaine Hydrochloride Naropin® Injection, infusion.
  • DCHFT: Non-formulary item.
  • 02.12 Rosuvastatin Crestor® Tablets.
    14.04 Rotavirus vaccine Rotarix® Oral suspension.

    04.09.01 Rotigotine patches  Alternative prescribing option.

    Use in accordance with local guidance on drug treatment of Parkinson's Disease and the shared care guideline.

    Third line agent where ropinirole and pramipexole are ineffective or not tolerated. May be considered as first line for patients with swallowing difficulties.
    13.10.01.02 Rozex®  Cream, metronidazole 0.75%
    Excipients include benzyl alcohol, isopropyl palmitate

    For rosacea
    08.01.05 Ruxolitinib Jakavi® Commissioned by NHS England in line with NICE TA386.
    A2.04.01.01 S.O.S® 

    Includes:

    S.O.S 10

    S.O.S 15

    S.O.S 20

    S.O.S 25

    For use as an emergency regimen in the dietary management of inborn errors of metabolism (from birth).

    Contents of each sachet should be reconstituted with water to a total volume of 200 mL. S.O.S. products are age-range specific - consult product literature.

    02.05 Sacubitril valsartan Entresto® For the treatment of symptomatic chronic heart failure with reduced ejection fraction in accordance with NICE TA388. It is expected initiation would be the under direct supervision of a consultant cardiologist.

    • Do not use if the patient’s eGFR <30 mL/min/1.73m2. Monitor renal function
    • Do not prescribe with an ACE inhibitor or an angiotensin II receptor antagonist
    • For use in patients with NYHA Class II-IV
    13.07 Salactol® 

    Paint,Salicylic Acid 16.7% with Lactic Acid 16.7%

    Used by DCH

     

    03.01.01.01 Salbutamol  Inhalers, nebuliser solution, syrup.
    Short-acting beta 2 agonist.
    07.01.03 Salbutamol 
    03.01.01.01 Salbutamol IV  Hospital only.
    12.03.05 Salivix®  Pastilles, sugar-free, reddish-amber, acacia, malic acid and other ingredients.
    03.01.01.01 Salmeterol  Inhalers.
    Long-acting beta2 agonist.
    03.02 Salmeterol (as salmeterol xinafoate) / Fluticasone propionate Sirdupla® 25 micrograms of salmeterol (as salmeterol xinafoate) and 125 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex actuator) of 21 micrograms of salmeterol and 110 micrograms of fluticasone propionate.

    25 micrograms of salmeterol (as salmeterol xinafoate) and 250 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex actuator) of 21 micrograms of salmeterol and 220 micrograms of fluticasone propionate
    19.01 Salts adhesive remover spray 

    Salts HealthCare
    Product reference code WAP
    Approved pack size 50ml

    19.02 Salts Adhesive Remover Wipes Formally known as WipeAway Plus adhesive remover sachets

    Salts Healthcare
    Product reference code WAP2
    Approved pack size 30

    19.03 Salts Barrier Film Wipes® Formally known as Peri-Prep sensitive no sting protective film wipes®

    Salts Healthcare
    Product reference code PPS1
    Approved pack size 30

    19.13 Salts Odour Eliminating Spray™ formally known as FreshAire™

    Salts Healthcare
    Product reference code
    Approved pack size 50ml

    AMBER - Deodorising spray is only to be initiated by stoma nurse

    09.06.07 Sanatogen®A-Z Complete 

    10 day course for Refeeding Syndrome (Nutrition team only)


    09.05.01.01 Sandocal®  Tablets

    Sandocal®1000 only at RBCH
    09.04.01 Sapropterin Dihydrochloride  Kuvan® Commissioned by NHS England (for phenylalanine restriction). See NHS England Policy: E12/P/a.
    05.03.01 Saquinavir Invirase® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs) as per BHIVA Guidelines.
    10.01.03 Sarilumab  Kevzara®
    A2.04.01.02 Scandishake® Mix 
    Green in adult patients
     
    Amber in paediatric patients

    Generally use as a second choice to 1.5kcal/ml sip feeds as not nutritionally complete. However these supplements do provide more calories per ml approx. 600kcal in 250ml so useful for those with very high calorie needs (when reconstituted with whole milk) e.g. CF Patients

    Paediatric patients: not suitable in children under the age of 3, use with caution in children aged 3-6 years. 

    01.07.02 Scheriproct®  Ointment, suppositories.
    13.05.02 Sebco®  Scalp ointment, coal tar solution 12%, salicylic acid 2%, precipitated sulfur 4%, in a coconut oil emollient basis
    Excipients include cetostearyl alcohol
    06.07 Secretin  unlicensedUnlicensed
    RBCH: used as a diagnostic agent in various disorders of the pancreas.

    Not DCHFT as of Nov 2014. Radiology exploring the possibility of new MRI study of the pancreas to evaluate the pancreatic duct and pancreatic exocrine function. Local Formulary application not yet received.
    10.01.03 Secukinumab  Cosentyx® In accordance with NICE guidance.
    13.05.03 Secukinumab Cosentyx®

    for treatment of plaque psoriasis as per NICE TA 350

    19.07 SecuPlast Aloe ring®   Salts Healthcare

    Product size: 25mm Product reference code:SAR25
    Pack size: 30

    Product size: 32mm Product reference code:SAR32
    Pack size: 30

    Product size: 38mm Product reference code:SAR38
    Pack size: 30

    Product size: 45mm Product reference code:SAR45
    Pack size: 30
    19.07 SecuPlast mouldable seals®   Salts Healthcare

    Product size: Thin. Product reference code:SMST
    Pack size:30

    Product size: Large Product reference code:SMSL
    Pack size: 10
    04.09.01 Selegiline Hydrochloride  Tablets.
    For use in conjunction with levodopa at the onset of motor fluctuations in Parkinson's Disease, as an alternative to dopamine agonists or COMT inhibitors. It should not be used as monotherapy. See local shared care guideline.

    DCHFT: New patients to be initiated only by consultant.
    13.09 Selsun® 

    Restrict to where moderate to severe skin condition requires it

    Shampoo, selenium sulfide 2.5%
    Excipients include fragrance

    Self Care Self Care Medicine

    01.06.02 Senna  Tablets, syrup.
    04.03.03 Sertraline 
    09.05.02.02 Sevelamer Carbonate Renvela® Commissioned by NHS England (for adult renal dialysis only) as per Trust Guidelines. Also rRefer to local shared care guideline.
    09.05.02.02 Sevelamer Hydrochloride  Renagel® Commissioned by NHS England (for adult renal dialysis only) as per Trust Guidelines. Also rRefer to local shared care guideline.

    15.01.02 Sevoflurane  Anaesthetic.
    23.02 Sheaths 
    Company Code Price Comment

    Bard

    Clear Advantage Spirit –

    Sizes
    24mm(43),28mm(83),32mm(23), 6mm(63) & 40mm(03)

    Codes
    Standard
    5243,5283,5223,5263 & 5203
    Pop on
    7243,7283,7223,7263,7203
    Wide band
    9243,9283,9223,9263,9203

    £1.66

    (Box of 30)

    Good instructions,

    starter packs are available from the company.

    Great bear

    Libra


    Sizes - 24mm, 28mm, 31mm, 35mm, 40mm.

    Codes
    Standard : GBLSS + Size of sheath
    Pop on : GBLSP + Size of sheath
    Wide band : GBLSW + Size of sheath

    £1.56

    (Box of 30)

    No collar, so sticks directly to skin and flat to the surface. Starter packs are available from the company.

    02.05.01 Sildenafil all brands Only to be initiated by approved Tertiary Centres in accordance with NHS England commissioning policies for Pulmonary Hypertension.


    For use in digital ulceration under specialist initiation
    07.04.05 Sildenafil 

    Dose when required.

    Always prescribe generically.

    13.05.02 Silkis®  Ointment, calcitriol 3 micrograms/g,

    DCHFT: Not routinely stocked.

    13.07 Silver Nitrate 

    DCHFT: 75% 'stick applicator' on local formulary.

    RBCH: For surgical procedures.

    Poole: approved for hospital only use.

    13.07 Silver Nitrate 95% with Potassium Nitrate 5% AVOCA®

    DCHFT: 95% 'caustic pencil' on local formulary.

    RBCH: For colposcopy procedures.

    Poole: approved for hospital only use.

    01.01.01 Simeticone  Infacol® and other brands

    Approved for use as a "red" drug for endoscopy use only

    A2.03.01 Similac Alimentum® 

    Alternative option for cow’s milk protein allergy 

    02.12 Simvastatin  Tablets.
    08.02.02 Sirolimus Rapamune®

    Commissioned by NHS England (for transplant immunosuppression only). As per Trust Guidelines. Use product with lowest procurement cost. Not recommended for new patients as per NICE TA481 and TA482.

    Not routinely commissioned by NHS England (for Lymphangioleiomyomatosis - LAM). As per IFR approval.

    06.01.02.03 Sitagliptin Januvia® Dosing adjustment required in renal impairment, see SPC

    Use in accordance with NICE NG28 i.e. if metformin is not tolerated, or in combination for first and second treatment intensification
    13.06.01 Skinoren®  Cream, azelaic acid 20%
    Excipients include propylene glycol

    Not RBCH
    A2.03.01 SMA LF® 

    For use in proven lactose intolerance - not suitable for use in cow's milk protein allergy. 

    If used for temporary lactose intolerance following a bout of gastroenteritis, this should only be for a period of 6-8 weeks before titrating back onto standard infant formula. 

    A2.01.03.01 SMA Pro Gold Prem 2® 

    For promoting catch up growth in pre-term and small for gestational age infants. Use up to 6 months corrected age. 

    A2.01.03.01 SMA Pro High Energy 

    For use in disease related malnutrition, malabsorption and growth failure. 

    From birth to 18 months of age. 

    A2.03.01 SMA Staydown® 

    Pre-thickened feed for use in severe gastro-oesophageal reflux.

    10.01.03 Sodium Aurothiomalate Myocrisin® For rheumatoid arthritis in accordance with NICE CG79 recommendations.
    09.02.02.01 Sodium Bicarbonate  1.26% and 8.4% IV infusion
    8.4% injection
    09.02.01.03 Sodium Bicarbonate capsules 
    12.01.03 Sodium Bicarbonate ear drops 5% 
    18 Sodium bicarbonate infusion  Use for urinary alkalinisation & tricyclic antidepressant overdose & class 1a and 1c antiarrhythmic drugs.
    09.02.01.02 Sodium Chloride Slow Sodium® Modified release tablets
    07.04.04 Sodium chloride 0.9% 
    12.03.04 Sodium Chloride 0.9%  RBCH: Use plastic ampoules for injection
    13.11.01 Sodium chloride 0.9% irrigation solution  
    11.08.01 Sodium Chloride 5% drops / ointment 
    09.02.02.01 Sodium Chloride and Glucose Intravenous Infusion  Sodium chloride 0.45% and glucose 2.5%
    Sodium chloride 0.18% and glucose 4%
    09.02.02.01 Sodium chloride IV infusion  0.18%, 0.45%, 0.9% intravenous infusion
    DCHFT: Also stocks 2.7% polyfusor
    01.06.04 Sodium Citrate (Rectal)  Micro-enema.
  • Alternative prescribing option.

  • Various brands are available (Micolette®, Relaxit® and Micralax®) and choice may vary between Trusts.
  • 11.99.99.99 Sodium Citrate 10.11 (equiv 6.5%) Eye Drops  unlicensedUnlicensed
    Preservative-free

    DCHFT: Not routinely stocked.
    06.06.02 Sodium Clodronate Bonefos®, Clasteon®, Loron 520® For use in the management of multiple myeloma.
    03.03.01 Sodium Cromoglicate  Intal® Inhaler.
    Not used at RBCH
    11.04.02 Sodium Cromoglicate drops 2%  First choice for
  • Seasonal allergies

  • Long term allergies
  • 12.02.01 Sodium Cromoglicate nasal spray 4% 
    09.01.01.01 Sodium Feredetate Sytron®

    For paediatrics, to be initiated in hospital

    05.01.07 Sodium fusidate Fucidin® Oral formulations for skin, soft tissue or bone/joint infections.
    07.04.03 Sodium Hyaluronate 

    For PBS with recurrent symptoms: Cystistat® 40mg or Hyacyst® 120mg


    DCHFT:Restricted Item  Consultant Urologist only, as a licensed alternative to dimethylsulphoxide (RIMSO - named patient basis).

    11.08.01 Sodium Hyaluronate 0.1%   Preservative-Free

    NOT RBCH – if admitted convert to 0.15%
    11.08.01 Sodium Hyaluronate 0.15%   Preservative-Free

    11.08.01 Sodium hyaluronate 0.15% & Trehalose 3% Thealoz Duo®

    Preservative free.

    11.08.01 Sodium hyaluronate 0.15%, Trehalose 3% & Carbomer 0.25% Thealoz Duo Gel ®

    Preservative-free gel unit dose vials.

    Drops (Thealoz Duo drops) are significantly more cost-effective (see above)

    11.08.01 Sodium Hyaluronate 0.2% 

    Preservative-free

    11.08.01 Sodium Hyaluronate 0.4%  Clinitas® Multi 10ml Preservative-free
    11.08.02 Sodium hyaluronate syringe  For hospital use during surgical procedures

    RBCH: Healonid®, Healonid 5®, Healonid GV®
    07.04.03 Sodium Hyaluronate/Sodium Chondroitin Sulfate i-ALURIL®

    For PBS with recurrent symptoms where sodium hyaluronate (Cystistat® or Hyacyst®) has been ineffective.

    Not at DCHFT.

    18 Sodium nitrite injection  For cyanide poisoning.

    RBCH: kept in Emergency Drug Cupboard
    02.05.01 Sodium Nitroprusside  Injection.
  • unlicensedUnlicensed product available from specialist importing companies.

  • 04.01.01 Sodium Oxybate Xyrem® Licensed for narcolepsy with cataplexy (under specialist supervision).

    An individual patient request needs to be submitted to the CCG and approval received before commencing treatment.

    Not routinely commissioned by NHS England (for narcolepsy - paediatric services only). As per individual funding request (IFR) approval.
    09.08.01 Sodium Phenybutyrate Ammonaps® Commissioned by NHS England (for urea cycle disorders). As per NHS England Service Specification, according to highly specialised criteria only.

    For initiation by specialist centres only.

    DCHFT: Injection stocked.
    01.06.02 Sodium picosulfate 
    21 Sodium Picosulfate  
    02.13 Sodium Tetradecyl Sulphate Fibrovein® Injection.
    18 Sodium thiosulphate  For cyanide poisoning.

    RBCH: kept in Emergency Drug Cupboard
    04.08.01 Sodium Valproate 

    April 2018: Valproate must no longer be used in any woman or girl able to have children, unless she has a Pregnancy Prevention Programme in place, further guidance and resorces are awaited from the MHRA. 

    Epilepsy Indications

    Amber 2nd line choice for women, 1st line for men

    • E/C tablets, modified release tablets, liquid, crushable tablets.
    • Injection - secondary care only.

    Options based on licence.

    AEDs have been divided into three risk-based categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturers product. For further information on this click here

    Mental Health Indications:

    Amberwith Shared Care Guideline

    Hospital initiation

    Treatment of acute hypomania within bipolar disorder and for long term treatment of bipolar disorder

    Prophylaxis of migraine: Non-Formulary for this indication 

     

     

    04.08.01 Sodium Valproate Prolonged Release Episenta®

    April 2018: Valproate must no longer be used in any woman or girl able to have children, unless she has a Pregnancy Prevention Programme in place, further guidance and resorces are awaited from the MHRA. 

    05.03.03.02 Sofosbuvir Sovaldi®

    Treatment of hepatitis C commissioned in line with latest rate card from NHS England.

    05.03.03.02 Sofosbuvir with ledipasvir Harvoni®

    Treatment of hepatitis C commissioned in line with latest rate card from NHS England.

    05.03.03.02 Sofosbuvir with velpatasvir Epclusa®

    Treatment of hepatitis C commissioned in line with latest rate card from NHS England.

    05.03.03.02 Sofosbuvir with Velpatasvir and Voxilaprevir Vosevi®

    Treatment of hepatitis C commissioned in line with latest rate card from NHS England and retreatment where the first DAA has failed to achieve cure for the patient in accordance with NICE TA507.

    11.04.01 Sofradex®  Dexamethasone (as sodium metasulphobenzoate) 0.05%, framycetin sulfate 0.5%, gramicidin 0.005%

    Not at RBCH
    12.01.01 Sofradex®  Dexamethasone drops 0.05% with framycetine sulfate 0.5% and gramicidin 0.005%
    19.04 Soft Paste  Dansac Ltd
    Product reference code 77550-0
    Approved pack size 50g
    A5.01.02 Softpore  

    All Sizes

    Topical dressing for lightly exuding wounds, such as surgical incisions, cuts and abrasions.

    • Water repellent
    • Soft and conforming
    • Breathable
    • Non-linting
    • Available on prescription
    A5.01.01 Softpore Adhesive Surgical Dressings 

    All sizes

    Topical dressing for lightly exuding wounds, such as surgical incisions, cuts and abrasions.

    • Water repellent
    • Soft and conforming
    • Breathable
    • Non-linting
    07.04.02 Solifenacin succinate 

    Choice should be based on selecting the most cost-effective option.

    09.03 Solivito N® 
    07.04.04 Solution G  RBCH: Uro-Tainer® Twin Suby G
    07.04.04 Solution R  Not RBCH
    06.05.01 Somatropin (growth hormone)  - For growth hormone deficiency in children in accordance with NICE CG TA188 recommendations.
    - For growth hormone deficiency in adults in accordance with NICE TA64 recommendations.

    Please refer to the CCG commissioning statement on growth hormone products.

    Preparations include Genotropin®, Humatrope®, Norditropin®, NutropinAq®, Omnitrope®, Saizen®, Zomacton®
    08.01.05 Sorafenib Nexavar®

    Commissioned by NHS England in line with NICE TA474 and by CDF as per NICE TA535 and CDF policy.

    02.04 Sotalol  Tablets.
    Specialist initiation.
    23.13 Specialist Bags 
    Company Product Codes Price per unit Comments
    Teleflex / Rusch Belly Bag B1000 10.50 (One Bag)

    One bag lasts for 28 days and is suitable for use with all catheters.

    Separate extendable drainage tube and replacement belts are available

    Great Bear

    Chambered bag lever action tap.

    Sizes: 500mls & 750ml as short and long tube.

    Codes:

    • 10114Q-S
    • 10115R-L
    2.87 (Box of 10)

    Tap can be turned to avoid accidental opening.

    For use by patients who find the "sloshing" sound from ordinary bags an issue

     

    23.20 Specialist Catheters 
    Company Product codes and sizes Price per unit Comments
    Qufora

    Standard and female sizes 12ch-24ch

    Silicone Long Term (12 weeks)

    Standard - 342205+ catheter size

    Female - 342405+ catheter size

     

    Open tipped Long Term (12 weeks)

    Standard - 342302 + catheter size

    4.29

     

     

     

     

    5.50

    Sizes in standards and female, also paediatrics can be used for supra-pubic as well as urethral catheters.

    Has integral balloon so can reduce the risk of the balloon cuffing on removal.

    Open tipped catheter is licensed for supra-pubic catheterisation only, please contact the service for open tipped catheter for in-dwelling catheterisation

    Bard

    Bardex IC Silver Catheter

    Standard sizes 12ch-22ch

    Female sizes 12ch-16ch

    Standard

    D236512s- D236522s (Highlighted numbers = size)

    Female

    D236912s - D236916s

     

    9.66

    The silver coating last for 28 days howeve, the catheters are long term catheters (12 weeks)

    To be recommended by the specialist

     

    23.03 Specialist sheaths 
    Company Code Price Comment

    Manfred Sauer

    P-sure sheath – Latex Free
    Sizes – 18mm – paediatrics
    20mm, 22mm, 24mm, 26mm, 28mm, 30mm, 32mm, 35mm,
    37mm, 40mm.

    Codes – 97 + Size (e.g. 9720 for size 20mm)

    £1.55

    (Box of 30)

    For use of patients with large diuresis, where other sheaths have fallen off. Can be worn for dribbling with a valve, hold approx. 100mls

    05.01.07 SPECTINOMYCIN Injection 2 g  unlicensedUnlicensed
    GUM only:
  • First line treatment for uncomplicated Gonorrhoea (GC) in those with β lactam sensitivity (and as alternative when option to standard first line treatment)

  • Complicated Gonorrhoeal infections- conjunctivitis in adults and Disemminated Gonococcal Infection (DGI)
  • 02.02.03 Spironolactone  Tablets, suspension.
  • DCHFT: The 10mg/5mL suspension (unlicensedunlicensed) is restricted to paediatric use only.
  • 13.06.02 Spironolactone  Unlicensed use of licensed product
    09.02.01 St Marks solution  For use in short bowel syndrome
    05.03.01 Stavudine Zerit® Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs), as per BHIVA Guidelines.
    A5.07.01 Sterile dressing packs 

    In primary and secondary care: DMAG approved prescribable sterile dressing pack is 'Nurse It'

    District nurses and health visitors should use Softdrape sterile dressing packs, and procure them through the NHS supply chain (not prescribable)

    A5.06 Sterile larvae (maggots) BioBag ® on specialist advice only.
    Also has an antimicrobial affect

    The larvae, along with either one or multiple foam spacers, are sealed within a finely woven polyester net pouch
    12.02.03 Sterimar®  Saline sterile atomised nasal spray
    Post-operative nasal cleansing
    19.04 Stoma Paste  Salts Healthcare
    Product reference code SP60
    Approved pack size 60g
    12.03.03 Strepsils®  RBCH In-patients only
    02.10.02 Streptokinase Streptase® Injection.
    01.03.03 Sucralfate  Antepsin® Dispersible tablets, suspension.

  • Current supply problem with tablets and suspension. IDIS have a supply of unlicensed tablets available if alternatives are not an option.
  • 13.02.02 Sudocrem® 

    Cream, benzyl alcohol 0.39%, benzyl benzoate 1.01%, benzyl cinnamate 0.15%, hydrous wool fat (hypoallergenic lanolin) 4%, zinc oxide 15.25%
    Excipients include beeswax (synthetic), propylene glycol, butylated hydroxyanisole, fragrance

    DCHFT: Restricted Item  Consultant, specialist or tissue viability nurse only.

    This product is indicated for use in Paediatrics and is not included in the Moisture Pathway.

    04.07.02 Sufentanil citrate Zalviso® RBCH only: Consultant Anaesthetist only for patients at high risk of post-op pain following hip/knee arthroplasty. Patients will be identified pre-operatively as part of service evaluation.
    15.01.06 Sugammadex Bridion® Injection.
  • RBCH: Emergency reversal of neuromuscular blockade induced by rocuronium only.
  • DCHFT: Consultant anaesthetist only. Emergency reversal of neuromuscular blockade induced by rocuronium or vecuronium.
  • 12.01.03 Suitable Oil for ear drops 

    Suitable Oil for ear drops e.g. Olive Oil (circa. £1.40 for 10ml, Drug tariff April 17) or almond oil (91p for 50ml, Drug tariff April 17)

    Almond Oil: Beware of nut allergies / intolerences 

    05.04.07 Sulfadiazine  On recommendation by Consultants in Sexual Health, Ophthalmology or Microbiology for treatment of toxoplasmosis.
    01.05.01 Sulfasalazine  Tablets, EN-tablets, suspension, suppositories.
  • Alternative prescribing option.
  • 10.01.03 Sulfasalazine EC Salazopyrin En-Tabs® 1st choice for RA
    04.02.01 Sulpiride  Hospital or specialist initiation.
    Option based on NICE guidance and licence.
    Tablet & solution available.

    04.07.04.01 Sumatriptan  Tablets, nasal spray, injection.
    08.01.05 Sunitinib Sutent®

    For use in line with NICE TA169, TA179 and TA449.

    BlueTeq Blueteq prior approval required for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression (TA449).

    13.08.01 Sunsense® Ultra  DCHFT: On local formulary.
    Sunsense® Ultra is included as a borderline substance and regarded as a drug when prescribed for skin protection against ultraviolet radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photodermatoses, including vitiligo and those resulting from radiotherapy; chronic or recurrent herpes simplex labialis. Preparations with SPF less than 30 should not normally be prescribed
    A5.03 Suprasorb® X+PHMB  

    All sizes.

    Indicated for light to moderately exuding, superficial and deep, infected wounds E.g. pressure ulcers, venous/arterial ulcers, diabetic ulcers, partial thickness burns, post-operative wounds, skin donor and skin grafting sites

    It is able to absorb exudate and donate fluid at the same time, dependent on the condition in different areas of the wound bed. Providing a moist wound healing environment.

    13.11.01 Surgical Spirit, BP 
    A2.03.01 Survimed® OPD 

    If patient dislikes or does not tolerate Modulen IBD then trial of Elemental 028 extra can be considered

    Available in 2 flavours or the unflavoured one can be made more palatable using the flavour modjuls

    Use liquid E028 for patients who need to take product away from home or who dislike the taste of powdered E028

    Short bowel syndrome, intractable malabsorption, inflammatory bowel disease, bowel fistulae.

    06.04.02 Sustanon®  

    Active Ingredients:

    • testosterone propionate
    • testosterone phenylpropionate
    • testosterone isocaproate
    • testosterone decanoate

    For the induction of male puberty in the following situations:

    • Hypopituitarism
    • Hypogondism e.g. Klinefelters Syndrome
    • Short term use for induction of pubertal growth spurt with constitutional delay in puberty

     

    15.01.05 Suxamethonium Chloride Anectine® Injection.
    13.04 Synalar 1 in 4 Dilution®  Cream, fluocinolone acetonide 0.00625%
    Potency: moderate
    Excipients include benzyl alcohol, cetostearyl alcohol, polysorbates, propylene glycol

    Ointment, fluocinolone acetonide 0.00625%
    Potency: moderate
    Excipients include propylene glycol, wool fat

    DCHFT and RBCH: Not routinely stocked.
    13.04 Synalar C®  Cream, fluocinolone acetonide 0.025%, clioquinol 3%
    Potency: potent
    Excipients include cetostearyl alcohol, disodium edetate, hydroxybenzoates (parabens), polysorbates, propylene glycol

    Ointment, fluocinolone acetonide 0.025%, clioquinol 3%
    Potency: potent
    Note stains clothing
    Excipients include propylene glycol, wool fat

    Not RBCH
    Not DCHFT
    13.04 Synalar®  Cream, fluocinolone acetonide 0.025%
    Potency: potent
    Excipients include benzyl alcohol, cetostearyl alcohol, polysorbates, propylene glycol

    Gel, fluocinolone acetonide 0.025%
    For use on scalp and other hairy areas.
    Potency: potent
    Excipients include hydroxybenzoates (parabens), propylene glycol

    Ointment, fluocinolone acetonide 0.025%
    Potency: potent
    08.02.02 Tacrolimus  

    Red

    • Commissioned by NHS England (for transplant immunosuppression only). Renal transplant under the care of Dorset County Hospital or Portsmouth Hospitals Trust – RED (where GPs are still prescribing immunosuppressants in these cases please inform the CCG Medicines Management team)

    Amber

    • Renal or other organ transplant under the care of a tertiary centre other than Dorset County Hospital or Portsmouth Hospitals Trust – AMBER drug with shared care guideline (Trust specific). GPs are expected to continue supplies for existing patients only until repatriation occurs, no dates yet confirmed by NHS England.

    MHRA/CHM advice:
    Oral tacrolimus products: prescribe and dispense by brand name only, to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012)
    Inadvertent switching between oral tacrolimus products has been associated with reports of toxicity and graft rejection. To ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, oral tacrolimus products should be prescribed and dispensed by brand name only.

    • Adoport®, Prograf®, Capexion®, Tacni®, and Vivadex® are immediate-release capsules that are taken twice daily, once in the morning and once in the evening;

    • Modigraf® granules are used to prepare an immediate-release oral suspension which is taken twice daily, once in the morning and once in the evening;

    • Advagraf® is a prolonged-release capsule that is taken once daily in the morning. Not recommended for new patients as per NICE TA481 and TA482.

    Switching between tacrolimus brands requires careful supervision and therapeutic monitoring by an appropriate specialist.

    13.05.03 Tacrolimus  

    Hospital use only - unlicensed

    13.05.03 Tacrolimus (topical) Protopic®

    Ointment, tacrolimus (as monohydrate) 0.03% & 0.1%. Excipients include beeswax.

    For atopic eczema, in accordance with NICE recommendations (TA82). Refer to local shared care guideline.

    13.05.03 Tacrolimus in Orabase 0.1% ointment  Extemporaneous product.
    Hospital only.

    DCHFT: Not routinely stocked.
    02.05.01 Tadalafil Adcirca® Only to be initiated by approved Tertiary Centres in accordance with NHS England commissioning policies for Pulmonary Hypertension.
    07.04.05 Tadalafil 10mg & 20mg tablets Not prescribable on the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIB of the Drug Tariff. The prescription must be endorsed ’SLS’.

    Dose "when required"
    11.06 Tafluprost 15micrograms/mL + Timolol 5mg/mL preservative free eye drops Taptiqom® For patients who are unable to tolerate or are contraindicated for Ganfort® and where a preservative free formulation is truly required.
    11.06 Tafluprost drops 15micrograms/ml Saflutan® Preservative free.

    DCHFT: Consultant use only. 2nd line in patients with proven intolerance to preserved eye drops.
    16.01 TALC BP purified sterile   unlicensedUnlicensed
    For pleurodesis in the management of pleural effusions.

    NOT for intravenous administration!!!
    08.01.05 Talimogene laherparepvec Imlygic®

    In accordance with NICE guidance.

    08.03.04.01 Tamoxifen 
    07.04.01 Tamsulosin hydrochloride 
    04.07.02 Tapentadol sustained release  Modified release tablets.
    For Chronic Pain.
    Sustained release (not immediate release) for use as a second line opiate option where morphine has not been tolerated.

    DCHFT: Consultant use only.
    08.01.03 Tegafur with Uracil Teysuno® Each hard capsule contains 15 mg tegafur, 4.35 mg gimeracil and 11.8 mg oteracil (as 14.7 mg of oteracil monopotassium).

    05.01.07 Teicoplanin Targocid® PHT: For microbiology use only.

    RBCH: As per surgical prophylaxis policy or on advice of microbiology
    23.19 Teleflex / Rusch Catheters 
    Company Product codes and sizes Price per unit Comments
    Teleflex / Rusch

    Standard and female sizes 12ch-24ch

    All silicone (Long term 12 weeks) Codes:

    • Standard DA3101+Size
    • Female DA2101+ Size

    Sympacath Hydrogel - long term 12 weeks codes:

    • Standard DH3101+Size
    • Female DH2101+Size

    PTFE (Short Term 1-3 weeks)

    • Standard DP3100+Size
    • Female DP21001+Catheter + Size

     

    6.00

     

     

     

    6.60

     

     

    2.13

    Rusch catheters include sterile water pre-filled syringe for balloon deflation

     

    01.09 Telotristat Xermelo®

    Poole: Oncology team only for the treatment of carcinoid syndrome diarrhoea.

    To be supplied free of charge as part of an early access to medicine scheme (EAMS) until NHSE reimbursement is evaluated.

    04.01.01 Temazepam  • Insomnia, short term use up to 4 weeks maximum

    • Oral solution reserved for those with swallowing difficulties or specific clinical need.

    15.01.04.01 Temazepam  Tablet, oral solution.
  • Red - when used as a premedication. See section 4.1.1 for other uses.
  • 05.01.01.02 Temocillin Negaban®

    Consultant microbiologist only.


    08.01.05 Temozolomide  Commissioned in accordance with NICE TA.

    Not routinely commissioned by NHS England for non-malignant endocrinology conditions. As per IFR approval.
    02.10.02 Tenecteplase Metalyse® Injection.
    05.03.01 Tenofovir Disproxil Generic, Viread®

    Generic product should be used where possible.

    Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs) as per BHIVA Guidelines.

    05.03.03.01 Tenofovir Disproxil Generic, Viread®

    Generic product should be used where possible.

    05.03.01 Tenofovir with etricitabine and rilpivirine Eviplera® Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.
    05.03.01 Tenofovir, elvitegravir, cobicistat, &and emtricitabine Stribild® Commissioned by NHS England for HIV in combination with other anti-retrovirals, as per NHS England policy B06/PS/a.
    07.04.01 Terazosin Hytrin®
    05.02.05 Terbinafine  For use in fungal toenail / fingernail infection as per Primary care antibiotic prescribing guidance
    13.10.02 Terbinafine  Cream, terbinafine hydrochloride 1%
    03.01.01.01 Terbutaline  Inhalers, nebuliser solution, tablets, syrup.
    Alternative prescribing option.
    Short-acting beta2 agonist.
    03.01.01.01 Terbutaline IV  Hospital only.
    07.01.03 Terbutaline sulfate 
    08.02.04 Teriflunomide Aubagio®

    Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA303.

    Not recommended in highly active or rapidly evolving severe relapsing-remitting MS as per NICE TA303.

    06.06.01 Teriparatide Forsteo®

    NHSE Commissioned by CCG for the secondary prevention of osteoporotic fragility fractures in postmenopausal women in accordance with NICE TA161.

     

    • Commissioned by NHSE for the secondary prevention of osteoporotic fragility fractures in men in accordance with Clinical Commissioning Policy 170064P via specilaised rheumatology and endocrinilogy centres/networks only.
    • Not routinely commissioned for use in juvenile patients - by NHS England IFR approval only.
    06.05.02 Terlipressin acetate Glypressin®, Variquel® For bleeding from oesophageal varices
    06.04.02 Testosterone gel  

    Transdermal preparations
    Tests for testosterone levels should be undertaken at 9am for more accurate results

    March 2018: We have been made aware of supply issues with Testogel sachets and Testim Gel. Please note that Tostran is an alternative option at an equivalent dose of 50mg (x5 presses) per day and Testogel pump is now available and can be prescribed on SystmOne as an alternative to the sachets.

     

    06.04.02 Testosterone injection IM Nebido® Tests for testosterone levels should be undertaken at 9am for more accurate results
    18 Tetanus Immunoglobulin antidote botulism For treatment of tetanus infection (botulism)
    04.09.03 Tetrabenazine  Tablets.
    For patients with:
  • movement disorders

  • tardive dyskinesias
  • 15.02 Tetracaine (Amethocaine) Ametop® Topical gel.
    06.05.01 Tetracosactide Synacthen®, Synacthen Depot® Hospital use only

    RBCH:Needs Consultant Endocrinologist approval.
    13.06.02 Tetracycline  Not DCHFT.
    05.01.03 Tetracycline oral  DCHFT: Not routinely stocked.
    09.04.01 Tetrahydrobiopterin  Commissioned by NHS England (for phenylketonuria). As per NHS England Service Specification for highly specialist criteria and centres only.
    08.02.04 Thalidomide Thalidomide Celgene®

    Commissioned by NHS England as per NICE TA228. First line agent for multiple myeloma.